
Title: A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and 
Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Study ID: [REMOVED]
Protocol Approve Date: [ADDRESS_142857] 2020
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information ([COMPANY_003]) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.0 TITLE PAGE
PROTOCOL 
A Phase 2, Randomized, Open -Label Study Comparing Oral Ixazomib/Dexamethasone and 
Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Sponsor: Millennium Pharmaceuticals, Inc, a who lly owned subsidiary o f [COMPANY_005] 
Pharmaceut ical Co mpany Limited
[ADDRESS_142858]
Cambridge, MA [ZIP_CODE], [LOCATION_003]
Telephone: +1 (617) 679 -7000
Note: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of [COMPANY_005] 
Pharma ceutical Company Limited, may be referred to in this protocol as 
“Millennium,” “Sponsor,” or “[COMPANY_005].”
Study Number: C16029
IND Number: IND 104,[ADDRESS_142859] Number: 2016-004742-28
Compound: Ixazo mib (NINLARO)
Date: 31August 2020 Version/Amendment 
Number:06 (gl obal)
Amendment History :
DateAmendment 
NumberAmendment Type 
(for Regional Europe Purposes Only) Region
[ADDRESS_142860] 2020 06 Substantial Global
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 2of [ADDRESS_142861] Type/RoleNorth America
Contact[CONTACT_126886] 10.2 See Section 10.2 See Section 10.2
Medical Monitor
(medical advice on 
protocol and 
compound)See Study Manual See Study Manual See Study Manual
Responsible Medical 
Officer 
(carries overall 
responsibility for the 
conduct of the study)See Study Manual See Study Manual See Study Manual
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_142862] for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmoni sation E6 Good Clinical Practi ce: Consolidated
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical
trial disclosure laws, and regulations.
SIGNATURES
The signature [CONTACT_126966] (and other signatories, as applicable) 
can be found on the signature [CONTACT_3264].
Electronic Signatures can be found on the last page of this document.
[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedance ance
wing:wing:
olidatedidate
a privacprivac
and nd otheoth
his docuis do
nd 
Non-Commercial Use Only and
Ixazomib
Study No. C16029 Page 4of [ADDRESS_142863] igator’s Brochure, package 
insert, and any other product information provided by [CONTACT_456]. I agree to conduct this study in 
accordance with the requi rements of thi s protocol  and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conferenc e on Harm onisati on, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.0 of this 
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature [CONTACT_4235] (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 5of [ADDRESS_142864] 2020
1.3 Protocol Amendment 06 Summary of Changes
Rationale for Amendment 06
This document describes the changes in reference to the protocol incorporating Amendment 06. 
The primary  reason for thi s amendment is to modify  the study  assessments, now that the data 
cutoff date for the study analysis (the only planned formal analysis) has been reached (31 May  
2020). Only  patients who continue to demonstrate clinical benefit but who do not have other 
means of access to the study drugs will cont inue o n the study. Because no further formal statist ical 
analyses will be performed, only assessments contribut ing to long -term safet y data are required. 
Most study  assessments besides safet y are discont inued to ease the burden of protocol -mandated 
assessments o n patients.
Patients continuing their current study  treatm ent may  do so until  such time as other m eans of 
accessing the study  drugs are arranged. When possible, patients should co mplete an End of 
Treatment (EOT) visit and transit ion onto an alternative sup ply of (eg, commercially available) 
ixazo mib or pomalido mide, as well as dexamethasone, or onto another standard of care treatment. 
Discontinued pati ents will  be treated by  [CONTACT_79043] l ocal standard of care.
Upon implementation of Amendment 06, da ta collection requirements will be limited to collectio n 
of adverse events (AEs) and serious adverse events (SAEs). All other study  assessments are no 
longer required. All central laboratory assessments are discontinued. Qualit y of life and healt hcare
utilization (HU) assessments and co llection of concomitant medicat ions and procedures are 
discontinued. Patients will not be fo llowed for the progression -free survival (PFS)or overall 
survival (OS) fo llow-up peri ods, because PFS and OS data are no longer bei ng co llected. See the 
updated Schedule of Events in Appendix Afor more detailed informat ion (the previous, full 
Schedule of Events is now moved to Appendix Lfor reference only).
Descript ions of how to manage study  procedures during unavo idable circumstances, such as the 
coronavirus disease 2019 ( COVID -19) pandemic, have addit ionally  been added.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only.
For specific descript ions of text changes and locat ion of the changes, see
 Appendix M.
Changes in Amendment [ADDRESS_142865] long-term safet y data.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 6of [ADDRESS_142866] no access to 
study  drugs other than staying in the study  may stay in the study .
5.To cl arify that, as of the current amendment, the reason for a patient’s treatment 
discontinuat ion must be recorded in the electronic case report form ( eCRF )but no approv al by 
[CONTACT_456] i s requi red to di scont inue treatment.
6.To cl arify that l ocal laboratory  evaluat ions are to be used henceforth.
7.To simplify  the Schedule of Events to reflect the other changes noted.
8.To cl arify that pharmacokinetic ( PK)sample collecti on is now com plete.
9.To cl arify that the previous, full Schedule of Events and the now -completed PK sampling 
schedule have been moved to a new appendix ( Appendix L) for ref erence only.
10.Ident ify, as needed, text in the protocol that is no longer applicable as of the current 
amendment, now that the data cutoff date for the study  analysis has occurred.
11.To add flexibilit y in study  conduct in unavoi dable ci rcumstanc es (eg, the COVID -19 
pandemic).
12.To indicate that, given the changes in the current amendment, patients remaining on study will 
need to be reconsented.
13.Update l anguage about management of clinical events in patients receiving ixazo mib.
14.To cl arify details ab out ixazo mib packaging, handling, and storage guidelines.
15.To cl arify that PFS and OS data will be analyzed using unstratified tests, among others.
16.To add informat ion about submitt ing SAE reports.
17.To correct a ty pographical error and clarify that there is o nly 1 study  analysis planned (and as 
such, no interim analyses).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 7of [ADDRESS_142867] igator/Coordinating Invest igator ...................................................... [ADDRESS_142868] of Abbreviat ions............................................................................................... 17
3.4 Corporate Identificat ion........................................................................................... 19
4.0 INTRODUCTION ......................................................................................................... 20
4.1 Background ............................................................................................................. 20
4.1.1 Ixazo mib Clinical Development Program ......................................................... 20
[IP_ADDRESS] Approval o f Ixazo mib+ Lenalido mide and Dexamethasone for Relapsed 
and/or Refractory  Mul tiple Myelo ma....................................................... 20
[IP_ADDRESS] Othe r Clinical Development .................................................................... 21
[IP_ADDRESS] Invest igator -Initiated Study  Relevant to Thi s Protocol ............................. 21
4.2 Background Informat ion on the Disease to Be Treated ............................................. 22
4.2.1 Current Medical Treat ments for MM ............................................................... 22
4.2.2 Unmet Medical Need Addressed by [CONTACT_126887] .................................. 22
4.2.3 Benefit/Risk Assessment .................................................................................. 24
[IP_ADDRESS] Benefit s................................................................................................... 24
[IP_ADDRESS] Risks ....................................................................................................... [ADDRESS_142869] ive Co mbinat ion Therapi[INVESTIGATOR_126842] ........... 27
4.3.2 Need for All -Oral Co mbinat ion Therapi[INVESTIGATOR_126843] h RRMM at Later 
Lines of Therapy .............................................................................................. 27
4.3.3 Possible Benefit -Risk of Ixa+Dex versus Pom+Dex ......................................... [ADDRESS_142870] ives...................................................................................... 31
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 8of [ADDRESS_142871] 2020
5.1.3 Safety Objective .............................................................................................. 31
5.1.4 Exploratory  Objective ...................................................................................... 31
5.2 Endpoints ................................................................................................................. 32
5.2.1 Primary Endpo int............................................................................................. 32
5.2.2 Secondary  Endpo ints....................................................................................... 32
5.2.3 Safety Endpo int............................................................................................... 32
5.2.4 Exploratory  Endpo int....................................................................................... 32
6.0 STUDY DESIGN .......................................................................................................... 33
6.1 Overview of Study  Design ....................................................................................... 33
6.1.1 Study  Popul ation............................................................................................. 33
6.1.2 Study  Therapy  Dosing ..................................................................................... 34
6.1.3 Study  Assessments .......................................................................................... 34
[IP_ADDRESS] Assessments During the Treatment Period ............................................... 35
[IP_ADDRESS] Assessments During the Follow -up Peri ods: PFS and OS ......................... 36
[IP_ADDRESS] Other Assessment Details ........................................................................ 38
6.1.4 Statistical Analyses .......................................................................................... 38
6.2 Number of Patients .................................................................................................. 38
6.3 Durati on of  Study .................................................................................................... 38
6.3.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on.................................... 38
6.3.2 End of Study /Study  Com pletion Definit ion...................................................... [ADDRESS_142872] igational Therapy: Ixazomib Administration (Arm A) .................................... 44
8.2 Reference/Control Therapy: Pomalido mide Administration (Arm B) ....................... [ADDRESS_142873] of Care Therapy: Dexamethasone Administration (Both Arms) ................. 45
8.4 Dose Modificat ion Guidelines .................................................................................. 46
8.4.1 Intrapatient Dose Escalation o f Ixazo mib (Arm A) ........................................... 46
8.4.2 Criteria for Beginning or Delaying a Subsequent Treatment Cy cle................... 46
[IP_ADDRESS] Criteria for Beginning the Next Treatment Cycle Wit h Ixa+Dex (Arm A)
................................................................................................................ 46
[IP_ADDRESS] Criteria for Beginning the Next Treatment Cy cle Wi th Pom +Dex (Arm  
B)............................................................................................................ 47
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 9of [ADDRESS_142874] 2020
8.4.3 Ixazomib Treat ment Modificat ion (Arm A) ..................................................... 47
8.4.4 Pomalidomi de Treatm ent Modificat ion (Arm B) .............................................. 50
8.4.5 Dexamethasone Treatm ent Modificat ion (Both Arms) ..................................... [ADDRESS_142875] igational Agents ...................................................................... 58
8.10.1 Ixazo mib.......................................................................................................... 58
[IP_ADDRESS] Preparati on, Reconstitution, and Dispensat ion......................................... 58
[IP_ADDRESS] Packaging and Labeling ........................................................................... 58
[IP_ADDRESS] Storage, Handling, and Accountabilit y..................................................... 58
8.10.2 Pomalidomi de (Control  Therapy )..................................................................... 59
[IP_ADDRESS] Preparati on, Reconstitution, and Dispensat ion......................................... 59
[IP_ADDRESS] Packaging and Labeling ........................................................................... 60
[IP_ADDRESS] Storage, Handling, and Accountabilit y..................................................... 60
8.10.3 Dexamethasone ................................................................................................ 60
[IP_ADDRESS] Preparati on, Reconstitution, and Dispensat ion......................................... 60
[IP_ADDRESS] Packaging and Labeling ........................................................................... 60
[IP_ADDRESS] Storage, Handling, and Accountabilit y..................................................... [ADDRESS_142876] ...................................................................................................... 61
9.1 Study  Personnel and Organizations .......................................................................... 61
9.2 Arrangements for Recruit ment of Patients ................................................................ 61
9.3 Treatment Group Assignments ................................................................................. 61
9.4 Study  Procedures ..................................................................................................... 61
9.4.1 Inform ed Consent ............................................................................................ 62
9.4.2 Enro llment ....................................................................................................... 62
9.4.3 Patient Dem ographi cs...................................................................................... 62
9.4.4 Physical Examinat ions..................................................................................... 62
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_142877] 2020
9.4.5 Medical History and Disease Staging...............................................................62
9.4.6 ECOG Performance Status ...............................................................................63
9.4.7 Vital Signs.......................................................................................................639.4.8 Height a nd Weight ...........................................................................................63
9.4.9 Electrocardi ogram ...........................................................................................63
9.4.10 QOL and HU Asse ssments ...............................................................................63
[IP_ADDRESS] QOL ........................................................................................................64
[IP_ADDRESS] HU ..........................................................................................................[ADDRESS_142878] ................................................................................................67
9.4.15 Clinical Laboratory Evaluations.......................................................................67
[IP_ADDRESS] Clinical Chemistry and Hemato logy ........................................................68
[IP_ADDRESS] Clinical Laboratory Evaluations  for Disease Assessmen ts........................68
9.4.16 AEs .................................................................................................................69
9.4.17 Concomitant Medications and Procedures ........................................................69
9.4.18 PK Samples and M easurements .......................................................................69
9.5 Completion of Study Treatmen t (for Individual Patients ) .........................................70
9.6 Completion of Study (for Individual Patients) ..........................................................[ADDRESS_142879] Complaints or Medication Errors (Including 
Overdose) ................................................................................................................76
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities ...........77
11.0 STUDY-SPECIFI C COMMITTEES .............................................................................78CCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to...........
...............
gyy.........
sfofor DirD
.............
d ProceProc
mentsment
mment (fent (f
r IndiviIndiv
reatmeneatm
atients Fents
e...........
mmpliancplianmm
E EVENEVE
finitnitioion
1.1.1PrP
[IP_ADDRESS].[ADDRESS_142880] ics............ 81
13.1.3 Efficacy Analysis ............................................................................................. 81
[IP_ADDRESS] Analyses for Primary Efficacy Endpoint .................................................. 82
[IP_ADDRESS] Analyses of Secondary Efficacy............................................................... 82
13.1.4 PK Analysis ..................................................................................................... 83
13.1.5 QOL and HU Analyses .................................................................................... 83
13.1.6 Safety Analysis ................................................................................................ 83
[IP_ADDRESS] New Primary Malignancy ........................................................................ [ADDRESS_142881] ions................................ 87
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 88
15.1 IRB and/or IEC Approval ........................................................................................ [ADDRESS_142882] OF IN -TEXT TABLES
Table 6.a Primary and Secondary  Endpo ints for Di sclosures ............................................. 39
Table 8.a Dose Reduction Steps for Ixazo mib................................................................... 47
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 12of [ADDRESS_142883] 2020
Table 8.b Ixazo mib Dose Modificat ion for Hem atologic Toxicit ies................................... 48
Table 8.c Ixazo mib Dose Modificat ion for Nonhematologic Toxicit ies.............................. 49
Table 8.d Criteria for Ixazomib Retreatment and Cy cle Delays Subsequent to 
Hem atologic and Nonhematol ogic Toxi cities..................................................... 49
Table 8.e Dose Reduction Steps for Dexamethasone ......................................................... 50
Table 8.f Dexamethasone -Related Treatm ent Modificat ion (Delays, Reductions, and 
Discontinuati ons) Gui delines Because of AEs [56] ............................................. [ADDRESS_142884] OF IN -TEXT FIGURES
Figure 6.a Study  Schema, Fro m Rando mizat ion Through End of Therapy .......................... 33
Figure 6.b Flow of  Patients Through Follow -up Periods After the EOT Vi sit (Only in 
Effect Before Amendment 06) ............................................................................ [ADDRESS_142885] igator Consent to Use of Personal Informat ion........................................ 104
Appendix D Revised IMWG Diagnostic Criteria for MM .................................................... 105
Appendix E ECOG Scal e for Perf ormance Status ................................................................ 106
Appendix FISS Staging Criteria ......................................................................................... 107
Appendix GIMWG Uniform Response Criteria for MM ..................................................... 108
Appendix HEORTC QLQ -C30 (version 3) ......................................................................... [ADDRESS_142886] ion Form ......................................................................... 117
Appendix LPrevious, Full Schedule of Events and PK Sampling Schedule (Schedules 
Before Implementation of Amendment 06)...................................................... 120
Appendix MDetailed Descript ion of Amendments to Text ................................................... 127
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 13of [ADDRESS_142887] 2020
2.0 STUDY SUMMARY
Name [CONTACT_790](s):
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of [COMPANY_005] 
Pharmaceutical Company LimitedCompound:
Ixazomib (NINLARO)
Title of Protocol : A Phase 2, Randomized, Open -Label Study Comparing Oral Ixazomib/Dexamethasone and Oral 
Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Study Number : C16029 Phase : 2
Study Design: 
Study C16029 is a randomized, open -label, phase 2 study. The 3 stratification factors are International Staging System 
stage (I or II vs III at study entry), prior lines of therapy (2 vs 3 or more), and age (<65 vs ≥65 years). Patients will be 
randomized i n a 3:2 ratio to receive ixazomib+dexamethasone (ixa+dex; Arm A) or pomalidomide+dexamethasone 
(pom+dex; Arm B), until first confirmed progressive disease (PD) or unacceptable toxicities.
Primary Objective:
As of Amendment 06, the objective is to continue to collect long -term safety data from patients who are continuing on 
ixazomib and dexamethasone or pomalidomide and dexamethasone because of continuing clinical benefit. Data 
collection for all other study objectives and endpoints is complete and no furth er formal analyses will be conducted. 
However, the original primary objective is retained below for reference only.
To compare the effect of ixa+dex versus pom+dex on progression -free survival (PFS) in patients with relapsed and/or 
refracto ry multiple myel oma (RRMM) who have received at least 2 prior lines of therapy, including lenalidomide and 
a proteasome inhibitor, and are refractory to lenalidomide but not refractory to proteasome inhibitors.
Secondary Objectives:
As of Amendment 06, the objective is to continue to collect long -term safety data from patients who are continuing on 
ixazomib and dexamethasone or pomalidomide and dexamethasone because of continuing clinical benefit. Data 
collection for all other study objectives and endpoints is complete a nd no further formal analyses will be conducted. 
However, the original secondary objectives are retained below for reference only.
To compare overall survival (OS) in patients treated with ixa+dex versus pom+dex.
To compare duration of response, overall re sponse rate (ORR), time to response, and time to progression with 
ixa+dex versus pom+dex.
To obtain health -related quality of life (QOL) data related to physical functioning of patients treated with ixa+dex 
versus pom+dex.
To assess health -related QOL by a dditional function and symptom domains of the European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire –Cor e 30 (EORTC QLQ - C30) 
instrument and by [CONTACT_126888] –multiple myeloma module (EORTC QLQ -MY20) 
and 5-level classification system of the EuroQol 5-Dimensional Health Questionnaire (EQ -5D-5L) instruments. 
To evaluate health care utilization (HU) by [CONTACT_126889]+dex versus those receiving pom+dex.
To collect plasma concentration -time data for ixazomib to contribute to population pharmacokinetic 
characterization of ixazomib and to conduct exposure -response analyses for patients receiving ixa+dex.
Safety:
To compare safety/tolerability of ixa+dex to that of pom+dex.
Study Population :Patients with RRMM, aged ≥[ADDRESS_142888] 2 consecutive cycles of bortezomib or carfilzomib 
(without having had PD during treatment with o r within [ADDRESS_142889] dose of bortezomib or carfilzomib), and 
are refractory to lenalidomide.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 14of [ADDRESS_142890] 2020
Number of Subjects:
Estimated total: approximately 120 patients randomized —approximately 72 in 
Arm A (ixa+dex) and approximately 48 in Arm B (pom+dex).Number of Sites: 
Estimated total: approximately 
100 globally 
Dose Levels:
Arm A
Ixazomib will be administered at a 4 mg starting dose, with escalation to 5.5 mg at 
Cycle 2 for patients who tolerate the 4 mg dose in Cycle 1 (specifically, patients 
who do not experience any new Grade 1 peripheral neuropathy with pain or other
ixazomib -related Grade ≥2 nonhematologic or Grade ≥3 neutropenia or 
thrombocytopenia in Cycle 1). Patients who have had any dose reductions, holds , 
or delay s because of ixazomib toxicities will not dose escalate. Dose escalation 
beyond the start of Cycle 2 is permit ted o nly when dose escalation was 
inadvertently missed at Cycle 2. 
Ixazomib will be administered orally on Days 1, 8, and 15 of each 28 -day cycle, 
combined with dexamethasone 20 mg (or 10 mg if patient is aged ≥75years) orally 
on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 -day cycle until PD .In cases where 
only 4 mg tablets for dexamethasone are available (eg, 4 mg dexamethasone is the 
only dosage available), the following dexamethasone schedule is recommended 
for patients aged ≥75 years: 12 mg dexame thasone will be given on Days 1, 8, 15, 
and 22 of every 28 -day cycle; and 8 mg dexamethasone will be given on Days 2, 9, 
16, and 23 of ever y 28-day  cycle.
Arm B
Pomalidomide will be administered at 4 mg orally on Days 1 to 21 of each 28 -
day 
cycle, combined with dexamethasone 40 mg (or 20 mg if patient is aged ≥75 years) 
orally on Day s 1, 8, 15, and 22 of each 28 -day cycle until PD.Route of Administration:
Arm A and Arm B are both 
all-oral therapi[INVESTIGATOR_014].
Duration of Treatment:
Patients will receive study thera py until PD, unacceptable toxicity, withdrawal of 
consent, or sponsor termination of study.Period of Evaluation:
Up to 28 months 
Main Criteria for Inclusion:
Adult patients (aged ≥18 years) who have been diagnosed with multiple myeloma (MM) according to standard 
criteria.
All patients must have had a relapse or PD after having received 2 or more prior lines of systemic therapy. 
(A line of therapy is defined as 1 or more cycle sof a planned treatment program; this may consist of 1 or more 
planned cycles of single -agent therapy or combination therapy, as well as a sequen ceof treatments administered 
in a planned manner. For example, a planned treatment approach of induction therapy followed by [CONTACT_126890] -cell transplantation, followed by [CONTACT_79035] 1 line of therapy . Typi[INVESTIGATOR_126844]. Discussion with the medical monitor may help clarify the number of prior lines of therapy for 
a prospective study participant.)
All patients must be refractory to lenalidomi de, defined as having received at least [ADDRESS_142891] been 25 
mg (or as low as 10 mg in the case of renal function impairment or other safety concern), and the final dose should 
have been a minimum of 10 mg. 
All patients must have received at least 2 consecutive cycles of a bortezomib -or carfilzomib -containing regimen, 
and either: 
–Achieved at least a partial response (PR) and did not have PD during treatment with or within [ADDRESS_142892] dose of bortezomib or carfilzomib, OR
–Had bortezomib and/or carfilzomib intolerance (defi ned as discontinuation because of drug -related adverse 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 15of [ADDRESS_142893] 2020
events (AEs) before completion of the planned treatment course) without PD upon the start of the next 
regimen.
All patients must have an Eastern Cooperative Oncology Group score of 0 to 2.
All patients must have measurable disease defined by [CONTACT_11084] M -protein ≥1 g/dL (≥10 g/L) or urine M -protein 
≥200 mg/[ADDRESS_142894] documented MM isotype by [CONTACT_5294] (central laboratory). 
Main Criterion for Exclusion: 
Patients must not have received prior ixazomib or pomalidomide and must not have participated in a previous 
ixazomib clinical study.
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is PFS, defined as the time from randomization to the first occurrence of 
confirmed PD, as evaluated by [CONTACT_126891] (IMWG) criteria, or death from any cause, whichever occurs first.
The secondary endpoints are OS; ORR (defined as complet e response, ver y good partial response (VGPR), or PR [per 
IMWG criteria]); duration of response; time to response; time to progression (TTP); health -related QOL as measured 
by [CONTACT_126892] -C30; health -related QOL as meas ured by [CONTACT_126893] -C30, by [CONTACT_20368] -MY20, and by [CONTACT_20367]-5D-5L; health care utilization as measured by [CONTACT_126894]; and safety/tolerability. 
After the data cutoff date for the study analysis (inclu ding for PFS) has occurred, all central efficacy and investigator 
assessments of response for protocol purposes will be discontinued.
As of Amendment 06, the data cutoff date for the study analysis (31 May 2020) has been reached. Only patients who 
continue to demonstrate clinical benefit but who do not have other means of access to the study drugs will continue on 
the study . As no further formal statistical analyses will be performed, only assessments contributing to long -term 
safety data are required. Most study assessments besides safety are discontinued to ease the burden of 
protocol -mandated assessments on patients.
Patients continuing their current study treatment may do so until such time as other means of accessing the study drugs 
are arranged. When possible, patients should complete an End of Treatment visit and transition onto an alternative 
supply of (eg, commercially available) ixazomib or pomalidomide, as well as dexamethasone, or onto another 
standard of care treatment. Discontinued patients will be treated by [CONTACT_79033].
Upon implementation of Amendment 06, data collection requirements will be limited to collection of AEs and serious 
AEs. All other study assessments are no longer required. All central laboratory as sessments are discontinued. Quality 
of life and health care utilization assessments and collection of concomitant medications and procedures are 
discontinued. Patients will not be followed for the PFS or OS follow -up periods, as PFS and OS data are no long er 
being collected.
Statistical Considerations:
There will be 1 study analysis for PFS and secondary endpoints.
Sample Size Justification:
Approximately 120 patients will be enrolled in total. 
The primary endpoint is PFS. Approximately 81 PFS events would be needed to provide 80% power at a 2 -sided 0.20 
level of significance with an HR of 0.62.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 16of [ADDRESS_142895] or equivalent. 
3.2 Principal Investigator/Coordinating Investigator 
[INVESTIGATOR_126845] a Signatory  Coordinat ing Investigator from the invest igators who 
participate in the study . Selection criteria for thi s inves tigator will include significant knowledge 
of the study  protocol , the study  medication, thei r experti se in the therapeutic area and the conduct 
of clinical research as well as study participation. The Signatory Coordinat ing Invest igator will be 
requi red to review and sign the clinical study  report and by [CONTACT_126895] .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 17of [ADDRESS_142896] computed tomography
DRESS Drug Reaction with Eosinophilia and Systemic Symptoms 
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EDC electronic data capture
EORTC QLQ -C30 European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire –Core 30
EORTC QLQ -MY20 European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire –multiple my eloma module
EOT End of Treatment
EQ-5D-5L 5-level classification system of the EuroQol [ADDRESS_142897] ratio
IB Investigator’s Brochure
ICH International Conference on Harmonisation
IDMC independent data monitoring committee
IEC independent ethics committee
IMiD immunomodulatory drug
IMWG International Myeloma Working Group
IRB institutional review board
IRT interactive response technology
ISS International Staging System
ITT intent -to-treat
IV intravenous
ixa+dex ixazomib+dexamethasone (investigational study therapy, given in Arm A)
KM Kaplan -Meier
LenDex lenalidomide and dexamethasone
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 18of [ADDRESS_142898] 2020
line of therapy 1 or mo re cy cles of a planned treatment program; this may consist of [ADDRESS_142899], followed by [CONTACT_79035] 1 line of 
therapy) [1].Typi[INVESTIGATOR_897] , each line of therapy is separated by [CONTACT_4002]. Discussion with the 
medical monitor may help clarify the number of prior lines of therapy for each prospective 
study parti cipant.
MedDRA Medical Dictionary for Regulatory Activities
MM multiple myeloma
MRI magnetic resonance imaging
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NDMM newly  diagnosed multiple myeloma
NSAIDs nonsteroidal anti -inflammatory drugs
ORR overall response rate
OS overall survival
PD progressive disease
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic
pom+dex pomalidomide+dexamethasone (control study therapy; given in Arm B)
PP per-protocol
PR partial response
QOL quality  of life
REMS Risk Evaluation and Mitigation Strategies
RRAL relapsed and/or refractory systemic light -chain amyloidosis
RRMM relapsed and/or refractory multiple myeloma
SAE serious adverse event
SJS Stevens -Johnson syndrome 
SmPC Summary of Product Characteristics
SPEP serum protein electrophoresis
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
TEAE treatment -emergent adverse event
TEN toxic epi[INVESTIGATOR_126846]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 19of [ADDRESS_142900] 2020
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of [COMPANY_005] 
Pharmaceutical Company Limited
TDC Japan [COMPANY_005] Development Center Japan
TDC Asia [COMPANY_005] Development Center Asia ,Pte Ltd
TDC Europe [COMPANY_005] Development Centre Europe Ltd
TDC Americas [COMPANY_005] Development Center Americas , Inc
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
[COMPANY_005] Millen nium Pharmaceuticals, Inc, TDC Japan, TDC Asia, TDC Europe and/or TDC 
Americas, as applicable
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 20of [ADDRESS_142901] 2020
4.0 INTRODUCTION
4.1 Background
4.1.1 Ixazomib Clinical Development Program
Ixazo mib, an oral inhibitor of the 20S proteasome, is under development for the treatment of 
multiple myelo ma (MM), pl asma cell dyscrasias, amylo idosi s, lympho ma, nonhematologic 
malignancies, an d lupus nephri tis. Inhibi tion of  the 20S proteasome has been validated as a 
therapeuti c target for the treatment of malignancies using VELCADE (bortezomib) for Injection, 
Millennium Pharmaceuticals, Inc’s first -in-class proteasom e inhibitor [2].
Ixazo mib (MLN2238) refers to the bio logically active boronic acid form of t he drug substance. 
The drug substance is administered as a stable citrate ester, designated as ixazo mib citrate 
(MLN9708). Under physio logical condi tions, ixazomib citrate rapi[INVESTIGATOR_126847] c acid, i xazo mib. Ixazo mib is a peptide boronic acid that is structurally 
different fro m bortezomib. Detailed informat ion regarding the nonclinical pharmaco logy and 
toxicology of ixazo mib can be found in the ixazo mib Investigator’s Brochure (IB).
[IP_ADDRESS] Approval of Ixazomib+ Lenalidomide and Dex amethasone for Relapsed and/or 
Refractory Multiple Myeloma
Ixazo mib in co mbinat ion with lenalido mide and dexamethasone (LenDex) was approved (under 
the brand name [CONTACT_126967]) by [CONTACT_24623] (US) Food and Drug Administration (FDA) in 
November [ADDRESS_142902] 1 prior therapy 
[3,4] , with approvals subsequent ly in Canada, Israel, Australia, the European Unio n (EU), and 
Singapore and in Switzerland forpatients who have received at least [ADDRESS_142903] in Venezuela.
The pi[INVESTIGATOR_30338] 3 Study  C16010 was the basis for the approval, invo lving 722 patients with 
relapsed and/or refractory  multiple myelo ma (RRMM) [
4]. The primary endpo int of PFS was met 
in the intent -to-treat (ITT) populat ion at the primary  analysis, with a significant PFS benefit for 
patients receiving ixazo
mib+LenDex versus placebo+LenDex (hazard ratio [HR]=0.742, p=0.012; 
median PFS 20.6 vs 14.7 months). The PFS benefit in the ixazomib regimen was supported by  
[CONTACT_126896]. At a median fo llow-up of  
approximately  23 m onths, the median OS had not been reached in either regimen. The rates of 
SAEs were similar in the 2 regimens (47% with ixazomib, 49% with placebo), as were the rates of 
death during the study period (4% and 6%, respectively); Grade ≥3 AEs occurred in 74% an d 69% 
of the pati ents, respectively . Overall , the addi tion of  ixazo mib to LenDex did not add substant ial 
toxicity. 
The PFS benefit and safety  profile seen in global Study  C16010 have been substant iated in the 
China Cont inuat ion study , a second doubl e-blind, placebo -controlled study  of similar design and 
the same inclusio n criteria, with 115 patients with RRMM, all enrolled in China [5]. In addition, an 
OS benefit in favor of the ixazo mib+LenDex group was observed at the final analysis [
6]. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_142904] 2020
More details are given in Section  [IP_ADDRESS].
[IP_ADDRESS] Other Clinical Development
Ixazomib has been tested as an intravenous (IV) and an oral formulation (during the early 
development of ixazomib); however, only the oral formulation is currently being developed for 
commercialization. Regardless of the route of administr ation, in the twice-week ly dosing schedule, 
ixazomib is given on Days 1, 4, 8, and 11 of a 21-day cycle, and in the weekly dosing schedule, 
ixazomib is given on Days 1, 8, and 15 of a 28-day cycle. 
Phase 1, phase 1/2, and phase 2 studies are ongoing in MM, relapsed and/or refractory systemic 
light-chain amyloidosis (RRAL), solid tumors, a nd lymphoma. In addition, phase [ADDRESS_142905] RRMM or advanced solid tumors 
(Study C16015); patients with hepatic impair ment who have advanced solid tumors or 
hematologic malignancies (Study C16018); and in an  absorption, distribution, metabolism, and 
excretion study in patients with advanced  solid tumors or lym phoma (Study C16016). Phase 3 
studies in RRMM, newly diagnosed multiple myeloma (NDMM), and RRAL are under way. 
As of [ADDRESS_142906] 1 
dose of either the IV or oral ixazomib formulations across the clinical development program; in 
addition, [ADDRESS_142907] been enrolled  in the following phase 3 clinical trials:
!Double-blind, placebo-controlled Study C16010 and Study C16010 China Continuation study 
of ixazomib versus placebo in combination with  LenDex in patients with RRMM (described in 
Section  [IP_ADDRESS]) .
!Double-blind, placebo-controlled Study C16014 a nd Study C16014 extension in South Korea 
of ixazomib versus placebo in combination with LenDex in patients with NDMM. 
!Double-b lind, placebo-contro lled Study C16019 of ixazomib versus placebo as maintenance in 
patients with NDMM who have undergone autologous stem cell transplantation (ASCT) 
before entering the study.
!Double-bli nd, placebo-controlled St udy C16021 of ixazomib versus placebo as maintenance in 
patients with NDMM who have not undergone ASCT.
!Open-label Study C16011 of ixazomib and dexamethasone (ixa+dex) versus physician’s 
choice of a de xamethasone-containing regimen in patients with RRAL. 
[IP_ADDRESS] Investigator-Initiated Study Relevant to This Protocol
Results of the investigator-initiated study of ixa+dex in patients with RRMM (MC1181, 
[STUDY_ID_REMOVED]; principal investigator, ) are of particular importance for 
Study C16029, the focus of this protocol [7,8] . In that study, patients with relapsed MM were 
treated with ixazomib 4.0 or 5.5 mg weekly for 3 of 4 weeks and with dexamethasone 40 mg 
weekly. The overall response rate (ORR) was 31% fo r the 4.0 mg arm and 54% for the 5.5 mg arm. 
Both arms had manageable toxicities. See Section  4.3.4 for more information.[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useed for d for
ng schedg sche
ng schedng sch
refractoefract
n, phasephase
r advancadvan
ced sod solidl
didistribustrib
phophoma (ma
DMM), aMM)
a total ototal
9patipatien
ns across acro
he follohe follo
dyy C160C16y
inatinatioion
olled Stolled 
bo in coo in c
o-concontrotnnnn
MM whoM w
the studhe stu
nd, placd, pla
wiwiththiii ND Nhh
enn-label labe
hohoice oice 
[IP_ADDRESS].1.1.
ReR
Ixazomib
Study No. C16029 Page 22of [ADDRESS_142908] 2020
4.2 Background Information on the Disease to Be Treated
MM is a clonal disease of plasma cells that is characterized by [CONTACT_126897] (and other organs) an d som etimes results in bone marrow failure, bone 
destruction, hypercalcemia, anemia, infect ion, and renal failure. It is the second most common 
hematol ogical malignancy , consti tuting approximately  1% of  all reported neoplasms and 
approximately  13% of  hemat ologic cancers worldwide [9].The incidence of MM is expected to 
increase over the next decade , which highlights the need for more effect ive MM therapi[INVESTIGATOR_014] [
10]. 
Moreover, to a greater extent in the future than now, MM will be a disease that primarily affects 
older persons (those a
ged 64 to 84 years) [11], who generally have a worse prognosis than younger 
persons. 
4.2.[ADDRESS_142909] 2 decades because of advances in understanding the disease bio logy as well as 
improvements in treatment and supportive care strategies. Between 1990 and 2007, the cancer 
death rate for people wit h MM in the [LOCATION_002] decreased by [CONTACT_3450] 9% f or men and 
13% for women, owing to the introduction of stem cell transplantation and the novel agents 
bortezomib, thalido mide, and lenalido mide [
12]. Correspondingly, 5 -year survival improved fro m 
25% in 197 5 to 39% i n 2006 [
13]. Similar improvements in survival rates among European 
patients wi th MM have been shown, particularly amo ng younger pati ents [
14,15] . Moreover, 
newer agents continue to be introduced, including carfilzo mib, pomalido mide, elotuzumab, and 
daratum umab. These newer agents have been shown to improve survival amo ng ol der pati ents, 
with the 6 -year OS among patients older than 65 years increasing fro m 31% am ong those 
diagnosed in 2001 -
2005 to 56% among those diagnosed in 2006 -2010 (p<0.001) [16].Nonetheless, 
responses to currently  available therapi[INVESTIGATOR_126848] , and m ost pati ents receive mult iple 
therapi [INVESTIGATOR_126849].
First-line treatment options are determined by a patient’s eligibilit y, or lack thereof, for ASCT 
[
17,18] .Regardless of whether the patient is transplant eligible, MM is sensit ive to a number of 
cytotoxi c drugs, including proteasome inhibitors such as bortezomib and carfilzo mib, alkylat ing 
agents, immuno modulatory  drugs (IMi Ds) (eg, thalido mide and lenalido mide), corti costeroi ds, 
and mo noclonal ant ibodies (eg, elotuzumab and daratumumab) [
19-24 ]. However, even wit h suc h 
advances and risk -adapted approaches, nearly  all pati ents eventually  relapse or become refractory 
and require subsequent treatment [25,26] ; thus, new treatment options are urgent ly needed . In 
particular, new therapi[INVESTIGATOR_126850] y are needed for elderly pat ients to continue to improve 
the prognosi s of this populat ion that comprises most MM patients [
16].
4.2.[ADDRESS_142910] ive for 
all patients [
27]. Consequent ly, treatment decisio ns are carefully based on patient and disease 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 23of [ADDRESS_142911] a lower 
probabilit y of responding to therapy  [28-33] . Therefore, there is a need for regimens that are 
effect ive in later therapi[INVESTIGATOR_014]. In addit ion, patients who require treatment after receiving 2 prior lines 
of therapy  may experience l ong-term side effects as a consequence of being exposed to mult iple 
cytotoxi c drugs wi th varying toxicit y profiles (eg, neuropathy , dec reased bone marrow reserve). 
Many  patients in their third or later line of therapy  are not abl e to tol erate the toxi city of a 3-drug 
regimen and would benefit fro m a less toxic doublet (see Section
 4.3.3 ). (A line of therapy is 
defined as 1 or more cycles of a planned treatment program; this may consist of [ADDRESS_142912], fo llowed by [CONTACT_79035] 1 line o f therapy [1].Typi[INVESTIGATOR_897], 
each line of therapy is separated by [CONTACT_126898] [PD]. Discussion wit h the medical mo nitor 
may help clarify  the number of pri or lines of therapy  for each prospective study  parti cipant. ) 
As the incidence of MM in older patients increases, so does the need for therapy  that is effect ive 
but also tolerable and that maintains qualit y of life (QOL) [
34]. At fir st relapse, the goal of therap y 
is often similar to that for newly diagnosed patients, with a focus on a more aggressive treatment 
and a higher acceptance for toxicit y, but at l ater stages and wit h older age, therapeuti c goals m ay 
change significant ly, toward an increased emphasis on QOL, safet y, tolerabilit y, and c onvenience, 
in addit ion to efficacy. Pat ients typi[INVESTIGATOR_126851] m the hospi[INVESTIGATOR_126852]. Therefore, these patients may  prefer an ent irely oral  treatm ent regimen. In 
addition, many elderly pat ients may also be unable to tolerate more -toxic 3-drug combinat ions and 
thus woul d benefit fro m an efficacious but less toxic doublet.
Real-world clinical  pract ice data illustrate a significant correlation between duration o f therapy  
and probabilit y of survival. Recently, this was docum ented wi th real-world electroni c medical  
record data from a US -based study showing that each addit ional mo nth of treatm ent in second -line 
RRMM was associated with a reduced risk o f death at 1 year after init iation of second -line therap y 
(HR=0 .67; 95% CI] 0.59, 0.77) [
35].
Further, currently available therapi[INVESTIGATOR_126853] -limit ing toxicit ies and added 
treatm ent burdens to patients and their care givers. For example, proteasome inhibitors approved in 
the relapsed setting require frequent hospi[INVESTIGATOR_126854] (bortezomib and carfilzo mib) or 
subcutaneous (bortezomib) administration [
2,36] . Similarly, ne wly approved m onocl onal 
antibodies such as daratumumab require frequent, prolonged IV infusio ns [
37]. IV infusio ns of 
anticancer agents, or any parenteral agents, require admi nistrati on in a hospi[INVESTIGATOR_126855] m ore than drug costs to the healt h econo mic burden, including, but not limited to, the cost of 
the use of the facilit y and i ts staff plus the cost of transportation to the facilit y in addit ion to the 
overa ll costs associated with therapy. Moreover, AEs that are associated with current ly available 
agents impact a patient’s QOL and can lead to dose reductions and/or early treatment 
discontinuat ion, which in turn result in suboptimal treatment as well as poten tial loss of t ime able 
to perform work
. Such AEs include peripheral neuropathy  and hypotension (bortezomib), second 
primary  malignancies (l enalido mide), neutropenia, allergic react ions, infusio n-related reactions 
(daratum umab), vascular events (carfilzo mib), thrombot ic events (lenalido mide and 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 24of [ADDRESS_142913] 2020
pomalidomide), and myelo suppressio n (pom alidomide) [2,17 ,36-42] . Finally, concern regarding 
the risk of teratogenicit y of the IMiDs (including pomalido mide) has led to creation of the 
Pregnancy Prevent ion Programme in the European Union and the Risk Evaluat ion and Mit igation 
Strategies (REMS) programs in the [LOCATION_002]. These programs increase the burdens placed on 
patients, heal th care providers, and health care clinics.
Consideration o f the toxicit y and the treatm ent b urden to patients is important in this populat ion 
because pat ients with relapsed MM are often sicker and carry  with them  som e of the residual  
effects of their init ial therapy [43]. Minimizing potent ial long-term adverse effects while 
maintaining efficacy is an important goal in the treatment of RRMM [43,44] . However, currently 
available therapi[INVESTIGATOR_126856]. For example, the 
median PFS for pomalidomide+dexamethasone (pom +dex) in patients in their third or later line of 
therapy  in the registrati on-enabling MM -003 study (NIMBUS) [
45]was 3.8 months (95% CI, 
3.4-4.6 months) versus 1.9 months (95% CI 1.9 -2.1 months) with high -dose dexamethasone. 
Although the 3.[ADDRESS_142914] ically significant improvement 
over the 1.9 months, it was not a prolonged response. In that same study , pom +dex provi ded a 
4.1-mont
h improvement in OS. In addit ion, a study o f single -agent daratumumab used to treat a 
similar populat ion—US and EU patients with RRMM —showed a m edian PFS of 3.7 months and 
an ORR o f 29.2% [
46]. These survival and response findings support the observation that 
advanced MM cont inues to be an ar ea of high unmet need, including a need for treatment 
approaches that prolong disease control while minimizing burden to patients (safet y, oral 
convenience) and to the healt h care system. 
The convenience of the all -oral ixazo mib regimen benefits act ive wo rking pat ients in addit ion to 
those elderly or frail patients who would prefer to avo id traveling for frequent long hospi[INVESTIGATOR_6042]. 
Furtherm ore, the nursing t ime involved wit h administration of IV regimens as co mpared with the 
all-oral ixazo mib regimen is an important consideration, while the safet y profile speaks to patients’ 
abilit y to have a l ong-term regimen wit h maintenance o f disease control .
4.2.3 Benefit/Risk Assessment
[IP_ADDRESS] Benefits
Ixazo mib in co mbinat ion with LenDex has been approved by  [CONTACT_126899] r agencies for 
the treatment of patients with MM who have received at least 1 prior therapy  
[3,4]. The 
explorat ion of ixazomib for other therapeutic areas is ongoing. To date, activit y in MM has been 
seen with single -agent ixazo mib and wit h ixazo mib co mbined with established therapi[INVESTIGATOR_014]. In 
addition, single -agent activit y has been observed in relapsed amylo idosis and indo lent 
non
-Hodgkin lympho ma.
The pi[INVESTIGATOR_30338] 3 Study  C16010 was the basis for the ap proval , involving 722 patients with 
RRMM [4]. The primary endpoint of PFS was met in the ITT populat ion at the primary  analysis, 
with a significant PFS benefit for patients receiving ixazomib+LenDex versus placebo+LenDex 
(HR=0.742, p=0.012; median PFS 20.6 vs 14.7 months). The PFS benefit in the ixazo mib regimen 
was supported by  [CONTACT_126896]: ORR (78% vs 
72%), time to progression (TTP) (median, 21.4 vs 15.7 months), and duration of response (median, 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 25of [ADDRESS_142915] 2020
20.5 vs 15.0 months) at the primary analysis. At a median fo llow-up of approximately 23 months, 
the median OS had not been reached in either regimen; nevertheless, the 2-year OS rate was 77.5%, 
which is one of the largest achieved to date in phase [ADDRESS_142916] acebo -controlled study  of similar desi gn and the same inclusio n 
criteria, wi th 115 patients with RRMM, all enro lled in Chi na[5]. In thi s study , the primary 
endpo int of PFS was significant ly improved in the ixazo mib regimen as co mpared with the 
placebo regimen, wi th HR=0.598 and p=0.035 (with a median fo llow
-up of  approximately 
8months, the m edian PFS was 6.7 vs 4.0 months, respectively ). The PFS benefit in the ixazomib 
regimen was supported by  [CONTACT_126900] (56% vs 31%) and TTP (median 7.3 vs 4.1 months). The reasons for the shorter median 
PFS in the China Cont inuat ion populat ion than in the Study C16010 ITT populat ion are likely the 
fact that Chinese patients are diagnosed with MM when their disease is m ore advanced as 
compared with the global popul ation[47,48] and t hat the China Cont inuat ion pat ients were more 
frequently refractory to thalido mide (54% vs 12%, respectively ), which can cause reduced efficac y 
of subsequent lenalidomide -containing regimens [
49].At the final analysis, an OS benefit in favor 
of the ixazo mib+LenDex co mbination was observed [
6].In summary, the data fro m the China 
Continuat ion study  support Study  C16010 data, showing a positive treatment effect with the 
ixazo mib regimen.
The St udy C16010 and China Cont inuat ion findings are supportive of the current study . In both 
studi es, the addi tion of  ixazo mib to LenDex was associated with a survival benefit ; notably, all 
patients had RRMM that could have been pretreated with, but not refract ory to, IMi Ds and 
proteasome inhibitors. In Study  C16010 [
4],theIMiD -pretreated populat ionhad a similar PFS 
benefit with ixazo mib as did the IMiD -naïve population (HRs, 0.74 and 0.70), and the proteasome 
inhibitor -pretreated populat ion hada similar PFS benefit as did the proteasome inhibitor
-naive 
popul ation (HRs, 0.74 and 0.75). Thus, there is randomized evidence of an ixazo mib treatment 
effect in pat ients with at least 2 pri or lines of therapy , including pri or IMi D treatm ent and pri or 
proteasome inhibitor treatm ent, similar to the patients who will be enro lled in t he current study. On 
the basis of these findings, as well as support for doublet (rather than triplet) therapy (eg, [50], and 
the approval o f pom+dex for RRMM), thi s study  is being conduc ted to test the hy pothesis that 
ixazo mib in combinat ion with a corti costeroi d may be an effect ive treatment of RRMM.
Overall, i xazo mib show ssigns of  antitumor acti vity, as evi denced by [INVESTIGATOR_136] l east 50% reduction in 
disease burden in so me pat ients, including patients that have been heavily  pretreated as well as 
those wi th newly  diagnosed MM, and prolongs stabilizat ion of the underlying disease in other 
patients across all ongoing studies. Though addit ional data con tinue to be obtained to further 
establish the c linical benefit of this drug, the emerging data support the continued development of 
ixazo mib for the treatm ent of pati ents wi th hematol ogic and solid tum or malignancies as well as 
ixazo mib as part of doublet therapy for RRMM.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_142917] 2020
[IP_ADDRESS] Risks
Safety data supporting the higher ixazomib dose (5.5 mg weekly for 3 weeks in each 28-day cy cle) 
are available from  and colleagues at the Mayo Clinic [7,8] . The initial group of this study 
investigated single-agent oral ixazomib administered at 5.5 mg weekly for 3 weeks of a 28-day 
cycle with dexamethasone added if a patient had a suboptimal response (minimal response by [CONTACT_126901] 2 or lack of partial response [PR] at end of Cycle 4) or PD. Results observed in this initial 
experience with 5.5 mg ixazomib led to study modification, with the addition of a randomized 
portion, consisting of 2 treatment groups comparing oral ixazomib doses of 4 and 5.5 mg, each in 
combination with dexamethasone. These 2 groups inform the comparative safety, tolerability, and 
efficacy of ixazomib (4 or 5.5 mg) administered weekly for 3 weeks of a 28-day cycle plus oral 
dexamethasone (20 mg) administered on Days 1, 2, 8, 9, 15, and [ADDRESS_142918] received ≥1 prior lines of therapy and who are not refractory to 
proteasome inhibitor therapy.
Patients received a median of 7 cycles of therapy (range, 1-31 cycles) across the study; 53 (76%) 
and 34 (49%) patients received at least 4 and 8 cycles, respectively, and 21 (30%) patients 
continued in the study for >12 cycles. The median number of treatment cycles was similar for the 2 
groups: 8 (range, 1-28) and 7 (range, 1-31) for the 4 mg and 5.5 mg dose groups, respectively. The 
total number of cycles delivered was similar between the 2 groups, with 347 cycles administered to 
the 4 mg dose group and 341 for the 5.5 mg dose group.
Dose modifications for ixazomib were required in a higher proportion of pa tients in the 5.5 mg 
dose group compared with the 4 mg dose group (43% vs 17%), while dose modifications for 
dexamethasone occurred in 34% and 23%, respectively. Thus, more than half the patients starting 
treatment at 5.5 mg ixazomib continued treatmen t without dose modification. Treatment delays 
were equivalent between the 2 ixazomib dose levels, with 26% and 29% of patients requiring dose 
delays in the 4 mg and 5.5 mg ixazomib groups, resp ectively. In terms of delivered dose, 95% of 
the intended dose of ixazomib was delivered in the 4 mg group compared with 85% of the intended 
dose in the 5.[ADDRESS_142919] possibly related was reported in 100% of the 
patients in both groups. There were no treatment-related deaths in either group; 2 patients died on 
study in the 4 mg ixazomib group (respi[INVESTIGATOR_126857] [ADDRESS_142920] dose; pancreatic cancer approximately [ADDRESS_142921] dose; 
all were assessed as unrelated to study medication). Grade [ADDRESS_142922] possibly 
related to study treatm ent were reported for 9 (26%) and 2 (6%) patients in the lower-dose group 
and in 19 (54%) and 2 (6%) patients in the higher-dose group, respectively. Both of the Grade [ADDRESS_142923] 
common Grade ≥[ADDRESS_142924] possibly related to study treatment was seen in 33 patients 
(Grade 1), 8 patients (Grade 2), and 2 patient s (Grade 3; both in the 5.5 mg dose group). No 
cumulative hematological toxicity was observed in either group of the study, and the reported 
thrombocytopenia AEs usually resolved before the next cycle. Overall, the majority of AEs were 
Grade 3 or less in both the 4 mg and 5.5 mg ixazomib dose groups. Five patients discontinued the[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedy
dayay
eby [CONTACT_126902] e
n this inthis i
andomiandom
d 5.5 md 5.5 m
etty,y, tol to
8--daydayccy
he 28e 28-d
d who awho
 cycles)cycle
ectivelyectivel
er of trer of tr
mg and 5g and
en the 2en the 
se groupse grou
uired in red in
e group grou
23%, re23%, r
nued trued t
xazoazomibm
g ixazoixazo
mib wasmib w
up.p.
e that wthat w
groups. group
mmg ixagim
ately [ADDRESS_142925] 2020
study because of an AE (2 in the 4 mg ixazomib group; 3 in the 5.5 mg ixazomib group); these 
events included continued Grade 2 neuropathy and heart failure.
These data indicate that there is a subpopulation of patients who are able to tolerate 5.5 mg ixa+dex. 
In the current study design, the intent is to  identify this subpopulation based on excellent 
tolerability of ixazomib [ADDRESS_142926] the potential to dose escalate.
The investigators in the  study  recommended that careful attention be given to the toxicity 
associated with the hi gher dose and that timely dose reductions be considered to mitigate the 
adverse effects [7,8] . Indeed, to mitigate the inherent risks in clinical studies of ixazomib, patients 
are monitored closely for anticipated toxicities. Guidance for the management of AEs (see 
Section 8.8) and procedures for reducing doses (see Section  8.4) are provided, and drug dosage 
can be reduced either by [CONTACT_126903]. 
Further information is provided in the IB.
4.[ADDRESS_142927] will develop lenalidomide-resistant 
disease, alternatives to lenalidomide will be re quired in later lines of therapy. Also, use of a 
non-IMiD combination in this setting will lower the burdens placed on patients, health care 
providers , and health care clinics, because a Pregnancy Prevention Programme (European Union) 
or a REMS program ([LOCATION_002]) will no longer be required.
Although the typi[INVESTIGATOR_126858]-line therapy for patients with RRMM is triplet therapy, some triplet 
combinations have not shown superior efficacy over doublets involving dexamethasone 
(eg, bortezomib, melphalan, and prednisone [VMP] or bortezomib, thalidomide, and 
dexamethasone [VTD] vs bortezomib with dexamethasone [VD])—even among elderly patients 
being treated in community practices [50]. Dexamethasone-based doublets like VD have also been 
shown as effective and tolerable for elderly patients with RRMM [51]. Ixa+dex is a new 
potentially beneficial doublet therapy for RRMM patients. Furthermore, many elderly and/or 
heavily pretreated patients may not be able to tolerate the toxicity of a triplet drug combination.
4.3.2 Need for All-Oral Combination Therapi[INVESTIGATOR_126859]+dex and the comparator, pom+dex, are pa rticularly compelling options for third-line 
RRMM patients because many of these heavily pretr eated patients, who are in the later stages of 
their disease, may prefer an all-oral regimen. Such  a regimen will benefit patients who are not able 
or do not wish to travel to treatment clinics for week ly or more-frequent IV infusions. An entirely 
oral treatment option may therefore afford pati ents a better QOL. Furthermore, because the 
investigational regimen is an entirely oral th erapy, an all-oral, standard-of-care comparator, 
pom+dex, provides a balanced treatment burden between the 2 regimens.[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedex. x. 
 the toxthe to
mititigate igate
ixazomixazom
nt of AEt of A
ided, aned, a
g of the of th
ion Theon Th
e MM bMM
therapytherapy
elapse anlapse a
requireequir
l lower l lowe
ause a Puse a 
) will nowill n
therapy herap
wn supern supe
an, and n, and
 vs bortvs bor
munitmunit y
ve and tve and
neficial eficia
treated reate
Need Need
ThT
Both iBoth 
RRRR
t
Ixazomib
Study No. C16029 Page [ADDRESS_142928] 2020
A recently published study [52] summarizes cross-sectional data from >[ADDRESS_142929] commonly used induc tion regimens, and 61% of patients who received 
bortezomib at first line went on to receive lenalidomide at second line. Third-line therapy was 
more variable, with the therapi[INVESTIGATOR_126860], other agents (eg, bendamustine), 
and bortezomib retreatment (used in 43% of patients who had received it at first line). In the 
third-line setting, salvage therapy with either regimen in Study C16029—that is, an entirely oral 
combination of either pom+dex or ixa+dex—may be preferred by [CONTACT_126904] (either IV or subcutaneous) or treatment with another IV therapy, such as 
daratumumab, recently approved by [CONTACT_126905] a pro teasome inhibitor and an IMiD [37,53] .
Furthermore, the efficacy of available therap ies could be improved upon for this patient population. 
As noted above, in the NIMBUS study, use of pom+low-dose dex resulted in a median PFS of only 
4.0 months (95% CI, 3.6- 4.7 months). S imilarly, the median PFS with daratumumab was 4.0 
months (95% CI, 2.8-5.6 months) [54]. For this study, daratumumab was considered as a potential 
comparator; however, given that treatment with daratumumab requires travel to a clinic for IV 
infusion and premedication, an entirely oral combination was determined to be a more appropriate 
control for this study. In addition, a comparis on of ixa+dex to daratumumab single agent would 
not allow for the characterization of the ixazomib contribution to the observed treatment effect, 
unlike a comparison of ixa+dex to pom+dex, in which the dexamethasone contribution would be 
similar in both treatment groups. For this reason, this study will compare an experimental regimen 
including ixazomib, which typi[INVESTIGATOR_126861], but here will 
be combined with dexamethasone only. As a control regimen, pomalidomide will be used in 
combination with dexamethasone. 
4.3.3 Possible Benefit-Risk of Ixa+Dex versus Pom+Dex
Preliminary data suggest that, under some circumstances, ixa+dex may have favorable efficacy as 
compared with pom+dex.  and colleagues at the Mayo Clinic have conducted an 
investigator-initiated phase 2 study of ixazomib in patients with RRMM who were considered not 
refractory to bortezomib [ 7,8]. The preliminary data suggested that greater clinical benefit may be 
achieved with the use of ixa+dex, with 4 mg  and 5.5 mg doses of ixazomib, compared with 
historical data with pom+dex (described in Section  4.2.2 above). Therefore, this 
company-sponsored study is intended to provide furt her assessment on the feasibility and safety of 
the dose escalation of [ADDRESS_142930] received ≥[ADDRESS_142931] therapy. In this study , pom+dex will be administered to patients who 
have received ≥[ADDRESS_142932] of care for 
this patient population.[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses 
uststine), ine)
n the n the 
entntirirelyl
o retrearetre
apypy, suc, su
AgencyAgenc
pon for n for th
resulted esulte
FS with S wit
umumabmuma
umab remab r
on was dn was
ixa+dexa+de
b contribcon
in whichn whi
eason, thason, 
been stbeen 
ly. As ay. A
k of Ixaof Ix
that, unhat, u
dex. ex. 
ed phased phas
tezomibtezom
h the usethe 
data wita w ti
nyy--sponsspon
ose escose es
Pomomalidal
have hav
dedn-C[COMPANY_003]P
Ixazomib
Study No. C16029 Page [ADDRESS_142933] 2020
The risks of both pomalidomide and ixazomib in  the patient population eligible for this study 
appear manageable with appropriate prophylaxis, dose holds, and/or dose modification. In 
summary, patients receiving pomalidomide are likely to have greater risks of thromboembo lic 
events and neutropenia, while those receiving ixazomib are more at risk of experiencing 
thrombocytopenia and gastrointestinal events—all of which appear to be largely manageable with 
appropriate monitoring, prophylaxis, dose holds, and/or dose modifications.
4.3.4 Ixazomib Dose Rationale
The ixazomib dosing regimen for this study wa s informed by [CONTACT_16646] 2 Mayo Clinic study 
(conducted by  [INVESTIGATOR_20040] [7,8] and described in Section  [IP_ADDRESS]) of ixazomib in 
combination with dexamethasone conducted in patients with relapsed MM who were not 
refractory to bortezomib. In the randomized portion of the study with 2 treatment groups, patients 
received ixazomib at either 4 mg or 5.5 mg on Days 1, 8, and 15 of each 28-day cycle, in 
combination with 20 mg dexamethasone on Days 1, 2, 8, 9, 15, and 16 of each cycle. Thirty-five 
patients were randomized to each group.
The ORR for patients randomized to receive ixazomib at 5.5 mg was found to be higher (54%) 
than that for the 4 mg patients (31%). Additionally, a trend was observed between the average 
ixazomib dose (calculated to first best response [PR or better]) and the probability of ≥PR 
(p=0.0795, N=70), suggesting that higher doses of ixazo mib may result in higher ORR. Event-free 
survival was similar across the tertiles of average ixazomib dose; however, it should be noted that 
this small study was not powered to detect a statistically significant difference in event-free 
survival.
As noted in Section  [IP_ADDRESS],  a higher frequency of Grade ≥[ADDRESS_142934] 
possibly related to study therapy was observed in the 5.5 mg ixazomib group than in the 4 mg 
ixazomib group (54% vs 26%). Dose reductions for ixazomib were also required for a higher 
percentage of patients in the 5.5 mg ixazomib group (43%, vs 17% in the 4 mg ixazomib group).
Collectively, the available data from the randomized phase 2 study [7,8] indicate that both the 
4 mg and 5.5 mg doses of ixazomib are active, with  the 5.5 mg dose being associated with a higher 
ORR, although it is not yet known whether this dose will result in longer PFS. The 5.5 mg dose 
was associated with a higher frequency of AEs and more dose modifications.
As a result, in an effort to provide an opportunity for maximum clinical benefit without excessive 
toxicity, a 4 mg starting dose for ixazomib will be used in this study, with escalation to 5.5 mg at 
the start of Cycle 2 for those patients who tolerate the 4 mg dose in Cycle 1 (as specified in Section 
8.4.1) . Because the study  population is patie nts with advanced disease in later-line therapy, the 
timing of dose escalation at the start of Cycle 2 was selected so that patients who appear to be 
tolerating ixazomib can escalate quickly to a higher dose and potentially improve their chance of 
achieving disease control before experien cing PD. Also, the main potential AEs (eg, 
thrombocytopenia, gastrointestinal events, rash) are acute AEs that are expected to be seen early in 
the treatment course, further providing a rationale for an intrapatient dose escalation decision after 
Cycle 1.[COMPANY_003]
Property of Takyykeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useble e wiwiththiiii
yo Clinio Clin
))ofofiiffxax
MM whoM who
2 treatm2 trea
f each 2f each
and 16 and 1
t 5.5 mgt 5.5 m
trend wrend 
R or betor be
of ixazoof ixaz
rage ixage ix
t a statisa sta
er frequr freq
ywas obwas o
%). Dose). Do
he 5.5 mhe 5.5 m
able datble d
oses oes of ixf
t is not t is not
d with awith 
lt, in an , in a
, a 4 m, a 4 m
start start ofoff
.4.1.1)). B
timtiming
tolto
Ixazomib
Study No. C16029 Page 30of [ADDRESS_142935] developed 
resistance to lenalido mide in the second or later line. This study is designed to determine whether 
there is a subpopulat ion of pat ients for who m pom+dex is clinically  indicated but who m ay 
preferentially benefit from ixa+dex.
The sponsor expects there to be a significant number of patients in the [LOCATION_002] and Europ ean 
Unio n who would qualify for third -line salvage therapy in this study and would potentially benefit  
from either of these all -oral, doubl et study  therapi[INVESTIGATOR_014].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_142936] of ixa+dex versus pom+dex on PFS in patients with 
RRMM who have received at least 2 prior lines of therapy, including lenalidomide and a 
proteasome inhibitor, and are refractory to lenalidomide but not refractory to proteasome 
inhibitors.
5.1.2 Secondary Objectives
Secondary objectives are: 
!To compare OS in patients treated with ixa+dex versus pom+dex.
!To compare duration of response, ORR, time to response, and time to progression with 
ixa+dex versus pom+dex.
!To obtain health-related QOL data related to physical functioning of pa tients treated with 
ixa+dex versus pom+dex. 
!To assess health-related QOL by [CONTACT_126906] (EORTC) Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) instrument and by [CONTACT_126888]–
multiple myeloma module (EORTC QLQ-MY20) and 5-level classification system of the
EuroQol 5-Dimensional Health Questionnaire (EQ -5D-5L) instruments in patients receiving 
ixa+dex versus those receiving pom+dex.
!To evaluate HU by [CONTACT_126889]+dex versus those receiving pom+dex.
!To collect plasma concentration-time data for ixazomib to contribute to population PK 
characterization of ixazomib and to conduct exposure-response analyses for patients receiving ixa+dex.
5.1.3 Safety Objective
The safety objective is to compare the safety/tolerability of ixa+dex to that of pom+dex.
5.1.4 Exploratory Objective
[COMPANY_003]Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseHoweverHoweve
dex on Pdex on 
g lenalidenal
efractorfracto
dex versex v
time to ime t
a relatea rela
OL by [CONTACT_126907]--C30C3
momoduldu
mensioensio n
sus thossus th
uate HUuate H
collect collec
charactecharact
ixa+dixa
5.15.[ADDRESS_142937] occurrence of 
confirmed PD, as evaluated by [CONTACT_31691], according to International Myeloma Working 
Group (IMWG) criteria [55], or death from any cause, whichever occurs first.
5.2.2 Secondary Endpoints
Secondary endpoints are:
!OS, measured as the time from randomization to death from any cause.
!ORR, defined as PR, very good partial response (VGPR), or complete response (CR), as 
evaluated by [CONTACT_093], according to IMWG criteria [55].
!Duration of response, defined as the time from th e first documentation of PR  or better to first 
documentation of PD.
!Time to response, defined as the time from rando mization to the first documen tation of PR or 
better. 
!TTP, defined as the time from rando mization to first documentation of PD.
!Health-related QOL as measured by [CONTACT_126908]-C30.
!Health-related QOL as measured by [CONTACT_126909]-C30, by [CONTACT_70128]-MY20, and by [CONTACT_20367]-5D-5L.
!HU as measured by [CONTACT_126910].
5.2.3 Safety Endpoint
The safety endpoint is the safety/tolerability of ixa+dex versus pom+dex.
5.2.4 Exploratory Endpoint
[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee of of 
rking rking 
use.e.
mmplete pletemm
5]]..
documocum e
mizatmizat ioi
ioon to fn to 
he physhe phy
red by[CONTACT_126911]
Q-5D-5D-5L5
numbenumb
ointint
ntt is th is t
oratoryrato
perty of [COMPANY_005]:
Ixazomib
Study No. C16029 Page 33of [ADDRESS_142938] 2 prior lines of therapy. Eligible pat ients will be rando mized to 
receive ixa+dex (Arm A) or pom+dex (Arm B) in a 3:[ADDRESS_142939] ive response techno logy 
(IRT). The study  design is illustrated in Figure 6.a.
Figure 6.a Study Schema, From Randomization Through End of Therapy
Ixa=ixazomib; pom=pomalidomide; RRMM=relapsed and/or refractory multiple myeloma.
Note: There are 3 stratification factors in the study: International Staging System stage (I or II vs III at study entry), 
prior lines of therapy (2 vs 3 or more), and age (<65 vs ≥65 years).
6.1.[ADDRESS_142940] of adult patients (aged ≥18 years) who have an Eastern 
Cooperative Onco logy Group (ECOG) score of 0, 1, or 2; who have been diagnosed with MM 
according to IMWG criteria [55]; and who have measurable disease and document able isotype. All 
patients m ust have had a rel apse or PD after having received 2 or more prior lines of systemic 
therapy .
(Aline o f therapy is defined as 1 or morecycle sof a planned treatment program; this ma y
consist of [ADDRESS_142941], followed by [CONTACT_126912] 1 line o f therapy[1].Typi[INVESTIGATOR_897], each line of therapy  is separated by  [CONTACT_4002]. Discussio n 
with the medical monitor may help clarify the number of prior lines of therapy for each prospective 
study  participant. )
1.All patients must be refractory  to lenalido mide, defined as having received at least 
2consecutive cycles of lenalidomide as a single agent or within a lenalido mide-containing 
regimen and having had PD during treatment with or within [ADDRESS_142942] been 25 mg (or as low as 10 mg in 
the case of renal fun ction impairment or other safety  concern), and the final dose should have 
been a minimum o f [ADDRESS_142943] not be 
refractory  to proteasome inhibitors (ie, must have achieved at least a PR and not have had PD 
during treatment with or within [ADDRESS_142944] dose of bortezomib or carfilzo mib) or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 34of [ADDRESS_142945] bortezomib and/or carfilzo mib intolerance (i e, must have dis continued because of 
drug-related AEs before completion o f the planned treatm ent course) wi thout PD before the 
start of the next regimen. A Millennium project clinician or designee will confirm pat ient 
eligibilit y before rando mizat ion by [CONTACT_3170].
2.Patients wi th a pri or all ogenic bone marrow transplantation in any  prior line of therapy  are 
excluded. Patients with a prior autologous SCT in the last prior line of therapy are excluded, 
unless the autologous SCT was done a y ear or m ore before di sease pro gression. Exclusio n of 
patients on this basis aims not to interfere with the immune profiling endpo int. 
The 3 stratificat ion factors that will be used are ISS stage (I or II vs III) at study entry, prior lines o f 
therapy  (2 vs 3 or m ore), and age (<65 vs ≥65 y ears).
6.1.2 Study Therapy Dosing
Patients randomized to Arm A will receive oral ixazomib on Days 1, 8, and 15 of every  28-day 
cycle, as well as 20 mg oral dexamethasone (or 10 mg if patient is aged ≥75 years) on Days 1, 2, 8, 
9, 15, 16, 22, and 23 of every 28-day cycle. In cases where only 4 mg tablets for dexamethasone 
are available (eg, 4 mg dexamethasone is the only dosage available), the fo llowing dexamethasone 
schedule is recommended for patients aged ≥75 years: 12 mg dexamethasone will be given on 
Days 1, 8, 15, and 22 of every 28
-day cycle; and 8 mg dexamethasone will be given on Days 2, 9, 
16, and 23 of every  28-day cycle.
For Cy cle 1, all patients will receive a starting dose of 4 mg of ixazomib. Pat ients who do not 
experience any new Grade 1 periph eral neuropathy wi th pain or other ixazomib -related Grade ≥2 
nonhematologic or Grade ≥[ADDRESS_142946] clin ician or desi gnee.
Patients rando mized to Arm B will receive oral pomalido mide at a dose of 4 mg daily on Days 1 to 
21 of each 28- day cycle, as well  as 40 m g oral  dexam ethasone (or 20 m g if pat ient is aged 
≥75years) on Days 1, 8, 15, and 22 of each 28 -daycycle unt il PD. 
Neither pom alidomide nor dexamethasone will be dose escalated in this study .
6.1.3 Study Assessments
Secti on 9.4provides more informati on on study procedures, and Appendix Acontains the detailed, 
updated Schedule of Events for this study  (the previ ous, f ull Schedule of Events i s now m oved to 
Appendix Lfor reference only).
Only patients who continue to demonstrate clinical benefit but who do not have other means o f 
access to the study drugs will cont inue on the study. As no further formal statistical analyses will 
be perform ed, only  assessments contribut ing to long -term safet y data are requi red. Most study  
assessments besides safet y are discontinued to ease the burden of protocol -mandated assessments 
on pati ents.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 35of [ADDRESS_142947] udy drugs are arranged. When possible, patients should co mplete an EOT visit and 
transi tion onto an alternat ive supply of (eg, commercially available) ixazo mib or pomalido mide, 
as well as dexamethasone, or onto another standard of care treatment. Discont inued pati ents will  
be treated by  [CONTACT_79015] l ocal standard of care.
Upon implementation of Amendment 06, data collection requirements will be limited to collectio n 
of AEs and SAEs. All other study  assessments are no longer required . All central  laboratory  
assessments are discont inued. Qualit y of life and HUassessments are discont inued. Patients will 
not be fo llowed for the PFS or OS fo llow-up periods, because PFS and OS data are no longer being 
collected. See the updated Schedule of Events in Appendix A(the previous, full Schedule of 
Events is now moved to Appendix Lfor reference only).
[IP_ADDRESS] Assessments During the Treatment Period
Assessments Effect ive Only Before Amendment [ADDRESS_142948] study  assessments perform ed at regul ar intervals while they are participat ing in 
the study: weekly (Days 1 and 15) for 2 cycles and then once a cycle (on Day 1) for the remainder 
of the Treatm ent peri od, until  PD or di scontinuati on. In a ddition, in Arm B only, on Day  8 and 
Day 22 of  Cycles 1 and 2, hematologic laboratory  assessments will be performed. Patients will 
receive study  therapy  until  docum ented, confirmed PD (on the basis of the IMWG criteria), 
intolerable toxi cities, wi thdrawal  of consent, or sponsor terminat ion of study , whichever com es 
first. 
Patients will be assessed for disease response and progression, according to the IMWG criteria by 
[CONTACT_3170], for the purpose of treatment decisions, at every cycle during the Treat ment period.
ECOG performance score and AEs will be assessed, and laboratory  values and vital signs will be 
obtained to evaluate the safet y and tol erabili ty of the study  therapy . Toxi city will be evaluated 
according to National Cancer Inst itute Commo n Term inology Criteria f or Adverse Events (NCI 
CTCAE), versio n 4.03, effect ive date 14 June 2010. Clinical, laboratory, response, and QOL data, 
with an em phasis on tol erabili ty and symptom  burden, will be collected. 
QOL assessments will be collected at Screenin g. QOL and HU assessments will be collected on 
Day 1 of every  treatm ent cycle and at the EOT visit (as well as during the PFS Fo llow-up peri od 
and, for EQ -5D- 5L only, the OS Fo llow-up period; see next section). QOL and HU assessments 
shoul d be com pleted on the sam e day  as the study  visit, bef ore any other study  procedures are 
perform ed or study  therapy  is administered. 
Assessments Still in Effect as of Amendment 06
Unscheduled visits may  occur between treatm ent cycles as required. For example, symptomat ic 
pain progression should result in an interim unscheduled visit, as would ongoing Grade 3 or worse 
AEs. 
Patients will attend an EOT visit 30 days (+1 week) after receiving their last dose of study therap y 
or prior to the start of a new line of ant i-myelo matreatm ent, should that line start within [ADDRESS_142949] 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 36of [ADDRESS_142950] with the patient will be utilized as the EOT visit date. AEs/SAEs will be mo nitored
for all patients up to [ADDRESS_142951] dose of study  therapy  regardless of 
whether a patient starts a new line of therapy. 
Note: Related SAEs occurring during fo llow-up periods after the EOT visit must be reported to the 
Global P harm acovigilance department or designee. This includes deaths that the invest igator 
considers related to study  therapy  that occur during posttreatment follow -up. In addit ion, new 
primary  malignancies that occur during follow- up peri ods, i rrespect ive of cau sality to study 
therapy , must be reported tothe Global Pharmacovigilance depart ment or designee. Refer to 
Secti on 10.0 for details regarding defin itions, documentation, and reporting of SAEs.
[IP_ADDRESS] Assessments During the Follow -up Periods: PFS and OS
The fo llowing sect ion describes the study  design before Amendment 06 was implemented and is 
no longer relevant after that time but is retained below for refe rence only .
After a patient completes the EOT visit or a patient discont inues study therapy before confirmed 
PD, he/she will enter either a PFS or OS follow -up period ( Figure 6.b). Informat ion about any new 
primary  malignancies will be collected during the study, including during both follow -up peri ods. 
Patients who have stopped treatment for any  reason other than PD will enter the PFS Follow -
up 
period. Pati ents who have PD while on study  therapy  will skip the PFS Follow -up period and will 
enter direct ly into the OS Follow -up period. Patients in the PFS Follow -up period who have PD or 
start subsequent anticancer therapy  during this follow -up period will end PFS Fo llow-up and will 
enter into the OS Follow -up peri od.
Figure 6.bprovi des m ore detail  about both fo llow -up periods .
QOL and HU assessments will be co llected during the PFS Fo llow-up peri od at every  PFS 
Follow-up visit. QOL and HU assessments should be co mpleted on the same day as the fo llow-up 
visit, before any other study  procedures are performed. 
The only QOL assessment collected during the OS Fo llow
-up period is the EQ -5D- 5L assessment. 
This assessment will be co llected during the OS Follow -up peri od at every  OS Follow -up visi t. 
The assessmen t shoul d be co mpleted on the same day as the fo llow-up visit, before any other study 
procedures are performed. 
All assessments during the OS Follow- up period (including the EQ -5D- 5L) may be made over the 
telephone by  [CONTACT_126913] a clinic visit. Data may  be collected by  [CONTACT_126914], but are n ot limit ed to, tel ephone, em ail, mail , and soci al securi ty indexes. Both the 
patient and the current treating physician will be contact[CONTACT_126915] -up period to 
provi de info rmation about all MM treatments (best response, date of progression, drug regimen, 
start/stop date).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 37of [ADDRESS_142952] 2020
Figure 6.b Flow of Patients Through Follow -up Periods After the EOT Visit (Only in 
Effect Before Amendm ent 06)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 38of [ADDRESS_142953] 2020
[IP_ADDRESS] Other Assessment Details
An independent data monitoring co mmittee (IDMC) will review safet y data at regular intervals, 
approximately  every  [ADDRESS_142954]. 
After the data cutoff date for the study analysis has occurred, no further analyses are planned, and 
all central  efficacy  and investi gator assessments of disease response (ie, PFS, response rates, and 
TTP) for protocol purposes will be discont inued. As such, no further laboratory samples related to 
response assessments will be sent to the central laboratory.
6.1.[ADDRESS_142955] been observed (after 
approximately  [ADDRESS_142956] pati ent enrollment), for 80% power at a 2- sided 0.20 level of 
significance. Analysis o f all secondary endpo ints will occur at the same time as this study analysis, 
which is the only planned formal analysis for this study; no further formal analyses are planned. 
Long -term safet y dat a collected after the data cutoff date for the study analysis will be summarized 
descript ively in a clinical study  report addendum.
See Secti on 13.[ADDRESS_142957] been enrolled at 
approximately  100 study  sites gl obally: approximately  72 in Arm  A (ixa+dex) and approximately 
48 in Arm B (pom+dex). Enrollment is defined as rando mizat ion to a study  therapy .
6.3 Duration of Study
6.3.1 Duration of an Individual Patient’s Study Participation
Patients, including those who achieve a clinical response, may  receive st udy therapy  until  they 
experience PD, have an unacceptable toxicit y, or wit hdraw consent, or until the sponsor terminates 
the study .
6.3.2 End of Study/Study Completion Definition
The study  will be considered com plete after the study  analysis (for PFS and all se condary  
endpo ints) has been co mpleted or the study  has been terminated by  [CONTACT_456]. The estimated 
time frame for study  com pletion is approximately 28 months. 
6.3.3 Timeframes for Primary and Secondary Endpoints to Support Disclosures
Refer to Table 6.afor disclosures informat ion for all primary  and secondary  endpoints.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 39of [ADDRESS_142958] 2020
Table 6.a Primary and Secondary Endpoints for Disclosures
Endpoint Definition Maximum Time Frame
Primary : PFS The time from randomization to the first occurrence of 
confirmed PD, as evaluated by [CONTACT_093], according to 
IMWG criteria [55], or death from any cause, whichever occurs 
firstUp to 4 years
Secondary: OS The time from randomization to death from any cause Up to 4 years
Secondary: ORR PR, VGPR, or CR, as evaluated by [CONTACT_093], according 
to IMWG criteriaUp to 4 years
Secondary: Duration 
of responseThe time from the first documentation of PR or better to first 
documentation of PDUp to 4 years
Secondary: Time to 
responseThe time from randomization to the first documentation of PR 
or betterUp to 4 years
Secondary: TTP The time from randomization to first docume ntation of PD Up to 4 years
Secondary: 
Health -related QOL 
related to physical 
functioningThe phy sical functio ning domain of the EORTC QLQ -C30 Up to 4 years
Secondary: Other 
health -related QOLHealth -related QOL as measured by [CONTACT_126916] -C30, by [CONTACT_20368] -MY20, and by [CONTACT_941] 
5-level classification system of the EQ -5D -5LUp to 4 years
Secondary: Health 
care utilization (HU)HU as measured by [CONTACT_126917] 4 years
EORTC QLQ -C30: European Organizat ion for Research and Treatment of Cancer Quality of Life Questionnaire –
Core 30; EORTC QLQ -MY20: European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire –multiple myeloma module; IMWG: International Myeloma Working Group ; ORR : overall response 
rate; OS: overall survival; PD: progressive disease; PFS: progression -free survival; TTP: time to progression; QOL: 
quality  of life. 
6.3.[ADDRESS_142959] for approximately 28 months. However, the study durat ion 
is dependent on rate of accrual and of maturation of the different endpoints.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 40of [ADDRESS_142960] meet all of the fo llowing inclusion criteria to be enrolled in the study :
1.Male or female pat ients aged [ADDRESS_142961] a confirmed diagnosis of MM requiring therapy  according to IMWG criteria (see 
Appendix D).
3. ECOG performance status of 0 to 2 (see Appendix E). 
4.Must have had a relapse or PD after having received 2 or more prior lines of systemic therapy.
Note: A line of therapy is defined as 1 or more cycles of a planned treatment program; this ma y 
consist of [ADDRESS_142962], followed by  [CONTACT_126912] 1 line of therapy [1]. Typi[INVESTIGATOR_897] , each line of therapy is separated by [CONTACT_4002]. Discussio n 
with the m edical m onitor may  help clarify the number of lines of the rapy that a prospective 
study  participant had.
5.Must be refractory to lenalidomide, defined as having received at least [ADDRESS_142963] been 25 mg (or as low as 10 mg in the case of renal function 
impairment or other safet y concern), and the final dose should have been a minimum o f [ADDRESS_142964] 2 consecut ive cycles of a bortezomib -or carfilzo mib-containing 
regimen, and either:
– Achieved at least a PR and did not have PD during treatment with or within [ADDRESS_142965] dose of bortezomib or carfilzo mib, OR
–Had bortezomib and/or carfilzo mib intolerance (defined as discont inuat ion because of 
drug-related AEs before completion o f the planned treatm ent course) wi thout PD before 
the start of the next regimen.
7.Patients m ust have m easurable disease defined by: 
–Serum  M-protein ≥1 g/dL (≥10 g/L), OR
–Urine M -protein ≥200 m g/[ADDRESS_142966] documented MM isotype by 
[CONTACT_126918] (central laboratory ).
8.Patients m ust meet all of the fo llowing clinical laboratory  criteria:
–Absolute neutrophil count (ANC) ≥1000/mm3andplatelet count ≥75,000/mm3,without 
growth factor or transfusion support.
–Total  bilirubin ≤1.5 times the upper limit of normal (ULN).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 41of [ADDRESS_142967] 2020
–Alanine aminotransferase and aspartate aminotransferase ≤3×ULN.
–Calculated creatinine clearance ≥30 mL/min (see Section [IP_ADDRESS] ).
9.Female pat ients who:
–Are postm enopausal  for at l east 1 y ear before the Screening Visit, OR
–Are surgically  sterile, OR
–If they  are of  childbearing potential, agree to practice [ADDRESS_142968] ive (barrier) method at the same time, for [ADDRESS_142969] dose of study  therapy , 
OR
–Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulatio n 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not ac ceptable 
methods of contraception. Female and male condoms should not be used together.), AND
–In wom en of childbearing potential (if rando mized to Arm B), agree to have [ADDRESS_142970] (the first test 
shoul d be perform ed wi thin 10- 14 days before; the second, within 24 hours before); then 
have a negat ive pregnancy test weekly during the first month and monthly thereafter in 
wom en wi th regul ar menstrual  cycles or every  2 weeks thereafter in women with irregular 
menstrual cycles; and have a negative pregnancy test [ADDRESS_142971] dose of study  
therapy .
10.Male patients, even if surgically  sterilized (ie, status postvasectomy), who:
– Agree to practice effective barrier contraception durin g the ent ire study  Treatm ent peri od 
and through [ADDRESS_142972] dose of study therapy , OR
–Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulatio n 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.), AND
–Do not donate semen or sperm during treatment and for [ADDRESS_142973] medical care, with the understanding that consent may be withdrawn by 
[CONTACT_126919].
12.Suitable venous access for the study -requi red bl ood sam pling, including PK sampling.
13.Patient is willing and able to adhere to the study visit schedule and other protocol requirements 
including blood sampling and bone marro w aspi[INVESTIGATOR_39870] n.
14.Recovered (ie, Grade ≤1 nonhematologic toxicit y) from the reversible effects of prior 
anticancer therapy .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 42of [ADDRESS_142974] be willing and able to adhere to pomalido mide -related risk mit igation activit ies if 
rando mized to the pom+dex arm (eg, REMS, pregnancy prevent ion program s).
7.2 Exclusion Criteria 
Patients m eeting any o f the following exclusio n criteri a are not to be enrolled in the study :
1.Patients must not have received prior ixazo mib or pomalido mide and must not have been a 
participant in a previous ixazo mib clinical study.
2.Prior all ogenic bone marrow transplantation in any prior line of therapy  or pri or autol ogous 
SCT in the last prior line of th erapy —unless the autologous SCT was performed a year or more 
before disease progression. 
3.Female pat ients who are lactating and breastfeeding or have a positive serum pregnancy test 
during the Screening period. 
4.Any serious medical or psy chiatri c illness t hat could, in the invest igator’s opi[INVESTIGATOR_3078] n, potenti ally 
interfere wi th the com pletion of treatment according to this protocol, such as life -threatening 
illness unrelated to cancer.
5.Diagnosed wi th or treated for another malignancy  within [ADDRESS_142975] undergone co mplete resection.
6.Diagnosis of smo ldering MM (see
 Appendix D), Waldenström’s macroglobulinemia, POEMS 
(polyneuropathy , organom egaly, endocrinopathy , monoclonal gammopat hy, and skin 
changes) syndrome, plasma cell leukemia, primary amylo idosis, myelodysplast ic syndro me, 
or myelopro liferat ive syndro me.
7.Known allergy  to any  of the study  medicat ions or their analogues, or excipi[INVESTIGATOR_126862].
8.Peripheral  neuropathy  Grade [ADDRESS_142976] igational products or with chimeric or fully human monoclonal 
antibodies wit hin 30 days before rando mizat ion, systemic ant icancer therapy  or radi otherapy  
within 14 days before randomizat ion (Note: “spot” radiation for areas of pain is permitted), and 
major surgery  within [ADDRESS_142977] ion within 
14days before randomizat ion.
12.Central  nervous system invo lvement with MM (by [CONTACT_126920]).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 43of [ADDRESS_142978] ion, known human immunodeficiency virus -RNA posi tive, 
known hepat itis B surface ant igen seroposit ive, or known hepat itis C virus -RNA posi tive.
Note: Patien ts who have posit ive hepat itis B core ant ibody  can be enrolled but must have 
hepat itis B virus -DNA negative. Patients who have posi tive hepatit is C ant ibody  can be 
enrolled but must have hepatit is C virus -RNA negative.
14.Systemic treatment with strong cytoch rome P-450 3A inducers (rifampin, rifapent ine, rifabut in, 
carbamazepi[INVESTIGATOR_050], phenyto in, phenobarbital) or use of St. John’s wort within [ADDRESS_142979] ions such as 
Stevens -Johnson syndro me (SJS) , toxic epi[INVESTIGATOR_78950] (TEN), and drug reaction with 
eosinophilia and systemic symptoms (DRESS) , in the context of treatment with lenalido mide 
or thalido mide (see Section 8.7for more inform ation).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 44of [ADDRESS_142980] igator or ident ified subinvestigator(s). One cycle of study therapy at a time 
will be dispensed for oral dosing at home as direct ed in the Schedule of Events ( Appendix A). 
Patients m ay take study  therapy  at hom e as di rected. The date and time of each dose of study  
therapy  shoul d be recorded by  [CONTACT_126921]. Refer to the Study  Manual  for 
additional instructi ons regarding study  therapy  administrati on.
Patients shoul d be m onitored f or toxi city as necessary  and doses of the appropriate study  therapy  
shoul d be m odifie d as needed to accommodate patient tolerance to treatment; this may  include 
symptom atic treatment, dose holds, and adjust ments of the dose.
Each AE should be attributed to a specific drug (ie, ixazo mib, pomalido mide, or dexamethasone), 
if possible, so that dose modificat ions can be made accordingly. Only [ADDRESS_142981] ment per cycle 
will be performed for a given agent when toxicit y is suspected to be related primarily to that agent. 
Reduction o f 1 agent and not the other is appropriate if the toxicit y is suspected to be rel ated 
primarily to that 1 agent.
8.1 Investigational Therapy: Ixazomib Administration (Arm A)
Ixazo mib capsules will be supplied by [CONTACT_126922] 4 different dose strengths, 
containing 5.5, 4.0, 3.0, and 2.3 mg of ixazo mib. The dose strengths will allow for delivery o f the 
unit starting dose (4.0 mg), dose escalat ion to 5.5 mg, or dose reductions (2.3, 3.0 mg) as needed 
during treatment.
In patients randomized to Arm A, ixazo mib will be given as a single, oral dose weekly (Day s 1, 8, 
and 15) for [ADDRESS_142982] cycle of dose 
escalat ion to 5.5 m g of ixazomib; other cy cle doses m ay be taken at hom e. Refer to Section 
[IP_ADDRESS] and the Study Manual for addit ional instructi ons regarding study  therapy  administrati on.
The starting dose for ixazo mib is 4 mg, with escalatio n to 5.5 mg at the start of Cycle 2 for patients 
who tolerate the 4mg dose in Cycle 1 (specifically, patients who do not experience any new Grade 
1 peri pheral neuropathy  with pain or other ixazomib -related Grade ≥2 nonhemat ologi c or Grade 
≥3 neutropenia or thrombocy topeni ain Cycle 1). Patients who have had any dose reductions, holds, 
or delays because of ixazo mibtoxicities will not dose escalate. Dose escalat ion beyo nd the start of 
Cycle [ADDRESS_142983] . A 
doubl e dose shoul d not be taken to m ake up for a missed dose. If the patient vomits after taking a 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 45of [ADDRESS_142984] 2 hours before the ixazomib dose on the 
ixazo mib dosing days (see Section 8.3).
8.2 Reference/Control Therapy: Pomalidomide Administration (Arm B)
Patients rando mized to Arm B will be dosed with pomalido mide per local prescribing informat ion 
[41,42] :oral pom alidomide at a dose of 4 mg daily on Days 1 to 21 of each 28 -day cycle. 
Thromboprophylaxis is recommended (see Section 8.8.2). Also see local prescribing information
[
41,42] for further dosing instructions.
8.[ADDRESS_142985] of Care Therapy: Dexamethasone Administration (Both Arms)
Each treatm ent arm  will receive 40 m g of dexamethasone per week, with a difference in dosing 
schedule across study  arms. Patients in Arm A will receive a total of 40 mg dexamethasone split 
across 2 consecut ive days (to maximize the prophylact ic ant i
-emetic effect around the ixazo mib 
dosing) and patients in Arm B will receive a 40 mg dexamethasone dose in 1 day (as per the 
pomalidomide prescribing informat ion), as detailed below. 
Patients rando mized to Arm A will receive 20 mg oral dexamethasone (or 10 mg if patient is aged 
≥75 y ears) on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. In cases where only  4 mg 
tablets for dexamethasone are available (eg, 4 mg dexamethasone is the only dosage available), the 
following dexamethasone schedule is reco mmended for patients aged ≥75 y ears: 12 m g 
dexamethasone will be given o n Day s 1, 8, 15, and 22 of every  28-day cycle; and 8 m g 
dexamethasone will be given on Day s 2, 9, 16, and 23 of every  28-day cycle.
Patients rando mized to Arm B will receive 40 mg oral dexamethasone (or 20 mg if patient is aged 
≥75 y ears) on Days 1, 8, 15, and 22 of each 28
-day cy cle, per the pom alidomide local prescribing 
inform ationthat specifies dexamethasone dosing when used in co mbinat ion with pom alidomide 
[41,42] .
The dexamethasone dose will be determined by [CONTACT_102]’s age at time of rando mizat ion. In the 
event that a patient is aged 74 years or younger at rando mizat ion and turns 75 or older w hile taking 
part in the study , the pati ent’s dexamethasone dose will only  be changed fro m the dose at 
rando mizat ion in the event of dexamethasone -related AEs.
Dexamethasone should be taken at approximately the same t ime each dosing day. If a dose of 
dexame
thasone is missed, the dose should be taken as soon as the patient remembers it. If enough 
time has elapsed that it is almo st time for the next dose (within 6 hours), the missed dose should be 
skipped and the next dose taken according to the regular dosing schedule. A double dose should 
not be taken to make up for a missed dose. If the patient vomit s after taking a dose, the patient 
shoul d not repeat the dose but should resume dosing at the time of the next scheduled dose.
In patients randomized to Arm A, i t is recommended that dexamethasone be administered at least 2 
hours before the ixazo mib dose on the ixazo mib dosing days (to maximize the potential antiemet ic 
effect).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 46of [ADDRESS_142986] 2020
8.4 Dose Modification Guidelines
In general, if ixazomib , pom alidomide, or dexamethasone ar e delayed or held due to AEs or other 
safet y findings, then the corresponding study  therapy  shoul d also be del ayed or hel d, given that 
study  treatm ent is combinat ion therapy. Therefore, if ixazo mib is held, dexamethasone should also 
be held. Likewise, if p omalidomide is held, dexamethasone should be held. If dexamethasone is 
held, either ixazo mib or pomalido mide should be held, based on the patient’s treatment group 
determined at randomizat ion.
8.4.1 Intrapatient Dose Escalation of Ixazomib (Arm A)
A starting dos e of 4 mg of ixazomib will be used at Cycle 1 for all pat ients in Arm A. Patients who 
do not experience any new Grade 1 peripheral neuropathy  with pain or other ixazo mib-related 
Grade ≥2 nonhematologic or Grade ≥[ADDRESS_142987] clinician or designee. 
8.4.2 Criteria for Beginning or Delaying a Subsequent Treatment Cycle
[IP_ADDRESS] Criteria for Beginning the Next Treatment Cycle With Ixa+Dex (Arm A)
Treatment with ixazomib will be repeated every  28 day s in Arm  A. The cri teria for toxi city 
recovery  before the pati ent can begin the next cycle of treatment are as follows:
ANC ≥1000/mm3.
Platelet coun t ≥75,000/mm3.
All nonhematologi c toxicit y considered to be related to treatm ent with study therapy must have 
resolved to Grade ≤1 or to the patient’s baseline values or to a severit y level considered stable 
and tolerable by [CONTACT_093]/patient (eg, Grade 2 chronic kidney disease du e to underlying 
MM).
If the patient does not meet the above -cited cri teria for retreatm ent, ini tiation of  the next cycle of 
ixa+dex shoul d be delayed for [ADDRESS_142988] been met. If the patient continues to not meet 
the previously cited criteria, delay ixa +dex and continue to re -evaluate. Should the start of the next 
cycle need to be delayed ≥2 weeks because of incomplete recovery from treatment -related toxici ty, 
the ixa +dex doseswill be reduced by 1 dose level when therapy resumes. Should ixa +dex need to 
be delayed for 4 weeks because of inco mplete recovery  from treatm ent-related toxicit y, ixa+dex
shoul d be discont inued or dose reduction of [ADDRESS_142989] igator’s view, therapy st ill has a reasonable probabilit y of provi ding a benefit. 
Resumpt ion of cycles after [ADDRESS_142990] clinician or 
designee.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 47of [ADDRESS_142991] 2020
[IP_ADDRESS] Criteria for Beginning the Next Treatment Cycle With Pom +Dex (Arm B)
Treatment with pom+dex will be repeated every 28 day s in Arm  B. The cri teria for toxi city 
recovery  before the patient can begin the next cycle are outlined in the pom+dex local prescribing 
inform ation [41,42] .
8.4.3 Ixazomib Treatment Modification (Arm A)
Patients experiencing AEs attributed to ixazo mib may cont inue in the study but may have doses of 
ixazo mib held or reduced by [CONTACT_2669] [ADDRESS_142992] Dose Reduction Fourth Dose Reduction
4 mg 3 mg 2.3 mg Discontinue ixazomib --
5.5 mg 4 mg 3 mg 2.3 mg Discontinue ixazomib
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 48of [ADDRESS_142993] 2020
Table 8.b Ixazomib Dose Modification for Hematologic Toxicities
Criteria Action
Within -Cycle Dose Modifications
If platelet count ≤50109/L or ANC 
≤0.75 109/L on an ixazomib dosing day 
(other than Day 1)Ixazomib dose should be withheld. Complete blood count with 
differential should be repeated at least weekly or more frequently until 
the ANC and/or platelet counts have exceeded the prespecified values 
(ANC ≥1.0×109/L; platelet coun t ≥75×109/L). Upon recovery, 
ixazomib may be reinitiated and reduced by 1 dose level in 
accordance with reductions outlined in Table 8.a.
Dose Modifi cations for Subsequent 
Treatment Cycles 
Delay of ≥2 weeks at the start of a 
subsequent cycle because of lack of toxicity 
recover y as defined in Section 8.4.2 : 
ANC <1.0 109/L; platelet count <75 109/L 
(Or other nonhematologic toxicities Grade 
>1 or not to the patient’s baseline condition)Hold ixazomib until resolution per criteria.
Reduce ixazom ib by 1 dose level as outlined in Table 8.a.
The maximum delay before treatment should be discontinued will be 
4 weeks (except in the case of investiga tor-
determined clinical benefit 
and discussion with the project clinician or designee, at which time a 
reductio n of 1 or mo re dose levels should be made).
All hematologic toxicities For hematologic toxicity that occurs during a cycle but recovers in 
time for the start of the next cycle:
If dose was reduced within the cycle, start the next cycle at that same 
dose.
If because of timing –ie, a toxicity after Day 15 dosing such that a dose 
reductio n was not required at that point in the cycle –then reduce 
ixazom ib by [ADDRESS_142994] severe toxicity.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 49of [ADDRESS_142995] 2020
Table 8.c Ixazomib Dose Modification for Nonhematologic Toxicities
Criteria Action
Peripheral Neuropathy
Grade 1 peripheral 
neuropathy  No action Grade 1 signs and symptoms: asymptomatic, 
without pain or loss of function, clinical or 
diagnostic observations only
Worsening Grade 1 
peripheral neuropathy  (ie, 
Grade 1 with pain) or 
Grade 2Hold ixazomib until resolution to 
Grade ≤1 without pain or baseline.Grade 2 signs and symptoms: moderate 
symptoms, limiting instrumental activities of 
daily  living
New or worsening Grade 2 
peripheral neuropathy with 
pain or Grade 3Hold ixazomib until resolution to 
Grade ≤1 or baseline.
Reduce ixazomib to next lower dose 
upon recovery as outlined in 
Table 8.a.Grade 3 signs and symptoms: severe 
symptoms, limiting self -care activities of daily 
living, assistive device indicated
New or worsening Grade [ADDRESS_142996] clinician 
or designee may discuss considerations for dose modifications and symptom 
management.
All other Grade ≥2 
nonhematologic toxicitiesHold ixazomib until resolution to Grade ≤1 or baseline.
Reduce ixazomib by 1 dose level as outlined in Table 8.a.
Note: A dose level reduction will be made either on the basis of within -
cycle criteria or 
subsequent cycle criteria but not both for the same cycle.
Grade [ADDRESS_142997] 1 level.
ANC: absolute neutrophil count. 
Table 8.d Criteria for Ixazomib Retreatment and Cycle Delays Subsequent to 
Hematologic and Nonhematologic Toxicities
Criteria Action
Both hematologic and 
nonhematologic 
eventsDelay ixazomib for 1 week.
Re-evaluate patient; if still not resolved, delay ixazomib for 1additional week.
Hematologic and 
nonhematologic 
events not resolved 
after 1 -week treatment 
delayIf initiation of subsequent therapy needs to be delayed for more than 2 weeks because of 
incomplete recovery from treatment -related toxicity, the dose of ixazomib will be reduced 
by 1 dose level as outlined in Table 8.awhen treatment resumes.
The maximum delay before treatment should be discontinued will be 4 weeks (except in the 
case of investigator -
determined clinical benefit and discussion with the project clinician or 
designee at which time dose reduction by [CONTACT_2669] 1 dose level should be considered). 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 50of [ADDRESS_142998] 2020
8.4.4 Pomalidomide Treatment Modification (Arm B)
All po malidomide treatment modifications are according to the local prescribing informat ion 
[41,42] . 
Patients experiencing AEs attributed to pomalido mide may have doses of pomalidomide held or 
reduced by [CONTACT_2669] 1 dose level as noted in the local prescribing informat ion [
41,42] . When a dose 
reducti on of po malidomide is required because of toxicit y, no dose re -escalat ion will be permitted. 
If a patient experiences angioedema, skin exfo liation, bullae, or any other severe cutaneous 
reacti on such as SJS, TEN, or DRESS, treatment with pomalido mide should be immediately and 
perm anent ly discont inued. The patient should additional
ly discontinue treatm ent wi th 
dexamethasone and remain on study  for PFS and OS follow -up. 
8.4.5 Dexamethasone Treatment Modification (Both Arms)
Patients experiencing AEs attributed to dexamethasone may have doses of dexamethasone held or 
reduced by [CONTACT_2669] [ADDRESS_142999] Dose 
Reduction
Arm A
For patients aged <75 yr
20 mg 
on Days 1, 2, 8, 9, 15, 16, 22, and 2320 mg
on Days 1, 8, 15, and 
2210 mg
on Days 1, 8, 15, and 22
OR, if only 4 mg tablets are available
12 mg on Day 1, 8 mg on Day 8, 12 mg 
on Day 15, and 8 mg on Day 22Discontinue 
dexamethasone
For patients aged ≥75 yr
10 mg
on Days 1, 2, 8, 9, 15, 16, 22, and 23
OR, if only 4 mg tablets are available
12 m g on Days 1, 8, 15, and 22
8 mg on Days 2, 9, 16, and 2312 mg
on Days 1, 8, 15, and 
228 mg
on Days 1, 8, 15, and 22Discontinue 
dexamethasone
Arm B (per pomalidomide local 
prescribing information )
For patients aged <75 yr
40 mg
on Days 1, 8, 15, and 2220 mg
on Days 1, 8, 15, and 
2210 mg
on Days 1, 8, 15, and 22
OR, if only 4 mg tablets are available
12 mg on Day 1, 8 mg on Day 8, 
12 mg on Day 15, and 8 mg on Day 22Discontinue 
dexamethasone
For patients aged ≥75 yr
20 mg
on Days 1, 8, 15, and 2212 mg
on Days 1, 8, 15, and 
228 mg
on Days 1, 8, 15, and 22Discontinue 
dexamethasone
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 51of [ADDRESS_143000] 2020
Table 8.f Dexamethasone -Related Treatment Modification (Delays, Reductions, and 
Discontinuations) Guidelines Because of AEs [56]
AE (Severity) Actio n on Dexamethasonea
Gastrointestinal Dyspepsia, gastric, or duodenal ulcer, 
gastritis Grade 1-2 (requiring medical 
management)Treat with histamine -[ADDRESS_143001] despi[INVESTIGATOR_126863], decrease dexamethasone by 1 dose level.
Grade ≥3 (requiring hospi[INVESTIGATOR_78947] )Hold dexamethasone until symptoms adequately 
controlled. Restart and decrease [ADDRESS_143002] despi[INVESTIGATOR_37104], discontinue 
dexamethasone and do not resume.
Acute pancreatitis Discontinue dexamethasone and do not resume.
Cardiovascular Edema Grade >2 (limiting function and 
unresponsive to therapy or anasarca)Diuretics as needed and decrease dexamethasone by [ADDRESS_143003] 
despi[INVESTIGATOR_64332].
Neurological Confusion or mood alteration Grade >[ADDRESS_143004] 
despi[INVESTIGATOR_37104], discontinue dexamethasone 
and do not resume.
Musculoskeletal Muscle weakness Grade >2 (inter fering 
with function interfering with 
activities of daily living)Decrease dexamethasone dose by [ADDRESS_143005].
Metabolic Hyperglycemia Grade ≥3 Treatment with insulin or oral hypoglycemics as 
needed. If uncontrolled despi[INVESTIGATOR_37104], 
decrease dose by 1 dose level until levels are 
satisfactory.
Other: Grade 3 dexamethasone -related events Hold dexamethasone u ntil symptoms resolve to Grade 
≤2; then resume with dose reduced by 1 dose level.
AE: adverse event.
aIf recovery from toxicities does not occur within 14 days, then the dose of dexamethasone will be decreased by 
1dose level.
8.4.6 Criteria for Discontinuation of Study Drug
Grade 4 nonhematologic toxicit ies (considered related to treatment) will, in general, require that 
treatm ent wi th study  therapy  be perm anently discont inued. If, in the opi[INVESTIGATOR_3078] n of the investigator 
and the project c linician or designee, it is in the patient’s best interest to continue treatment with 
study  therapy , then the dose of study therapy will be reduced by [CONTACT_2669] 1 dose level in subsequent  
cycles of treatm ent after recovery  of the toxi city or toxi cities in q uestion to Grade 1 or to baseline 
values. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 52of [ADDRESS_143006] 2020
8.5 Excluded Concomitant Medications and Procedures
The fo llowing m edicat ions and procedures are prohibited during the study :
Systemic treatm ent wi th any of the fo llowing drug -metabolizing enzyme inducers should be 
avoided unless there i s no appropriate alternat ive medicat ion for the pati ent’s use. (Rationale: if 
there were to be a drug -drug interaction wit h an inducer, ixazo mib exposure would be decreased.)
Strong cy tochrom e P-450 3A inducers: rifampin, rifapent ine, r ifabutin, carbamazepi[INVESTIGATOR_050], 
phenyto in, phenobarbital, and St John’s wort.
Refer to the local prescribing informat ion for drug -drug interaction informat ion for pomalidomide 
[41,42] .
The fo llowing procedures are prohibited during the treatment period of the study :
Any ant ineoplast ic treatment with act ivity against MM, other than study  therapy .
Radiation therapy  (note that, in general, the requirement for local radiat ion therapy  indicates 
PD).
8.6 Permitted Concomitant Medication s and Procedures
All necessary  supportive care consistent with optimal patient care will be available to patients, as 
necessary . All bl ood products and concomitant medicat ions received fro m the signing of the 
inform ed consent form  until 30 days after the f inal dose of study  therapy  will be recorded in the 
eCRFs. 
The fo llowing m edicat ions and procedures are permitted during the study : 
Myel oid growth factors (eg, granulocy te col ony stimulating factor [G -CSF], granulocyte 
macrophage -colony stimulating factor ) are permitted. Their use should fo llow the l ocal 
prescribing information, published guidelines, and/or inst itutional practi ce; however, 
alternat ive usage may be reviewed wit h the Millennium pro
ject clinician or designee. 
Long -acting growth factors (eg, p egylated G -CSF) are not permitted, however. My eloid 
growth factors may  not be used during the Screening period to meet the neutrophil eligibilit y 
requi rements.
Erythropoi etin will be allowed in this study. The use of erythropoietic agents carries a risk of
thrombotic events including thromboembolism. Therefore, ery thropoi etic agents, as well as 
other agents that may increase the risk of thromboembo lic events, should be used with caut ion 
in combinat ion with pom alidomide therapy  (Arm B).
Patients shoul d be transfused with red cells and platelets as clinically indicated. Platelet 
transfusio ns m ay not be used during the Screening period to meet the platelet eligibilit y 
requi rements.
Patients who are receiving bone -healing agents, such as bisphosphonates or den osumab, for 
previously identified ly tic destructi on of  bone or wi th osteopeni a may  cont inue treatment 
according to the American Societ y of Clinical  Oncology Clinical  Practi ce Guidelines or 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 53of [ADDRESS_143007] ice in accordance wit h the l ocal prescribing inf ormation, unless specifically 
contraindicated. If bone -healing –agent therapy  was not started before the study start, init iation 
of treatm ent shoul d be discussed with the Millennium project clinician or designee. 
Supportive measures consistent with optimal patient care m ay be given throughout the study .
8.7 Precautions and Restrictions
Fluid deficit should be prompt ly corrected before init iation of, and during treatment with, 
ixazo mib(in Arm A).
Nonsteroidal ant i
-inflammatory drugs (NSAIDs) should be avo ided w ith impaired renal function 
given reported NSAID -induced renal failure in patients with decreased renal funct ion.
Cauti on shoul d be used when administering contrast materials for imaging.
It is not known what effects ixazomib and pomalidomide have on human pregnancy  or 
development of the embryo or fetus. Therefore, female pat ients participating in this study  shoul d 
avoid beco ming pregnant, and male patients should avo id impregnat ing a female partner. 
Nonsterilized female patients of reproductive age group a nd m ale patients should use effect ive 
methods of contraception through defined periods during and after study  treatm ent as specified 
below.
Female pat ients who:
Are postm enopausal  for at l east 1 y ear before the Screening visit, OR
Are surgically  sterile, O R
If they  are of  childbearing potential, agree to practice [ADDRESS_143008] ive (barrier) method at the same time, for [ADDRESS_143009] dose of stu dy therapy, OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the pati ent. (Peri odic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.), AND
In women o f childbearing potential who are randomized to Arm B (pom+dex), have [ADDRESS_143010] (the first test should 
be perform ed wi thin 10 -14 day s before; the second, within 24 hours before); then have a 
negat ive pregnancy test weekly during the first month and monthly thereafter in wo men with 
regul ar menstrual cycles o r ever y 2 weeks thereafter in women wit h irregular menstrual cycles; 
and have a negative pregnancy test [ADDRESS_143011] dose of study  therapy .
Male patients, even if surgically  sterilized (ie, status postvasectomy), who:
Agree to practice effective barrier contraception during the ent ire study  Treatm ent peri od and 
through [ADDRESS_143012] dose of study therapy, OR
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 54of [ADDRESS_143013] 2020
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the pati ent. (Peri odic abst inence [eg, cal endar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.), AND
Do not donate semen or sperm during treatm ent and for [ADDRESS_143014] ics (SmPC) of pomalido mide (Imnovid) [57]. 
Management of current study  patients and enrollment of future study  patients who have a history  
of severe cutaneous reactions, including hyp ersensit ivity react ions, in the context of treatment 
with pom alidomide, l enalido mide, or thalido mide, is required as fo llows: 
a.For all patients assigned to pomalido mide+dexamethasone treatment and who were 
enrolled prior to the C16029 protocol amendment [ADDRESS_143015] ive date:
i.Inform  patients of the newly ident ified safet y risk and document this step 
clearly  within the pati ent's source documentati on. 
ii.Obtain medical history  regarding severe cutaneous reactions to 
lenalido
mide, thalido mide, or pomalido mide (on -study) and immediately  
discontinue treatm ent wi th pomalido mide in those patients with a posit ive 
history  of skin reacti ons consistent wi th angioedema, skin exfo liation, 
bullae, or any  other severe cutaneous reactions such as SJS, TEN, or 
DRESS; do not resume therapy .
b.For all patients currently in screening and all future screened patients after the 
C16029 protocol amendment [ADDRESS_143016] ive date:
i.Inform  patients of this newly ident ified safet y risk and document this step 
clearly  within the pati ent's source docume ntation.
ii.If a patient has experienced a severe cutaneous reaction as part of prior 
treatm ent wi th lenalido mide or thalido mide, the patient must be excluded 
from Study C16029.
8.[ADDRESS_143017] ic ant iviral therapy, such as acyclo vir, valacyclo vir, or other antivirals, 
are recommended unless clinically  contraindicated. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 55of [ADDRESS_143018] 
(see Section 8.3). Any  fluid defici t occurring during treatment should be prompt ly corrected.
Diarrhea
Diarrhea shoul d be managed according to clinical practice, including the administration of 
antidiarrheals once infect ious causes are excluded. Fluid intake should be maintained to avoid 
dehydrat ion. Any fluid deficit occurring during treatment should be p romptly corrected.
Erythematous Rash With or Without Pruritus
Rash may  range from  limited ery thematous areas, macular or small papular bumps that may or 
may not be prurit ic over a few areas o f the body , to a m ore generalized eruption that is 
predominant ly on the trunk or extremit ies. Rash has been most commonly characterized as 
maculopapular or macular. To date, when it does occur, rash is most commo nly reported within the 
first [ADDRESS_143019] ions, etc.
Symptom atic m easures such as ant ihistamines or corticosteroids (oral or topi[INVESTIGATOR_2855]) have been 
succes sfully used to manage rash and have been used prophylactically  in subsequent cy cles. The 
use of a topi[INVESTIGATOR_2855], IV, or oral steroid (eg, prednisone ≤10 m g per day  or equivalent) i s permitted. 
Management of a Grade 3 rash may require IV antihistamines or cortico steroi ds. Administration of 
ixazo mib (and other causative agent if given in combinat ion) should be modified per protocol and 
reinit iated at a reduced level fro m where rash was noted (also per protocol).
In line with clinical practice, dermatology consult a nd biopsy of Grade 3 or higher rash or any SAE 
involving rash is reco mmended. Prophylactic measures should also be considered if a patient has 
previously developed a rash (eg, using a thick, alcohol -free emo llient cream on dry  areas of the 
body  or oral  or topi[INVESTIGATOR_12669]). 
The rare risks of Stevens -Johnson syndro me, TEN, drug reaction with eosinophilia and systemic 
symptoms (DRESS syndro me), and pemphigus vulgaris have been reported in onco logy studi es 
when ixazomib (or placebo) was given wit h conco mitant medicat ions that are known to cause rash 
(eg, Bactrim, lenalido mide, aspi[INVESTIGATOR_248]), and/or in the setting of confounding treatment -emergent 
adverse events (TEAEs). These severe, potentially life -threatening or deadly condit ions m ay 
involve rash with skin peeling and m outh sores and shoul d be clinically managed according to 
standard m edical practice. Punch biopsies for histopathological analysis are encouraged at the 
discreti on of the investigator. Additional information regarding these reactions can be fo und in the 
IB.
Thrombocytopenia
Blood counts shoul d be m onitored regul arly as outlined in the protocol, with addit ional testing 
obtained according to standard clinical pract ice. Thro mbocytopenia may be severe but has been 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 56of [ADDRESS_143020] ice. Ixazo mib 
administration should be modified according to dose modificat ion recommendat ions in the 
protocol  when thrombocy topenia occurs (see Section 8.4.3). Therapy  can be reinit iated at a 
reduced l evel upon recovery  of platelet counts. Thromboti c microangiopathy (TMA), including
thrombotic thrombocy topenia purpura (TTP) and hemo lytic uremic syndro me(HUS) , 
arerare, 
serious blood disorders that cause low levels of platelets and red blood cells and result in blood 
clots in small  blood vessels. Symptom s may  include fati gue, f ever, brui sing, nose bleeds, and 
decreased urinat ion. These disorders , including fatalcases, have been reported in patients 
receiving ixazo mib. TMA shoul d be managed according to standard medical pract ice.
Neutropenia
Blood counts shoul d be m onitored regul arly with addi tional testing, as appropri ate, according to 
standard clinical pract ice. Neutropenia may be severe but has been manageable. Growth factor 
support is not required but may be considered according to standar d clinical pract ice. Ixazo mib 
administration should be modified according to dose modificat ion recommendat ions in the 
protocol  when neutropeni a occurs (see Section 8.4.3 ). Febrile neutropenia should be managed as 
per local guidelines. Therapy can be reinit iated at a reduced level upon recovery  of ANC. 
Fluid Deficit
Dehydrat ion should be avo ided because ixazo mib may cause vo miting, diarrhea, and dehy dration. 
Acute renal failure has been reported in patients treated with ixazomib, commo nly in the setting of 
the previously  noted gastrointestinal toxicit ies and dehydrat ion.
Fluid deficit should be prompt ly corrected before administration of ixazomib and as needed during 
treatm ent to avoi d dehydrat ion.
Hypotension
Symptom atic hypotensio n and orthostatic hypotension wit h or without syncope have been 
reported with ixazo mib. Blood pressure should be closely mo nitored as per standard of care while 
the pati ent is on study  treatm ent, and fluid deficit should be corrected as needed, especially in the 
setting of conco mitant symptom s such as nausea, vomit ing, diarrhea, or decreased appetite. 
Patients taking m edicati ons or di uretics to manage their blood pressure (fo r either hypotensio n or 
hypertensio n) should be managed according to standard clinical practice, including considerat ions 
for dose adj ustments of their conco mitant m edicat ions during the course of the trial. Fluid deficit 
shoul d be corrected before adminis tration of  ixazomib and as needed during treatment to avoid 
dehydrat ion.
Posterior Reversible Encephalopathy Syndrome
Posterior reversible encephalopathy  syndrom e has been reported with ixazo mib. This condit ion is 
usually transient and reversible. It is c haracteri zed by  [CONTACT_12704], seizures, and visual loss, and 
abrupt increase in blood pressure. Diagnosis may be confirmed by  [CONTACT_79038] 
(MRI) or com puted tom ography  (CT). If the syndrom e is di agnosed or suspected, 
symptom -directed treatm ent sh ould be m aintained unt il the condit ion is reversed by [CONTACT_126923] n or other inst igating factors.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 57of [ADDRESS_143021] 2020
Transverse Myelitis
Transverse myelit is has been reported with ixazo mib. It is not known whether ixazo mib causes 
transverse myelit is; however, becau se transverse myelit is happened to a patient receiving 
ixazo mib, the possibilit y that ixazomib may have contributed to the transverse myelit is cannot be 
excluded. Transverse myelit is should be managed according to standard medical practice.
Overdose
An ove rdose is defined as a known deliberate or accidental administration of invest igational drug, 
to or by a study subject, at a dose above that which is assigned to that individual subject according 
to the study  protocol . If overdose occurs, consider close obs ervati on including hospi[INVESTIGATOR_126864]. Gastric lavage may be considered if inst ituted within [ADDRESS_143022] ion of 
ixazo mib overdose.
8.8.2 Pomalidomide
See the pomalido mide local prescribing informat ionfor more informat ion [41,57] .
Arterial and Venous Thromboembolism
Venous thromboembo lic events (deep venous thrombosis and pulmo nary embo lism) and arterial 
thromboembo lic events (myocardial infarct ion and stroke) have been observed in pat ients treated 
with pom alidomide. Pati ents wi th known risk factors, including prior thrombosis, may be at
greater ri sk, and act ions should be taken to try  to minimize all modifiable factors 
(eg,hyperlipi[INVESTIGATOR_035], hypertensio n, sm oking).
Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment 
of the pati ent’s underlying risk fa ctors and l ocal practi ce gui delines. Pati ents shoul d be instructed 
to seek m edical care if they develop symptoms such as shortness of breath, chest pain, arm or leg 
swelling. Anticoagulat ion therapy  (eg, acetylsalicylic acid, warfarin, heparin or clopi[INVESTIGATOR_126865]) is 
recommended unless contraindicated, especially in patients with addit ional thro mbotic risk 
factors.
The use of ery thropoi etic agents carries a risk of thrombotic events including thromboembo lism. 
Therefore, ery thropoi etic agents, as well as other ag ents that may  increase the risk of 
thromboembo lic events, should be used with caut ion.
Erythematous Rash With or Without Pruritus 
Pomalidomi de hol d or di scont inuat ion shoul d be consi dered f or Grade [ADDRESS_143023] be discont inued perma nently for any  Grade 4 rash.
Severe Cutaneous Reactions
Pomalidomi de administrati on shoul d be immediately  and perm anent ly discont inued for 
angioedema, skin exfo liation, bullae, or any  other severe cutaneous reaction such as SJS, TEN, or 
DRESS.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 58of [ADDRESS_143024] 2020
Thrombocytop enia
Pomalidomi de administrati on shoul d be m odified according to dose modificat ion 
recommendat ions in the protocol when thrombocy topeni a occurs (see Secti on 8.4.4 ). 
Neutropenia
Pomalidomi de administrati on shoul d be m odified according to dose modificat ion 
recommendat ions in the protocol when neutropenia occurs (see Section 8.4.4 ). Therapy can be 
reinit iated at a reduced level upon recovery  of ANC. In case of neutropenia, growth factor use 
shoul d be considered.
8.8.3 Dexamethasone
See the dexamethasone local prescribing informat ionfor management of any  
dexamethasone -related clinical events [58].
8.9 Blinding and Unblinding
This is an open -label study . 
8.10 Description of Investigational Agents
8.10.1 Ixazomib
The ixazo mib capsule formulat ion consists of the drug substance (ixazo
mib citrate), 
microcrystalline cellulo se, tal c, and magnesium stearate. There ar e 4 capsule strengths: 2.3, 3.0, 
4.0, and 5.[ADDRESS_143025] ease see the ixazo mib IB and Pharmacy Manual.
[IP_ADDRESS] Preparation, Reconstitution, and Dispensation
Ixazo mib is dispensed in a blister pack in a child -resistant carton. For the 2.3, 3.0, 4.0, and 5.5 mg 
capsule strengths, there are 3 capsules in each wallet/carton. 
Ixazo mib is an ant icancer drug, and as with other potentially  toxic com pounds, caution should be 
exercised during handling. See the Pharmacy Manual for more informat ion.
[IP_ADDRESS] Packaging and Labeling
Ixazo mib will be provided by [CONTACT_20555]. The ixazomib local prescribing informat ion will fulfill 
all requirements specified by [CONTACT_126924].
[IP_ADDRESS] Storage, Handling, and Accountability
On receipt at the invest igative site, ixazo mib should remain in the blister pack and carton provided 
until use or dispensation. For storage condit ions, refer to the Pharmacy Manual or equivalent. All 
excursio ns from  the tem perature storage guidelines shoul d immediately be brought to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 59of [ADDRESS_143026] 2020
sponsor’s attention for assessment and authorizat ion for continued use. Ensure that the drug is used 
before the retest expi[INVESTIGATOR_78952] . Expi[INVESTIGATOR_126866] h updated docum entati on to support the extended shelf life. In case of extenuat ing 
circumstances that prevent a patient from attending the study  site (eg, the COVID -19 pandemic), 
sites m ay usealternat ive strategies to deliver study drug to patients (eg, via courier or s ite staff), 
per local standard practi ce and regul ations and wi th prior approval  from the invest igator and the 
sponsor’s project clinician/designee.
Ixazo mib dispensed to the patient for take -home dosing should remain in the blister packaging and 
carton and stored as directed until the point of use. Patients who are receiving take -home 
medicat ion shoul d be given only  [ADDRESS_143027] igative site at their 
next visit, rather than discarding them, as permitted by  [CONTACT_19109] . Reconciliat ion will  occur 
accordingly when the patient returns at their next visit for take -home medicat ion. In case of 
extenuat ing circumstances that prevent a patient from attending the study  site (eg, the COVID -19 
pandemic), drug packs and dosing diaries should be returned at the next available on -site clinic 
visit. Any excursio ns in temperature should be reported and de alt with on a case -by-case basis. 
Ixazo mib is an ant icancer drug and, as with other potentially toxic co mpounds, caution should be 
exercised during handling. Patients should be instructed not to chew, break, or open capsules. In 
case of contact [CONTACT_126925] n capsules, raising dust should be avo ided during the clean -up operation. 
The product may  be harmful  by [CONTACT_79046], ingest ion, or skin absorption. Gloves and protective 
clothing shoul d be worn during clean -up and during return of broken capsules and powder to 
minimize skin contact. The area should be vent ilated and the site washed wit h soap and water after 
materi al pi[INVESTIGATOR_126867]. The material should be disposed of as hazardous medical waste in 
compliance wi th federal, state, and local regulat ions. 
Incase of contact [CONTACT_12700] (eg, from a broken capsule), skin should be washed 
immediately  with soap and copi [INVESTIGATOR_53298] [ADDRESS_143028] capsules.
Refer to the Pharmacy Manual for this s tudy for addi tional instructi ons.
8.10.2 Pomalidomide (Control Therapy)
[IP_ADDRESS] Preparation, Reconstitution, and Dispensation
Pomalidomi de is dispensed as a capsule as described in the local prescribing informat ion[41,42] .
Pomalidomi deis an ant icancer drug, and as with other potentially toxic compounds, caution 
shoul d be exercised during handling.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 60of [ADDRESS_143029] 2020
[IP_ADDRESS] Packaging and Labeling
Pomalidomi de will  be supplied from  commercial  sources.
[IP_ADDRESS] Storage, Handling, and Accountability
Pomalidomi de capsules sh ould be stored according to the instructions provided in the 
manufacturer’s package insert.
8.10.3 Dexamethasone
[IP_ADDRESS] Preparation, Reconstitution, and Dispensation
Dexamethasone is dispensed as a tablet as described in the local prescribing informat ion [58].
[IP_ADDRESS] Packaging and Labeling
Dexamethasone will be supplied fro m commercial sources.
[IP_ADDRESS] Storage, Handling, a nd Accountability
Dexamethasone tablets should be stored according to the instructions provided in the 
manufacturer’s package insert. 
8.11 Other Protocol -
Specified Materials
No other drugs or ancillary  material are supplied for use in this study .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 61of [ADDRESS_143030] ice (GCP), 
applicable regulatory  requi rements, and Internat ional Conference on Harmonisat ion (ICH) 
guidelines.
9.[ADDRESS_143031] of investigators is available in the sponsor’s invest igato r database.
9.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strategy , they  will be reviewed by  [CONTACT_4149] 
(IRB)/independent ethics committee (IEC). It is not envisioned that prisoners (or other populat ions 
that might be subject to coercion or exploitation) will be enro lled into this study .
9.[ADDRESS_143032] be shifted to ensure that collection o f assessments 
is co mpleted before dosing. 
Refer to the Schedule of Even ts (Appendix A) for timing of assessments. Addit ional details are 
provi ded as necessary in the sections that follow. ( For the timing of assessments performed before 
implementation of Amendment 06, please ref er to the previ ous, full Schedule of Events and 
Pharmacokinet ic Sampling Schedule in Appendix L.)
In acknowl edgement of hospi[INVESTIGATOR_307], local, state ,or nati onal government restri ctions, or other 
site-related factors caused by  [CONTACT_79051] (eg, the COVID -19 pandemic) that may 
prevent invest igators from conduct ing the study according to the Schedule of Events at the clinica l 
study  site, invest igato rs may cont inue patients in the study despi[INVESTIGATOR_126868]. Invest igators are expected to evaluate the impact to the safet y of the study participants and 
site personnel for patients to continue. In evaluating such requests, the inv estigator/study  site staff 
will give the highest priorit y to the safet y and welfare of the patients. Patients must be willing and 
able to continue taking study medicat ion and remain co mpliant with the protocol. For patients who
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 62of [ADDRESS_143033] 2020
are impacted by  [CONTACT_126926], any procedures not conducted per the study  
protocol  will be docum ented in the eCRF.
If a patient misses an in -person study  visit, the investi gator/study  team  staff will  speak di rectly 
with the pati ent by  [CONTACT_63195] (eg, a computer -based video communicat ion) 
during each visit window to assess subject safet y and overall clinical status. During this contact 
[CONTACT_126927], the study  site physician or other qualified site staff should at minimum conduct 
AE collect ion and an assessment of clinical symptoms. Other study  assessments may  be collected 
remotely  as is f easible and may  involve audio or video recording. Assessments/procedures that 
cannot be completed during the protocol -specified window because a site visit is done r emotely (ie, 
symptom -directed physical  examinat ion, hematol ogy, clinical chemistry ) are waived.
9.4.[ADDRESS_143034] provide written informed consent before any  study -requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
As of Amendment 06, patients remaining on study  treatm ent will need to be reconsented. 
Reconsent ing should be done in person. Remote reconsent ing is permitted as long as the process 
adheres to site, IRB/ IEC, and GCP st andards and local regulations.
9.4.2 Enrollment
A pat ient is considered to be enro lled in the study  when he/she has been rando mized to a study 
therapy . Procedures for complet ion of the enrollment information are described in the Study  
Manual.
9.4.3 Patient Demographic s
The date of birth, race, ethnicit y, and sex of the patient are to be recorded during Screening.
9.4.4 Physical Examinations
A co mplete physical examinat ion and symptom -directed phy sical examinat ion, including 
examinat ion for rash, performance status, and perip heral neuropathy, will be conducted at the time 
points specified in the Schedule of Events ( Appendix A).Please refer to the previous, full 
Schedule of E vents ( Appendix L) for the timing of assessments before implementation of 
Amendment 06.
9.4.5 Medical History and Disease Staging
During the Screening period, a complete medical history  will be com pi[INVESTIGATOR_126869]; a review of all current medications, prior radiat ion, 
and/or antineoplast ic therapy; and the patient’s current smoking st atus.
Diagnosis of MM 
(Appendix D) and ini tial ISS staging (based on serum albumin and 
β2-microglobulin levels; Appendix F), mye loma isotypi[INVESTIGATOR_007] (IgG, IgA, IgM, IgD, IgE, light 
chain kappa or lambda), and init ial cytogeneti c inform ation, if known. Note: Cy cle 1 Day  1 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 63of [ADDRESS_143035] 2020
dosing may  proceed if MM isoty pe tes ting has been submitted to, but not y et analyzed at, the 
central  laboratory .
MM- directed therapy  including ini tial and subsequent therapi[INVESTIGATOR_014], responses, dates and 
clinically significant toxicit ies. 
Review of all current medicat ions, prior radiat ion (as per mitted >14 days before rando mizat ion 
for symptom atic bone lesio n or >5 y ears before randomizat ion for another malignancy ), and 
the pati ent’s current sm oking status.
9.4.6 ECOG Performance Status 
Perform ance status will be assessed using the ECOG Performance Sca le (see Appendix E) at ever y 
cycle, as well as other times, as indicated in the previous, full Schedule of Events ( Appendix L). 
Upon implementation o f Amendment 06, ECOG data will no longer be collected.
9.4.7 Vital Signs 
Measurements of temperature and respi[INVESTIGATOR_126870], and thereafter, 
only as clinically indicated. Measurements of blood pressure and heart rate are to be performed at 
Screening and during the Treatment period as indicated in the previous, full Schedule of Events 
(Appendix L). Upon implementation of Amendment 06, vital signs data will no longer be 
collected.
9.4.8 Height and Weight 
Height will be measured only during Screening. Weight will be measured during Screening as well 
as other times, as indicated in the previous, full Schedule of Events ( Appendix L). Upon 
implementation of Amendment 06, weigh t data will no l onger be co llected.
9.4.9 Electrocardiogram
A 12 -lead el ectrocardi ogram  (ECG) will be conducted at Screening. It may be repeated as 
clinically indicated during the study  at the di scret ion of the invest igator. ECG data to be obtained 
include PR interval, QRS interval, and QT interval. 
9.4.10 QOL and HU Ass essments
QOL and HU assessments will be performed per the previous, full Schedule of Events 
(Appendix L), also described in this section. All QOL and HU assessments will be co mpleted 
before any other study  procedures are performed or study  therapy  is administered. The order of 
assessments will be the EORTC QLQ -C30 ( Appendix H), EORTC QLQ -MY20 ( Appendix I), and 
EQ-5D- 5L (Appendix J), followed by [CONTACT_126928] ( Appendix K).Upon implementation o f 
Amendment 06, PRO data will no longer be co llected.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 64of [ADDRESS_143036] 2020
[IP_ADDRESS] QOL
The patient -reported health -related QOL will be directly  self-reported by  [CONTACT_126929] -C30 ( Appendix H), EORTC QLQ -MY20 ( Appendix I), and 
EQ-5D- 5L (Appendix J), at m ultiple points throughout the study : at the Screening visit, on Day  1 
visits of ever y cycle during the Treatment period, at the EOT visit, and at the PFS Follow -up vis its, 
every 4 (±1) weeks during the PFS Follow -up period (see the previous, full Schedule of Events in 
Appendix L. Upon implementati on of  Amendment 06, PRO and PFS data will no longer be 
collected.
The EQ -5D-5L will also be assessed at the OS Follow- up visits, every 12 (±1) weeks during the 
OS Follow -up peri od; however, if a patient is unable to attend a study  visit during the OS 
Follow-up peri od, EQ -5D- 5L assessments may be collected from the patients via a telephone 
interview by [CONTACT_43065], who record the patient’s responses on the pat ient’s behalf. Upon 
implementation of Amendment 06, PRO and OS data will no longer be collected.
EORTC QLQ -C30
Cancer -specific health -related QOL will be assessed using the EORTC QLQ -C30 [59]
(Appendix H). The EORTC QLQ -C30 contains [ADDRESS_143037] ional scales (physical, role, 
cognitive, emotional, and social), 9 symptom scales (fat igue, nausea and vo miting, pain, dyspnea, 
sleep disturbance, appetite loss, const ipation, diarrhea, and financial difficult ies) and a global 
healt h status/QOL scale. Most of the [ADDRESS_143038] 4 response levels (not at all, a litt le, quite a bit, 
and very  much), wi th [ADDRESS_143039] ional subscales and the global 
healt h status/QOL subscale, higher scores represent better QOL; for the symptom subscales, lower 
scores represent better QOL.
The physical funct ioning domain of EORTC QLQ -C30 consists of 5 items covering the patient’s 
daily physical act ivities. It has been validated to measure physi cal activity changes in pat ients wit h 
MM [60,61] . Because of the relevance o f physical funct ion in MM, the physical funct ioning 
domain o f EORTC QLQ -C30 has been used as a primary  endpoint in som e MM studi es [
61]. 
Upon implementation o f Amendment 06, PRO data will no longer be collected.
EORTC QLQ -MY20
The EORTC QLQ -MY20 is an MM disease -specific [ADDRESS_143040] ional 
subscales and 2 symptom subscales ( Appendix I). The EORTC QLQ -MY20 has also been 
validated and used in clinical studies o f MM and has been demonstrated to have excellent 
measurement properties (validit y, reliabilit y, responsiveness). 
Raw scores are converted into scale scores ranging fro m [ADDRESS_143041] ional subscales, 
higher scores represent better QOL; for the symptom subscales, lower scores represent better 
QOL.
Upon implementation o f Amendment 06, PRO data will no longer be collected.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 65of [ADDRESS_143042] 2020
EQ-5D-5L
The EQ -5D-5L consists of 2 pages: the EQ-5D- 5L descript ive system and the EuroQol visual 
analogue scale (EQ VAS) ( Appendix J). The descriptive system  comprises 5 dimensions (mobilit y, 
self-care, usual act ivities, pain/disco mfort, and anxiet y/depressi on), each rated on 5 levels. The 
EQ VAS records the respondent’s self -rated heal th on a 20 cm , vert ical, visual analogue scale 
ranging from 0 (worst imaginable health state) to 100 (best imaginable healt h state).
Upon implementation o f Amendment 06, PRO data will no longer be collected.
[IP_ADDRESS] HU
HU data will be collected on Day  1 visit s of every  cycle during the Treatment period, at the EOT 
visit, and at the PFS Follow -up visits, every 4 (±1) weeks during the PFS Follow -up period (see the 
previous, full Schedule of Events ( Appendix L).Only non -protocol -directed healt h care 
encounters (ie, those not scheduled per this study  protocol ) are to be entered into the HU form 
(Appendix K). The form  is to includ e all hospi[INVESTIGATOR_36651], emergency  room  visit s, and 
non-protocol -directed outpati ent visi ts (eg, physician/clinic visits, 
laboratory /pathol ogy/radiology/bi omedical imaging workups); missed work by  [CONTACT_5363]/or 
caregiver is also collected on the form. 
Note that the HU form is NOT intended to be completed by  [CONTACT_126930]. At each HU 
assessment, the data collect ion recall timeframe is fro m the time of the previous study  visit. 
Upon implementation o f Amendment 06, HU and PFS data will no longer be co llected.
9.4.11 Imaging Disease Assessment
Imaging to assess status of bone disease will be performed at Screening (within 8 weeks before 
rando mizat ion) for all pat ients by [CONTACT_126931] , CT, MRI, or posi tron emissio n 
tomography  (PET) -CT. Addit ional as sessments can be done at the discret ion of the invest igator (ie, 
for suspected increased or new bone lesio ns or PD), and should be done by [CONTACT_126932] y. At 
least the fo llowing areas shoul d be assessed: head, neck, chest, abdomen, pelvis, arms, and leg s.
Imaging to assess extramedullary  disease will  be done at Screening (within 8 weeks before 
rando mizat ion) for all pat ients by [CONTACT_126933], MRI ,or PET -CT. In pati ents for whom 
extram edullary  disease is found at Screening, additio nalassessments should be done , using the 
same m odali ty, at Cycle 1 Day  1 and every 3 cycles thereafter, unless the Screening assessment is 
completed before 14 days before Cycle 1 Day 1; then the next assessment can be on Cycle [ADDRESS_143043] for 
review during monitoring visit s.
Upon implementation o f Amendment 06, imaging will no longer be performed at specified t imes 
per the Schedule of Events.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143044] 2020
9.4.12 Disease Response Asse ssment by [CONTACT_126934], 
version 2011 (see  Appendix G) , until the data cutoff date for th e study analysis (including for PFS) 
has occurred. At that time, all central efficacy and investigator assessments of disease response for 
protocol purposes will be stopped. Details of the clinical laboratory evaluations for disease 
assessment are given in Section [IP_ADDRESS].
Response categories are in  Table 9.a.
Table 9.a Response Assessment
Complete response CR
Subcategory: stringent complete response sCR
Very good par tial res ponse VGPR
Partial response PR
Stable disease SD
Progressive disease PD
CR must be confirmed with follow-up assessmen ts of serum protein electrophoresis, urine protein 
electrophoresis, immunofixation of blood and urine, and serum free light chains as outlined in 
Section  [IP_ADDRESS].  One bone marrow assessment must occur to document CR; no second bone 
marrow confirmation of CR is needed.
Note: To determine a response of stringent CR, bone marrow immunohistochemistry or 
immunofluorescence for kappa/lambda ratio should be performed for all patients suspected to be 
in CR to meet this response category’s requirements. 
The duration of stable di sease should be collected.
At any point during treatment, patients suspected  of having PD will have response assessments 
repeated to confirm PD. Per IMWG criteria, [ADDRESS_143045] be recorded in the eCRF but no approval is
required.
CCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseFS) ) 
nseefofor r
se e 
R
R
SDSD
PDPDSSS
of serumof ser
rine, andne, a
nt mustt mu
ngent CRgent C
mbda ratibda ra
goryory’s r’s
e shoulshou
tment, pent
PD. Per D. Pe
ese assese ass
nvestignvesti
m must bmust
d by a Mby a M
implemimple
nefit buefit b
The reahe re
requrequ
ropCCICC
Ixazomib
Study No. C16029 Page [ADDRESS_143046] be performed for women of childbearing potential: one at 
Screening, one at Cycle [ADDRESS_143047] be available and negative before dosing. 
In Arm B, for women of childbearing potential, 2 pregnancy tests (with 1 or both being serum 
tests) must be performed before starting pom+dex and results must be available and negative 
before dosing: the first within [ADDRESS_143048] month and monthly thereafter in 
women with regular menstrual cycles, or every 2 weeks (at Day 15) in women with irregular 
menstrual cycles. In Arm B at the EOT visit, the test must be a serum pregnancy test. The results of 
each test must be available and negative before the study therapy is administered.
Pregnancy tests may also be repeated during the study upon request by [CONTACT_80227]/IRBs or if required by 
[CONTACT_427].
9.4.[ADDRESS_143049] dose (Cycle 1 
Day 1), the tests will be repeated before dosing. The tes t closest to the first dose will be considered 
Baseline.
Hematology and chemistry laboratory samples will be collected locally and may be collected up to 
3 days before Day 1 of each cycle or prior to dos ing on Day 1. For Cycles 1 and 2, the laboratory 
samples may be collected 24 hours prior to dosing on Day 15 for Arm A (ixa+dex) or before 
dosing on Day 15. For Arm B (pom+d ex); hematology samples only will be collected at Cycle [ADDRESS_143050] assess 
any AEs or concomitant medication changes prior to dosing. Local laboratory evaluations may be 
done more frequently at the investigator’s di scretion (ie, for acute management of TEAEs). CCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Appf childbechild
ycle [ADDRESS_143051] 2020
[IP_ADDRESS] Clinical Chemistry and Hematology
Upon implementation of Amendment 06, centralized clinical laboratory evaluations are no longer 
required and local laboratories are to be used. Local laboratory evaluations should be entered into 
the eCRF only if required to understand a TEAE. For dosing decisions and all other safety 
assessments for the patient, local hematology and chemistry laboratory results should be used and 
do not need to be entered into the eCRF. Th ese laboratory evaluations may be done more 
frequently at the investigator’s discretion (ie, for acute management of TEAEs), per the 
investigator’s judgemen t of standard of care.
Blood samples for analysis of the clinical chemistr y and hematological parameters shown in 
Table 9.b will be obtained and recorded in the eCRFs as specified in the updated Schedule of 
Events (Appendix A) . (For the previous, full Schedule of Events, see  Appendix L. ) 
Table 9.b Clinical Chemistry and Hematology Tests 
Hematology Serum Chemistry
Hemoglobin
Leukocytes with differentialNeutrophils ANCPlatelet (count)Albumin
Alkaline phosphataseAlanine aminotransferaseAspartate aminotransferase
%2-microglobulin (at Screening only)
Bilirubin (total)
Blood urea nitrogenCalciumCreatinineGamma glutamyl transferase
Lactate dehydrogenase (at Screening only)MagnesiumPotassium
Urate
C-reactive protein
Quantification of B cells, T cells, and natural killer cells 
Measles
Varicella-zoster virus
Tetanus
If creatinine clearance is to be estimated, the Cockcroft-Gault formula will be employed as 
follows:
For female patients, the result of the formula above should be multiplied by 0.85. 
[IP_ADDRESS] Clinical Laboratory Evaluations for Disease Assessments 
Upon implementation of Amendment 06, all central laboratory assessments are no longer required.
See the updated Schedule of Events (Appendix A)  for more information.
CCI
Property ForForkeda: For Non-Command naturd nat
clearanclearaercial Use Only and Subject to the Applicable Terms of Usentoo
used anused a
ore re
r the r the 
meters smeters
updateddated
AppendiAppen
m Chemm Chemct
e
ferasease
at Screent Scr
)
nitrogenrogen
ninenebjjj
ia
tyooooooooooooooooofffffffffffffffff TTTTTTTTTTTTTTTTTTTTTTTaaaaaaaaaaaaaaaaaaaaaakemer
Ixazomib
Study No. C16029 Page 69of [ADDRESS_143052] 2020
A blood sam ple will be collected during Screening for measurement of serum 2-microglobulin 
and albumin for determinat ion of disease stage according to the ISS; these re sults will be analyzed 
centrally  and recorded on the eCRF.
Clinical laboratory  evaluat ions for disease assessments (serum protein electrophoresis [SPEP], 
urine protein electrophoresis [UPEP], serum free light chain, immuno fixation, and 
immunogl obulin) m ustbe sent to the central laboratory  for eval uation.
Immunofixation will also be done to confirm CR. Undetectable M -protein by [CONTACT_126935] d urine. Bl ood sam ples for IgM, IgG, and IgA will be obtained at 
Screening and throughout the study at the time po ints specified in the as indicated in the previous, 
full Schedule of Events ( Appendix L). Note that [ADDRESS_143053] clinical practice at the site. Quantitative IgD and IgE will be done 
at Screening (and Baseline if needed) only. For the rare patient with documented IgD or IgE MM, 
the quant itative test for that antibody  will be fo llowed at the same time points as IgG and IgA.
Bone m arrow aspi [INVESTIGATOR_126871] a local laboratory  to 
assess diseas e status at Screening and will be repeated if the pat ient is considered possibly to have 
resol ution of serum and urine M -protein consistent with CR or to invest igate suspected PD. A 
clinically indicated bone marrow aspi[INVESTIGATOR_126872] [ADDRESS_143054] dose.
9.4.16 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
the Schedule of Events ( Appendix A). Ref er to Secti on 10.[ADDRESS_143055] the gr ade of 
peripheral  neuropathy  at that visit. (This is in contrast to other AEs where only  increases in grade 
are recorded until the maximum grade is reached and then fo llowed at that grade until co mplete 
resol ution or return to Baseline.) Peripheral neuropa thy will be fo llowed m onthly unt il: 
1)resolut ion of peripheral neuropathy , 2) the start of a second- line alternat ive ant ineoplast ic 
treatm ent, or 3) [ADDRESS_143056].
9.4.17 Concomitant Medications and Procedures
Concomitant medications and therapeut ic procedures will be recorded in the eCRFs as specified in 
the Schedule of Events ( Appendix A). See Section
 8.5and Section 8.6for a list of medications and 
therapi [INVESTIGATOR_126873], respectively, during the study .
9.4.18 PK Samples and Measurements
PK data will be collected in Arm A (ixa+dex) only, as indicated Table A of the previous, full 
Schedule of Events 
(Appendix L). Plasma concentrations of ixazo mib (the co mplete hy drolysis 
product of ixazomib citrate) will be measured using a validated liquid chro matography  
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 70of [ADDRESS_143057] 2020
tandem -mass spectrometry  assay . Details r egarding the preparation, handling, and shippi[INVESTIGATOR_126874] . Blood samples (3 mL) for the determinat ion of 
plasma concentrations of ixazomib (the complete hydrolysis product of ixazo mib citrate) will be 
collected dur ing Cycles [ADDRESS_143058] date and t ime of each PK sample co llection should 
be recorded in the source documents and eCRF.
Upon implementation o f Amendment 06, PK sample co llection will be considered complete and 
no addi tional PK samples will be co llected or quantified.
9.5 Completion of Study Treatment (for Individual Patients)
Patients will  be considered to have completed study  treatm ent if they  experience PD, discont inue 
treatm ent because o f unacceptable toxicit y, or withdraw consent for any  reason. Before an 
investigator discont inues a patient fro m treatment for PD, the pertinent data must be confirmed by 
a Millennium pro ject clinician or designee. Patients will attend an EOT visit 30 days ( +1week) 
after receiving their last dose of study  therapy  orprior to the start of a new line of anti- myelo ma 
treatm ent. In the event a patient withdraws consent or has a death prior to the EOT visit, the last 
date of contact [CONTACT_126936]. AEs/SAEs will be mo nitored 
for all patients up to [ADDRESS_143059] study  drug dose regardless if a patient starts a new line of 
therapy . Pati ents will cont inue to be fo llowed for other fo llow-up assessments specified in Section 
[IP_ADDRESS] .Also refer to the updated Schedule of Events ( Appendix A) for EOT vi sit assessments.
Upon impl ementati on of  Amendment 06, only pat ients who continue to demonstrate clinical 
benefit but who do not have other means of access to the study  drugs will cont inue on the study. 
Patients continuing their current study  treatm ent may  do so until  such time as o ther means of 
accessing the study drugs are arranged. When possible, patients should co mplete an EOT visit and 
transi tion onto an alternat ive supply of (eg, commercially available) ixazo mib or pomalido mide, 
as well as dexamethasone, or onto another standar d of care treatment. Discont inued patients will 
be treated by  [CONTACT_79015] l ocal standard of care. The reason for treatment discont inuat ion 
must be recorded in the eCRF but no approval is required.
9.6 Completion of Study (for Individual Patients)
Patients will be considered to have completed the study  when the analysis for the study  (PFS and 
secondary  endpoints) i s completed or when the sponsor terminates the study. The study  will be 
considered complete after the study  analysis is completed or the study has been terminated (see 
Secti on 9.9).
9.[ADDRESS_143060] be perm anent ly discont inued for patients who beco me pregnant.
Treatment with study  therapy  may also be discont inued for any o f the following reasons:
AE.
Protocol  deviat ion.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 71of [ADDRESS_143061] 2020
Study  terminated by  [CONTACT_3211].
Withdrawal by [CONTACT_1130].
Lost to follow -up.
Pregnancy (patient m ust be discontinued ).
Progressi ve disease.
Death.
Other.
Upon implementation o f Amendment 06, only patients who continue to demonstrate clinical 
benefit but who do not have other means of access to the study  drugs will cont inue on the study. 
Patients continuing their current study  treat ment may  do so until  such time as other m eans of 
accessing the study drugs are arranged. When possible, patients should co mplete an EOT visit and 
transi tion onto an alternat ive supply of (eg, commercially available) ixazo mib or pomalido mide, 
as well as dex amethasone, or onto another standard of care treatment. Discont inued patients will 
be treated by  [CONTACT_79015] l ocal standard of care. The reason for treatment discont inuat ion 
must be recorded in the eCRF but no approval is required.
9.8 Withdrawal of Pa tients From Study
A pat ient will be withdrawn fro m the study  for any of the fo llowing reasons:
Study  terminated by  [CONTACT_3211].
Withdrawal by [CONTACT_1130].
Lost to follow -up. 
Other.
Upon implementation o f Amendment 06, PFS and OS fo llow-up will no l onger be perfor med. 
Patients will  now com plete the study  immediately  following the EOT visit. The consequence of 
study  withdrawal  is that no new informat ion will be collected fro m the withdrawn pati ent and 
added to the exist ing data or any  database.
9.[ADDRESS_143062] other means of access to the study  drugs will cont inue on the 
study . Pati ents continuing their current study  treatment may  do so until such t ime as other means 
of accessing the study  drugs a re arranged. When possible, patients should co mplete an EOT visit 
and transit ion onto an alternat ive supply o f (eg, commercially  available) ixazomib or 
pomalidomide, as well as dexamethasone, or onto another standard of care treatment. 
Discontinued pati ents will be treated by  [CONTACT_79043] l ocal standard of care.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 72of [ADDRESS_143063] igator or Millennium 
by [CONTACT_53346].
Circumsta nces that m ay warrant termination include, but are not limited to:
Determinat ion of unexpected, significant, or unacceptable risk to patients.
Failure to enter patients at an acceptable rate.
Insufficient adherence to protocol requirements.
Insufficient, i ncom plete, and/or unevaluable data.
Determinat ion of efficacy based on the study  analysis.
Plans to m odify , suspend, or di scont inue the development of the study drug.
Shoul d the study be closed prematurely, the site will no longer be able to access the electroni c data 
capture (EDC )application, will not have a right to use the EDC application, and will cease using 
the password or access materials once its part icipation in the study has concluded. In the event that 
any access devices for the EDC applicat ion have been provided, these will be returned to 
Millennium once the site’s participat ion in the study has concluded.
Within [ADDRESS_143064] igator(s). The appropriate study personnel wi ll maintain 
records of study  therapy receipt and di spensing.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 73of [ADDRESS_143065] who 
has signed informed consent to participate in a study but before administration of any study 
medicat ion; it does not necessarily have to have a causal relat ionship with study  parti cipat ion.
10.1.[ADDRESS_143066]; the untoward medical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), symptom, or disease temporally  associ ated w ith the use of a medicinal 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event, or a previous condit ion that has increased in severit y or frequency since the 
administration of study  thera py.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in treatment, dose modification, therapeutic intervent ion, or is considered 
by [CONTACT_2418] a clinically significant change fro m baseline.
10.1.[ADDRESS_143067] medical occurrence that at any  dose:
Results in death.
Is life-threatening (refers to an AE in which the patient was at risk of death at the time of the 
event. It does not refer to an event which hypothetically might have caused death if it were 
more severe).
Requi res inpat ienthospi[INVESTIGATOR_1324] (see 
clarificati onin the paragraph in Sect ion 10.2 on planned hospi[INVESTIGATOR_24509]).
Results in persistent or significant disability or incapacity . (Disabilit y is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal life functions).
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospi[INVESTIGATOR_059], but may be considered serious when, 
based on appropriate medical judgment, may  jeopardi ze the pati ent, requi re medical or 
surgi cal interventi on to prevent [ADDRESS_143068] ious agent. Examples of such medical events 
include al lergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsio ns that do not result in inpatient hospi[INVESTIGATOR_3094], or the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 74of [ADDRESS_143069] 2020
development of drug dependency  or drug abuse; any  organism , virus, or infecti ous part icle 
(eg,prion protein transmitt ing transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infect ious agent.
In thi s study , intensi ty for each AE, including any  laboratory  abnorm ality, will be determined 
using the NCI CTCA E, Versi on 4.03, effect ive date 14 June 2010 [62].Clarificat ion shoul d be 
made between an SAE and an AE that is considered severe in intensit y (Grade 3 or 4), because the 
terms seri ous and severe are NOT synonymous. The general term severe is often used to describe 
the intensit y (severi ty) of a specific event; the event itself, however, may  be of relatively  minor 
medical significance (such as a Grade 3 headache ). Thi s is NOT the sam e as serious , which is 
based on patient/event outcome or action criteria described above, and is usually associated with 
events that pose a threat to a patient’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does 
not necessa rily need to be considered serious. For example, a white blood cell count of 1000/mm3
to less than 2000 i s considered Grade 3 (severe) but may not be considered serious. Seriousness 
(not intensit y) serves as a guide for defining regulatory  reporti ng obliga tions.
10.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by  [CONTACT_53341]/or in response to an open question fro m study  
personnel or revealed by [CONTACT_4171], physical examinat ion, or other diagnostic procedures will be 
recorded on the appropriate page of the eCRF (see Section
 10.3 for the period of observat ion). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. Wh en possible, signs and symptoms indicating a commo n underlying patho logy shoul d be 
noted as 1 comprehensive event.
Regardless of causality, SAEs and serious pretreatment events (as defined in Section 10.1) must be 
reported (see Section 10.3 for the peri od of  observati on) by [CONTACT_126937] (contact [CONTACT_126938]). This 
shoul d be done by [CONTACT_51260] [ADDRESS_143070] be 
consistent with the data provided on the eCRF.
The paper SAE forms should be submitted via fax (see fax numbers below) within [ADDRESS_143071] be u pdated as soon as possible with the appropriate informat ion.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143072] Information
US and Canada
Japan
Emergency Center for Safety Information (available 24 hours a day, 365 days a year)
Planned hospi[INVESTIGATOR_126875] (eg, surgery wa s performed earlier or later than planned).
For both serious and nonserious AEs, the investigator must determine both the severity (toxicity 
grade) of the event and the relationship of the event to study therapy administration. For serious 
pretreatment events, the investigator must determine both the severity (toxicity grade) of the event 
and the causality of the event in  relation to study procedures.
Severity (toxicity grade) for each AE, including any laboratory abnormality, will be determined 
using the NCI CTCAE, Version 4.03, effective d ate 14 June 2010 [62]. The criteria are provided in 
the Study Manual.
Relationship of the event to study therapy adminis tration (ie, its causality) will be determined by 
[CONTACT_126939] (related) or no (unrelated) to this question: “Is there a reasonable 
possibility that the AE is asso ciated with the study therapy?”CCI
CCI
CCI
Property of [COMPANY_005]: For Non-Commeme or surgir surg
re not toe not 
ring the ng the
nd nonsenons
ent and ent an
events, vent
usalitality y
tty y (toxi(tox
ng the Ng the N
he Stude Stu
RelaRel
thly and Subjeavailablavailabe Applicable Terms of Usefof
bject to the A
mercial Use Only
Ixazomib
Study No. C16029 Page 76of [ADDRESS_143073] 2020
10.3 Monitoring of AEs and Period of Observation
AEs, both nonserious and serious, will be mo nitored throughout the study  as fo llows: 
AEs will be reported from the signing of informed consent through [ADDRESS_143074] dose of study therapy regardless of whether a pat ient starts a new line 
of therapy  and recorded in the eCRFs. AEs shoul d be m onitored until  they  are resolved or 
return to Baseline or are clearly determined to be due to a patient’s stable or chronic condit ion 
or intercurrent illness(es); the except ion is peripheral neuropathy, which will be fo llowed 
monthly until  1) resol ution of  peripheral  neuropathy , 2)the start of a second -line alternat ive 
antineoplastic treatment, or 3) [ADDRESS_143075].
SAEs
–Serious pretreatm ent events will be reported to the Millennium Glo bal Pharm acovi gilance 
departm ent or desi gnee fro m the time of the signing of the informed consent form up to 
first dose of study  therapy , and will also be recorded in the eCRF. 
–Related and unrelated treatm ent-emergent SAEs will be reported to the Millennium Global 
Pharmacovigilance depart ment or designee fro m the first dose of study therapy through [ADDRESS_143076] be reported to the Millennium Glo bal Pharmacovigilance depart ment or designee. 
SAEs shoul d be m onitored until  they are resolved or return to baseline or are clearly 
determined to be due to a patient’s stable or chronic condit ion or intercurrent illness(es); 
the except ion is peripheral neuropathy, which will be fo llowed m onthly  until  1) resol ution 
of peripheral  neuropathy , 2) the start of a second- line alternative ant ineoplast ic treatment, 
or 3) [ADDRESS_143077] al so be contact[CONTACT_126940] a completed Pregnancy  Form to the Millennium 
Global Pharm acovigilance department or designee (see Section 10.2). The pregnancy must be 
followed for the final pregnancy  outcome.
If a female partner of a male patient becomes pregnant during the male pat ient’s participat ion in 
this study, the sponsor must also be contact[CONTACT_53344] a completed Pregnancy Form 
to the Millennium Glo bal Pharmacovigilance department or designee (see Section 10.2). Every  
effort should be made to fo llow the pregnancy  for the final pregnancy  outcom e.
10.[ADDRESS_143078] Complaints or Medication Errors (Including 
Overdose)
A product complaint is defined as a verbal, written, or electronic expressio n that implies 
dissatisfact ion regarding the ident ity, strength, puri ty, quali ty, or s tabilit y of a drug product. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143079] complaint situation should immediately report this via 
the phone numbers or email addresses provided below.
A medication error is defined as a preventable event that involves an identifiable patient and that 
leads to inappropriate medication use, which may re sult in patient harm. Whereas overdoses and 
underdoses constitute medication errors, doses missed inadvertently by a patient do not. 
Individuals who identify a potential medication error (including overdose) situation should 
immediately report this via the phone number or email address provided below.
Product Call center Phone number Email Fax
NINLARO 
(ixazomib)
Product complaints or medication errors in and of themselves are not AEs. If a product complaint 
or a medication error results in an SAE, an SAE Form should be completed and sent to  
(refer to Section  10.2) . 
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory authorities, including the European 
Medicines Agency, investigators and IRBs or IECs, as applicable, in accordance with national 
regulations in the countries where the study is conducted. Relative to the first awareness of the 
event by/or further provision to the sponsor or sponsor’s designee, S[LOCATION_003]Rs will be submitted to 
the regulatory authorities as an expedited repor t within [ADDRESS_143080]’s administration or in the 
overall conduct of the trial. The investigational site also will forward a copy of all expedited 
reports to his or her IRB or IEC in accordance with national regulations.CCI
CCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to thethe
e not AEnot A
be cobe co m
IECs, aECs,
suspecteuspec
regulatoegulato
or IECsor IEC
udydyiiyys cos
ponsor oonsor 
pedidited rtediii
vents, unents, u
expeditexpedi
sk assesk asse
hanges iangesplicable Terms of Useat 
s and and 
hould uld 
FaxFaxab
pli
e trial. e trial
her IRB er IRBhe Appli
Ixazomib
Study No. C16029 Page 78of [ADDRESS_143081] incidence rates of AEs (including all 
SAEs, treatm ent-related AEs, serious treatment -related events, and events requiring the 
discontinuat ion of study  therapy ) will  be tabulated by  [CONTACT_2942], preferred term , and 
severit y grade. List ings and/or narratives of on -study  deaths and other serious and significant AEs, 
including any early wit hdrawals because of AEs, will be provided. Records of all meet ings will be 
archived. The IDMC will co mmu nicate major safety  concerns and recommendat ions regarding 
study  modificati on or terminati on to Millennium. Further details will be provided in the IDMC 
charter. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 79of [ADDRESS_143082] ionary for Regulatory Activit ies (MedDRA). Drugs will be coded 
using the World Healt h Orga nizati on Drug Di ctionary.
12.[ADDRESS_143083] research 
organi zation (CRO) partners, and regulatory  authori ties. Invest igative si tes m ust com plete eCRFs 
in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_126941] (or designees) and will be answered by [CONTACT_779].
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by [CONTACT_4180] . Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the correction was made, and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCR Fs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by [CONTACT_39810]. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospi[INVESTIGATOR_4077]. The completed eCRFs 
are the sole property  of the sponsor and should not be made av ailable in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.[ADDRESS_143084] igator agrees to 
keep the records stipulated in Section 12.1 and those documents that include (but are not limited 
to) the stud y-specific docum ents, the i dentificat ion log of  all parti cipat ing subjects, medical 
records, temporary  media such as thermal sensit ive paper, source worksheets, all original signed 
and dated informed consent forms, subject authorization forms regarding the use of personal 
healt h informat ion (if separate from the informed consent forms), electronic copy of eCRFs, 
including the audit trail, and detailed records of drug disposit ion to enable evaluat ions or audits 
from regulatory  authori ties, the sponsor, or it s designees. Any source documentation printed on 
degradable thermal sensit ive paper should be photocopi[INVESTIGATOR_126876] h the original in 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 80of [ADDRESS_143085]’s chart to ensure long -term legibili ty. Furtherm ore, ICH E6 Secti on 4.9.5 requires the 
investig ator to retain essent ial docum ents specified in ICH E6 (Section 8) unt il at least [ADDRESS_143086] igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specified by [CONTACT_63227] a 
time specifie d in the Clinical Study  Site Agreement between the investigator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator should contact [CONTACT_4182] m the sponsor before disposing of any 
such documents.
The fo llowing procedure is applied for Japanese sit esonly. The invest igator and the head o f the
institutionagree to keep the records stipulated in Section 12.1 and those documents that include 
(but are not limit ed to) the study -specific docum ents, the i dentification log of all part icipating 
subjects, medical records, temporary  media such as thermal sensit ive paper, so urce worksheets, all 
original  signed and dated informed consent forms, subject authorizat ion forms regarding the use of 
personal healt h informat ion (if separate from the informed consent forms), electronic copi[INVESTIGATOR_126877], including the audit trail, and de tailed records of drug disposit ion to enable evaluat ions or 
audits fro m regulatory authorit ies, the sponsor or its designees. Any source documentation printed 
on degradable thermal sensit ive paper should be photocopi[INVESTIGATOR_126876] h the origin al 
in the subject’s chart to ensure long -term legibilit y. Furthermore, ICH E6 Section 4.9.[ADDRESS_143087] itution to retain essent ial docum ents specified in ICH E6 
(Secti on 8) until at least [ADDRESS_143088] igator and/or the head of the institut ion and sponsor. Refer to the Clinical Study 
Site Agreem ent for the sponsor’s requirements on record retention. The investigator and the head 
of the inst itution should contact [CONTACT_4182] m the sponsor before disposing of 
any such documents.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143089] deviation, median, minimum, and maximum for continuous 
variables, and the number and percentage per category for categorical data. The Kaplan-Meier 
(KM) survival curves and 25th, 50th (median), and 75th percentiles will be provided along with 
their 95% CIs for time-to-event data.
Deviations from the statistical analyses outlined in this protocol will be indicated in the statist ical 
analysis plan; any further modifications will be noted in the clinical study report.
Study C16029 is a phase 2 study with PFS as the primary endpoint. The preliminary data from the 
phase 2 study by  [CONTACT_2297]., an investigator-initiated  study, demonstrated that greater clinical 
benefit (eg, ORR) may be achieved with the use of ixa+dex, with 4 mg and 5.5 mg doses of 
ixazomib, compared with pom+dex [ 7,8]. Therefore, this company-s ponsored study is intended to 
provide further assessment on 1) the feasibility and safety of the dose escalation of [ADDRESS_143090] cycle, and 2) the efficacy of ixa+dex.
13.1.1 Analysis Sets
The populations used for analysis will include the following:
!Safety population : The safety population is defined as all patients who receive at least 1 dose 
of any study therapy. Patients will be analyzed according to the treatment actually received. 
That is, those patients who are randomized to  the active arm but receive the regimen in the 
control arm will be included in the control arm; those patients who are randomized to the 
control arm but receive the regimen in the active arm will be included in the active arm for 
safety analyses.
!ITT population: The ITT population is defined as all patients who are randomized. Patients 
will be analyzed according to the treatment they are randomized to receive, regardless of any errors of dosing.
13.1.[ADDRESS_143091] data management 
operating procedures. In general, missing data will be treated as missing, and no data imputation 
will be applied, unless otherwise specified. [COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Useber of er of
n-MeierMeie
d along d alon
ated in ed in
report.epor
he prelime prel
onstratenstrat
th 4 mg 4 mg
mpanympany -s
oof tf the dhe d
+dex.dex.
e the fothe fo l
atioion is dn is
be analybe ana
andomindom
in the cn the c
e regimregim
The ITThe ITT
d accordaccor
ng.ng.
alysis oflysis 
mographmogra
valuatedaluate
nd otherd oth
13.113.[ADDRESS_143092] 2020
[IP_ADDRESS] Analyses for Primary Efficacy Endpoint
The analysis of the primary  endpoint, PFS, will be based on the ITT population using 
investigator -assessed PD data. PFS is defined as the time from randomization to the first 
occurrence of confirmed PD or death from any cause, whichever occurs first. Patients without 
docum entati on of  PD will  be censored at the date of the last response assessment that is SD or 
better.
PFS will be analyzed after approximately [ADDRESS_143093] to 
PFS at a 2 -sided alpha level of 0.20. In addition, an unadjusted unstratified Cox model will be used 
to estimate the HR and its 80% and 95% CIs for the treatment effect. The KM survival curves and 
KM m edians (if est imable), along with their 2 -sided 95% CIs, will also be provided for each 
treatm ent group. 
Sensit ivity analyses for PFS will include:
PFS assessed by  [CONTACT_126942].
Subgroup analyses will be perform ed for PFS rel ative to baseline stratificat ion factors and 
demographic data such as sex, race or ethnic group, and age, as appropriate. 
[IP_ADDRESS] Analyses of Secondary Efficacy
The primary  endpoint of PFS will be supported by  [CONTACT_126943]. Other secondary  efficacy parameters are OS, ORR, 
durati on of  response, time to response, and TTP. Disease response related endpoints will be 
analyzed using invest igator -assessed response rate for the ITT population.
OS will be analyzed on the basis o f the ITT population and is defined as the time from 
rando mizat ion to death fro m any cause. Patients wit hout documentation of death at the time of 
analysis will be censored at the date last known to be alive. A 2-sided, unstratified log -rank test 
will be used to compare the treatment and control groups with respect to OS. In addition, an 
unadjusted unstratified Cox model will be used to estimate the HR and its 80% and 95% CIs for the 
treatm ent effect. OS will be also tested at 2 -sided alpha=0.2. The KM survival curves and KM 
medians (if est imable), along with their 95% CIs, will also be provided for each study group.
ORR is defined as the rates of PR, VGPR, or CR, as evaluated by  [CONTACT_126944] [
55]. The percentage of each response 
category  (CR, VGPR, and PR) and of the combination CR +VGPR will be determined. 
Durati on of response is defined as the time fro m the first documentation of PR or bett er to the first 
docum entati on of PD. Responders wit hout documentation of PD will be censored at the date of the 
last assessed response of PR or better. Duration of CR will be summarized descript ively using the 
KM m ethod.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 83of [ADDRESS_143094] response 
assessment. TTP will be analyzed on the basis o f the ITT populat ion using methods similar to 
those used for PFS.
13.1.4 PK Analysis
PK data collected in this study may contribute to populat ion PK and exposur e/response (safety and 
efficacy) analyses. These analyses may include data fro m other ixazo mib clinical studies and will 
be separately developed and reported.
13.1.[ADDRESS_143095] ioning subscale. The main healt h-related QOL endpoint is time to maintained 
deteri oration of  Physical  Functioning domain scores from the EORTC QLQ -C30, based on a 
minimally important difference of 10 (primary  analysis) [63-65] and 5 (sensit ivity analysis) [ 66]. 
The summary and subscale scores of EORTC QLQ
-C30 and subscale scores of QLQ -MY20 will 
also be analyzed. Specifically, the actual value and change fro m baseline scores will be 
summarized using descript ive statist ics by [CONTACT_51250]. The chang e from baseline 
on summary and subscale scores may also be analyzed using linear mixed models by [CONTACT_126945]. Addit ionally , the number and percentages of 
patients showing a clinically  meaningful  change from  baseline will be summarized by [CONTACT_126946]. Quest ionnaire compliance will also be summarized. 
Published manuals/guidance for these quest ionnaires will be used for scoring and handling of 
missing data. Sensit ivity analyses may  be conducted to study the impact of missing data.
EQ-5D- 5L item scores and visual analogue scale (VAS) scores will be summarized using 
descript ive statistics by [CONTACT_51250]. 
HU as m easured by  [CONTACT_2360][INVESTIGATOR_36651], em ergency room  visits, non –protocol -directed ou tpatient 
visits, and missed days o f work by [CONTACT_126947]/or caregivers will be summarized using descript ive 
statist ics by [CONTACT_1570].
13.1.[ADDRESS_143096] data management operating 
procedures.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 84of [ADDRESS_143097] 2020
Safety will be evaluated by  [CONTACT_51253], severit y and t ype of AEs, and by [CONTACT_4184] m 
baseline in the patient’s vital signs, weight, and clinical laboratory  resul ts using the safet y 
popul ation. Exposure to study  therapy  and reasons for di scont inuat ion will be tabulated.
TEAEs that occur after administration of the first dose of study  therapy  and through [ADDRESS_143098] dose of study  therapy  will be tabulated. 
AEs will be tabulated according to MedDRA and will include the fo llowing categories: 
TEAEs.
Drug -related TEAEs.
Grade 3 TEAEs.
Grade 4 or higher TEAEs.
Grade 3 drug -related TEAEs.
Grade 4 or higher drug- related TEAEs.
The m ost comm only reported TEAEs (i e, those reported by  ≥10% of  all pat ients).
All SAEs.
Grade ≥2 peripheral neuropathy .
New primary malignancies. 
Any AE result ing in dose modificat ion or discont inuat ion of any  study  therapy .
Any other AE that in the opi[INVESTIGATOR_3078] n of the invest igator is a clinically significant event. 
Descript ive statistics for the actual values of clinical laboratory parameters (and/or change from 
Baseline in clinical laboratory  parameters) will be presented for all scheduled measurements over 
time. Mean labor atory  values over time will be plo tted for key  laboratory  parameters.
Descript ive statistics for the actual values (and/or the changes from Baseline) of vital signs and 
weight will be tabulated by  [CONTACT_51256]. ECOG performance scores will be summa rized 
using a shift table.
Shift tables for laboratory  parameters will be generated for changes in NCI CTCAE grade from 
baseline to the worst postbaseline value. Graphical displays o f key safet y parameters, such as 
scatter plots of baseline versus worst po stbaseline values, may be used to understand the ixazo mib 
safet y profile.
All conco mitant m edicat ions collected from the first dose of study therapy throughout the study  
period will be classified to preferred terms according to the World Healt h Organizatio n drug 
dictionary.
Addit ional safet y analyses m ay be performed to most clearly  enumerate rates of toxicit ies and to 
further define the safet y profile o f ixazomib.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143099] 2020
[IP_ADDRESS] New Primary Malignancy
Two types of incidence rates will be calculated for the safety population based on the new primary 
malignancy assessment:
!Incidence proportions, defined as the percentage of patients reporting any new primary 
malignancy in the safety population with available information.
!Incidence rates, defined as the number of patients reporting any new primary malignancy 
divided by [CONTACT_126948]-up in th e safety population with available information 
up to the onset of new primary malignancies.
For incidence proportions, the relative risks, defined as the ratio of incidence proportions between 
the 2 randomized treatment groups, will be provided along with their 95% CIs. For incidence rates, 
the relative risks, along with their 95% CIs, will be calculated using an exponential regression 
model for lifetime data (assuming constant hazards). 
Because of the distinct nature of hematologic and nonhematologic neoplasms, and the emerging 
signals of new primary malignancies for IMiDs, analyses of new primary malignancies may be 
performed separately for hematologic and nonhematologic malignancies.
13.1.[ADDRESS_143100] is planned for primary 
endpoint of PFS at a 2-sided level of 0.20.
13.2 Determination of Sample Size
Approximately 120 patients will be enrolled. The primary endpoint is PFS with assumption of an 
HR of 0.62 (median PFS, 7.3 months for ixa+dex vs 4.5 months for pom+dex). The analysis of 
PFS will be performed on the basis of approximately  81 PFS events in total (for 80% power at a 
2-sided 0.20 level of significance).
The PFS assumption for pom+dex is based on the PFS of 3.9 months (with a 95% CI of 3.5-4.6) for 
the subgroup of patients in  the NIMBUS study with 2 prior lin es who were lenalidomide refractory 
[45], with a higher value of 4.5 months chosen to be on the conservative side. The PFS assumption 
for ixa+dex is based on the PFS of 9.6 months in a similar population (2 prior lines, lenalidomide 
refractory), calculated on the basis of data from the  study as discussed above. Because this 
latter study had a smaller population and the PFS had a wider 95% CI (4.6- 16.3) than the NIMBUS 
study, a more conservative value of 7.3 months was chosen.[COMPANY_003]y
alignanaligna
able infoble in
nce e proppro
5% CIs. % CI
g an expan ex
ologic nlogic
of new of new 
ogic magic m
 PrimaPrim
point, beint, 
zeze
be enrobe enr
months month
he basishe bas
nificancifican
fofor pomr po
atients itient
gher valher va
is baseis ba
yy), cal), calyy cu
study hastudy h
dyy, a m, a 
Ixazomib
Study No. C16029 Page 86of [ADDRESS_143101] itution guarantee access to source documents by  [CONTACT_3210] i ts 
designee (CRO) and by [CONTACT_4186]. The CRO may also m onitor the site remotely as described 
in the Monitoring Plan.
All aspects of the study and its documentation will be subject to review by [CONTACT_36613], 
including but not limited to the Invest igator’s Binder, study  medicat ion, subject medi cal records, 
inform ed consent docum entati on, docum entati on of  subject authori zation to use personal healt h 
inform ation (if separate fro m the inform ed consent form s), and review o f eCRFs and associated 
source documents. It is important that the invest igator and other study personnel are available 
during the monitoring visits and that sufficient time is devoted to the process.
In the event a monitor cannot visit the site in a timely manner due to the COVID -[ADDRESS_143102] 
may be used to ensure data qualit y and integri ty and maintain pat ient safet y. Alternative 
monitoring approaches should be used only  where all owed by  [CONTACT_54003] l ocal regulati ons and 
permitted by  [CONTACT_32629] B/IEC.
14.[ADDRESS_143103] to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified pr ocedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The sponsor will assess any protocol deviat ion; if it is likely to affect to a significant degree the 
safet y and ri ghts of  a subject or the reliabilit y and robustness o f the data generated, it will be 
reported to regulatory  authori ties as a seri ous breach o f GCP and the protocol.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or EC, as 
requi red). Si gnificant devi ations inc lude, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviat ion Form  or equivalent form should be co mpleted by  [CONTACT_126949] b y the sponsor or designee for any  significant deviation from the protocol.
The procedure below applies to Japanese sites only. 
The invest igator can deviate and change from the protocol for any medically unavo idable reason, 
for example, to eliminate an imm ediate hazard to study subjects, without a prior written agreement 
with the sponsor or a prior approval from IRB. In the event of a deviat ion or change, the principal 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 87of [ADDRESS_143104] the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are co llected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by [CONTACT_17513], including 
those of foreign governments (eg, the FDA, the Unit ed Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contact[CONTACT_4190] a regulatory  body , the sponsor should be notified 
immediately . The invest igator an d inst itution guarantee access for qualit y assurance auditors to all 
study  docum ents as described in Section 14.1.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 88of [ADDRESS_143105] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declarat ion of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each invest igator will conduct the study 
according to applicable local or regional regulatory requirements and align his or her conduct in 
accordance with the “Responsibilit ies of the Investigator” that are listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
The rati onale for the open -study  design is primarily  to reduce the treatm ent burden on study  
patients. A pl acebo control  woul d requi re pat ients to ingest a large number of addit ional pi[INVESTIGATOR_3353] 
(23addit ional placebo tablets per cycle for patients receiving po m+dex, and 41 additional placebo  
tablets per cy cle for pati ents receiving ixa+dex). Furthermore, any  QOL benefi t attributed to 
taking oral medicat ions during just 8 out of 28 days (ixa+dex arm) versus 22 out of 28 days 
(pom +dex arm ) woul d be l ost.
Pom+dex was selected a s the control regimen for many reasons. Pom +dex i s a US -and 
EU-approved treatment regimen for RRMM. Because the invest igational regimen is an entirely 
oral therapy , the all -oral standard- of-care com parator of pom +dex provi des a m ore balanced 
treatm ent bur den between the 2 regimens than would a study where 1 regimen required periodic 
intravenous infusio ns. In addit ion, a com parison of ixa+dex to a single -agent com parator such as 
daratum umab woul d not all ow for the characteri zation of  the ixazo mib contribut ion to the 
observed treatment effect, unlike the comparison of ixa+dex to pom+dex, in which the 
dexamethasone contribut ion woul d be similar in both treatment groups.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American sites unwilling to provide names and tit les of all 
members because of privacy and conflict of interest concerns should instead provide a Federal 
Wide Assurance Number or comparable number assigned by [CONTACT_57813].
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy  of the inform ed consent 
form, and, if applicable, subject recruit ment materials and/or advertisements and other documents 
requi red by  [CONTACT_126950] l aws and regulat ions m ust be submitted to a central or local IRB or IEC 
for approval . The IRB’s or IEC’s wri tten approval  of the protocol and subject informed consent 
must be obtained and submitted to the sponsor or designee before commencement of the study (ie, 
before shipment of the sponsor -supplied drug or study -specific screening act ivity). The IRB or 
IEC approval must refer to the study  by [CONTACT_39819], number, and versio n date; ident ify 
versio ns of other documents (eg, informed consent form) reviewed; and state the approval date. In 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 89of [ADDRESS_143106] be obtained from the Competent Regulatory Authorit y before 
commencement of the study and, in the case of a substantial amendment, before implementation of 
the am endment. The sponsor will ship drug/notify site once the sponsor has confirmed the 
adequacy  of site regul atory  docum entati on and, when applicable, the sponsor has received 
permission fro m competent authorit y to begin the tri al. Until the si te receives notificat ion no 
protocol  activit ies, including screening, may  occur.
Sites m ust adhere to all requirements stipulated by  [CONTACT_4195]. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  [CONTACT_1766], l ocal safety  reporti ng requirements, 
reports and updates regar ding the ongoing review of the study at intervals specified by [CONTACT_39820], and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or i ts desi gnee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by [CONTACT_4197].
15.[ADDRESS_143107] authorizat ion form (if 
applicable) , and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject in formation sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if appl icable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by [CONTACT_55749].
The informed consent form, subj ect authori zation form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the inform ed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by [CONTACT_4186]. I n the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the sub ject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 90of [ADDRESS_143108]’s legally  acceptable representative, determines h e or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  [CONTACT_423], or the subject’s legally  acceptable representative, at the time of 
consent and before the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and before subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  [CONTACT_1289].
Once signed, the original info rmed consent form , subject authori zation form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copi[INVESTIGATOR_1681], the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by r elevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
15.[ADDRESS_143109]’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by [CONTACT_39823], limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to ve rify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representativ es fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical recor ds (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospi[INVESTIGATOR_45291] a subject’s study participation, 
and autopsy  reports. Access to a subject’ s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 15.2).
Copi [INVESTIGATOR_39757] (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s [e]CRF).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 91of [ADDRESS_143110] igators or to regulatory  agencies, except as required by  
[CONTACT_4201]. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  [CONTACT_3170]) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this sect ion and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinic al trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Millennium will, at a minimum register 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov or other 
publicly  accessible websites on or before start of study, as defined in Millennium Policy/Standard . 
Millennium contact [CONTACT_4203], alo ng with investigator’s cit y, state (for Americas invest igators), 
country , and recrui ting status will be registered and available for public viewing. 
As needed Millennium and invest igator/site contact [CONTACT_126951]. In certain situations/registries, Millennium may assist 
participants or potential participants to fi nd a clinical trial by [CONTACT_4205][INVESTIGATOR_126878], address, and phone number via email/phone or 
other m ethods callers requesting trial informat ion. Once subjects receive invest igator contact 
[CONTACT_3031], they  may call the si te request ing enro llment into the trial. The invest igative sites are 
encouraged to handle the trial inquiries according to their established subject screening process. If 
the caller asks addit ional questions beyo nd the topic of trial enro llment, they should be referred to 
the sponsor.
Any invest igator who objects to Millennium providing this informat ion to callers must provide 
Millennium wit h a wr itten notice requesting that their informat ion not be listed on the registry sit e. 
15.4.[ADDRESS_143111] the results of clinical trial son ClinicalTrials.gov and 
www.clinicaltrialsregister.eu, as well as other publicly accessible websites (including the 
Millennium corporate site) and registries, as re quired by  [CONTACT_126952] /Standard ,applicable 
laws, and/or regulat ions. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 92of [ADDRESS_143112] is participat ing. If a l ocal underwri ter is requi red, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clinical Study  Site Agreement regarding the sponsor’s policy on subject 
compensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact [CONTACT_4209]’s designee.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 93of [ADDRESS_143113] 2020
16.0 REFERENCES
1.Rajkumar SV, Ri chardson P, San Miguel JF. Guidelines for determinat ion of the number of 
prior lines of therapy  in multiple myel oma. Bl ood 2015;126(7):921-2.
2.VELCADE (bortezomib) for inject ion [package insert]. Cambridge (MA): Millennium 
Pharmaceut icals, Inc, 2015.
3.NINLARO (ixazo mib) capsules, for oral use [prescribing informat ion]. Cambridge, MA: 
[COMPANY_005] Pharmaceutical Company  Limi ted.
4.Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazo mib, 
Lenalido mide, and Dexamethasone for Mult iple Myelo ma. New England Journal of Medicine 
2016;374(17):1621 -34.
5.Hou J, Jin J, Xu Y, Wu D, Ke X, Daobin Z, et al. Ixazo mib plus lenalido mide -dexamethasone 
(IRd) vs pl acebo -Rd in patients with relapsed/refractory  multiple myelo ma: China 
continuat ion of TOURMALINE -MM1. American Societ y of Clinical  Oncol ogy (ASCO) 
Annual Meet ing, American Societ y of Clinical  Oncol ogy; 03 -07 June 2016; Chicago, IL. 
8036.
6. Hou J, Jin J, Xu Y, Wu D, Ke X, Daobin Z, et al. Improved PFS and OS with ixazo mib plus 
lenalido mide -dexamethasone (IRd) vs placebo -Rd in patients (pts) with relapsed/re fractory  
multiple myelo ma (RRMM): Final data from the phase 3 China cont inuat ion of 
TOURMALINEMM1. 16th International Myelo ma Workshop; March 1 -4, 2017.
7.Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, et al. Rando mized phase 
2 trial of ixazo mib and dexamethasone in relapsed mult iple myelo ma not refractory  to 
bortezomib. Blood 2016;128(20):2415 -
22.
8.Kumar SK, LaPlant B, Roy  V, Reeder CB, Lacy  MQ, Gertz MA, et al. Phase 2 trial of 
ixazo mib in pat ients with relapsed m ultiple myelo ma not ref ractory  to bortezomib. Blood 
Cancer Journal 2015;5:e338.
9.Palumbo A, Anderson K. Mult iple myelo ma. N Engl J Med 2011;364(11):1046 -60.
10.Kantar Health. Treatment Architecture: [LOCATION_002] Mult iple Myelo ma. CancerMPact® 
[LOCATION_002] 2012.
11.Rosenberg PS, Barker KA, Anderson WF. Future distribut ion of mult iple myelo ma in the 
[LOCATION_002] by  [CONTACT_4321], age, and race/ethnicit y. Blood 2015;125(2):[ADDRESS_143114] E. Cancer statistics, 2010. CA: a Cancer Journal for Clinicians 
2010;60(5):[ADDRESS_143115] ice Guidelines in Onco logy:Adult Cancer Pain, v.1.2010.
14.Turesson I, Velez R, Krist insson SY, Landgren O. Patterns of improved survival in pat ients 
with multiple myelo ma in the twent y-first century : a popul ation-based study . Journal  of 
Clinical Onco logy 2010;28(5):830 -4.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 94of [ADDRESS_143116] 2020
15.Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival 
among y ounger but not am ong ol der patients with Mult iple Myelo ma in the Netherlands, a 
popul ation-based study  since 1989. European Journal of Cancer 2010;46(1):160 -9.
16.Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued 
improvement in survival in mult iple myelo ma: changes in early mortalit y and outcomes in 
older pati ents. L eukemia 2014;28(5):1122-8.
17.Ludwig H, Avet -Loiseau H, Blade J, Boccadoro M, Cavenagh J, Cavo M, et al. European 
perspective on mult iple myelo ma treatment strategies: update following recent congresses. 
Onco logist 2012;17(5):592 -606.
18.NCCN Clinical Pr actice Gui delines in Onco logy: Mul tiple Myelo ma versio n 2.2015. National 
Com prehensive Cancer Network. 2014.
19.Facon T, Mary  JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and 
prednisone plus thalidomide versus melphalan and prednisone alone or reduced -intensity 
autol ogous stem  cell transplantation in elderly pat ients with mult iple myelo ma (IFM 99 -06): a 
rando mised trial. Lancet 2007;370(9594):1209 -
18.
20.San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpi[INVESTIGATOR_83868] O, Kropff M, et al.
Bortezomib plus melphalan and prednisone for init ial treatment of mult iple myelo ma. New 
England Journal of Medicine 2008;359(9):906 -17.
21.Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib wit h 
thalido mide plus dexameth asone co mpared wit h thalido mide plus dexamethasone as inductio n 
therapy  before, and consolidat ion therapy after, double autologous stem -cell transplantation in 
newly diagnosed mult iple myelo ma: a rando mised phase 3 study. Lancet 
2010;376(9758):2075-85.
22.Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, et al. Superiorit y of the 
triple combinat ion of bortezomib -thalidomi de-dexam ethasone over the dual co mbinat ion of 
thalido mide -dexamethasone in patients with mult iple mye loma progressing or relapsing after 
autol ogous transplantation: the MMVAR/IFM 2005 -04 Rando mized Phase III Trial fro m the 
Chronic Leukemia Working Party  of the European Group for Blood and Marrow 
Transplantation. J Clin Oncol 2012;30(20):2475-82.
23.Palumbo A, Chanan -Khan A , Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, 
Bortezomib, and Dexamethasone for Multiple Myelo ma. N Engl J Med 2016;375(8):754 -66.
24.Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spi[INVESTIGATOR_42239] I, et al. ELOQUENT -2: A 
phase III, randomi zed, open -label study  of lenalidomide (Len)/dexamethasone (dex) 
with/without el otuzum ab (El o) in pati ents (pts) wi th relapsed/refractory  multiple myel oma 
(RRMM). Journal of Clinical Onco logy 2015;33(suppl ). [ADDRESS_143117] of novel therapi[INVESTIGATOR_014]. Blood 2008;111(5):2516 -20.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 95of [ADDRESS_143118] 2020
26.Dimopoul os MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for 
relapsed and/or refractory  multiple myel oma. Nat Rev Clin Oncol 2015;12(1):42-54.
27.Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myelo ma at last: 
defining criteria and providing the evidence. Blood 2014;124(20):3043 -51.
28.Kumar SK, Therneau TM, Gertz MA, Lacy  MQ, Di spenzieri  A, Raj kumar SV, et al . Clinical  
course of patients with relapsed mult iple myelo ma. May o Clinic Proceedings 
2004;79(7):[ADDRESS_143119] Line Therapy for Mult iple Myelo ma in Austria: An Austrian Myelo ma 
Registry  (AMR) Analysis o f the Therapeutic Landscape and Clinical Outcomes prior to the 
Use of Next Generation Myelo ma Therapeut ics. PLoS One 2016;11(3):e0147381.
30.Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley  J, et al . Risk of 
progression and survival in mult iple myelo ma relapsing after therapy  with IMiDs and 
bortezomib: a mult icenter international myelo ma working group study . Leukemia 
2012;26 (1):149 -57.
31.Venner C, Bahlis N, Neri P, Sandhu I, Duggan P, Belch A, et al. In Mult iple Myelo ma 
Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early 
Exposure to Novel Agents: Experience fro m a Real -World Cohort. Am erica n Societ y of 
Hem atology 2015. ASH 57th Annual Meet ing & Exposit ion, 4261.
32.Jagannath S, Roy  A, Kish J, Lunacsek O, Globe D, Eaddy  M, et al . Real -world treatm ent 
patterns and associated progression -free survival in relapsed/refractory  multiple myel oma 
among US communit y onco logy pract ices. Expert Rev Hematol 2016;9(7):707 -17.
33.Kumar S ea. Outcomes after Init ial Relapse of Multi ple Myelo ma: An International Myelo ma 
Working Group Study . American Soci ety of Hematol ogy 2015. ASH 57th Annual Meeting & 
Expos ition, 4201.
34.Wildes TM, Rosko A, Tuchman SA. Mult iple myelo ma in the older adult: better prospects, 
more challenges. Journal of Clinical Onco logy 2014;32(24):2531-40.
35.Hari P, Tran L, Yong C, Noga S, Farrelly E, Raju A, et al. Duration of Second Lin e Treatment 
(2LT) and Overall Survival (OS) in Mult iple Myeloma (MM). 2016. 21st European 
Hem atology Associ ation Congress.
36.Kypro lis [Summary o f Product Characterist ics]. The Netherlands: [COMPANY_010] Europe B.V., 2016.
37.Darzal ex (daratum umab). Summary  of Product Characterist ics. United Kingdo m: 
Janssen -Cilag Ltd, [ADDRESS_143120] ics, and reversibilit y of peripheral neuropathy  during treatm ent of  advanced
multiple myelo ma wit h bortezomib. Journal o f Clinical Onco logy 2006;24(19):3113-20.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 96of [ADDRESS_143121] 2020
39.KYPROLIS (carfilzo mib) [package insert]. Thousand Oaks, CA: Onyx Pharmaceut icals, Inc., 
2015.
40.REVLIMID (lenalidomide) [package insert]. Melbourne, Australia: Celgene Pty  Limi ted, 
2016.
41.POMALYST (pom alido mide) capsules, for oral use [package insert]. Summit, NJ: Celgene 
Corporati on, 2014.
42.Imnovid [ADDRESS_143122] capsules [Summary of Product Characterist ics]. Uxbridge, United 
Kingdo m: Celgene Europe Ltd, 2014.
43.Lonial S, Kaufman JL. The era of combinat ion therapy  in myelo ma. Journal of Clinical 
Onco logy 2012;30(20):2434 -6.
44.Jakubowi ak A. Management strategies for relapsed/refractory  multiple myel oma: current 
clinical perspect ives. Seminars in Hematology  2012;[ADDRESS_143123] 1:S16-32.
45.San Miguel J, Weisel K, Moreau P, Lacy  M, Song K, Delforge M, et al. Pomalido mide plus 
low-dose dexamethasone versus high -dose dexamethasone alone for patients with relapsed and 
refractory  multiple myelo ma (MM -003): a randomised, open -label, phase 3 trial. Lancet Onco l 
2013;14(11):1055 -66.
46.Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab 
monotherapy  in pat ients with treatment -refractory mult iple myelo ma (SIRIUS): an open -label, 
rando mised, phase 2 trial. Lancet 2016;387([ZIP_CODE]):1551 -60.
47.Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of mult iple 
myelo ma in Asia-An Asian Myelo ma Network study . American Journal o f Hematol ogy 
2014;89(7):751 -6.
48.Lu J, Lu J, Chen W, Hu o Y, Huang X, Hou J, et al. Clinical features and treatment outcome in 
newly diagnosed Chinese patients with mult iple myelo ma: results of a mult icenter analysis. 
Blood Cancer Journal  2014;4:e239.
49.Dimopoul os MA, Kastrit is E, Christoulas D, Migkou M, Gav riatopoul ou M, Gkotzam anidou 
M, et al. Treatm ent of pati ents wi th relapsed/refractory  multiple myelo ma wit h lenalido mide 
and dexamethasone with or without bortezomib: prospective evaluat ion of the impact of 
cytogeneti c abnorm alities and of previous therapi [INVESTIGATOR_014]. Leukemia 2010;24(10):1769 -78.
50.Niesvizky  R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Communit y-Based 
Phase IIIB Trial of Three UPFRONT Bortezomib -Based Myelo ma Regimens. Journal of 
Clinical Onco logy 2015;33(33):3921-9.
51.Castelli R, Pantal eo G, Gallipoli P, Gidaro A, Arquati M, Wu MA, et al. Salvage therapy with 
bortezomib and dexamethasone in elderly patients with relapsed/refractory mult iple myelo ma. 
Anti-Cancer Drugs 2015;26(10):1078-82.
52.Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flino is A, et al . Mul tiple myelo ma: 
practi ce patterns across Europe. Br J Haematol 2016.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 97of [ADDRESS_143124] 2020
53.DARZALEX (daratumumab) [prescribing information]. USPI. Horsham, PA: Janssen Biotech, 
Inc., November, 2015.
54.Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Bel ch A, Lonial S, et al . Clinical efficacy  of 
daratum umab m onotherapy  in pat ients with heavily  pretreated rel apsed or refractory  multiple 
myelo ma. Bl ood 2016;128(1):37 -44.
55.Rajkumar SV, Dim opoul os MA, Pal umbo A, Blade J, Merlini G, Mateos MV, et al . 
International Myelo ma Working Group updated criteria for the diagnosis of mult iple myelo ma. 
Lancet Onco logy 2014;15(12):e538-48.
56.DEXAMETHASONE Tablets USP, DEXAMETHASONE Oral Solut ion [package insert]. 
Columbus (OH): Roxane Laboratories, Inc, a divis ion of Boehringer Ingelheim, September 
2007.
57.Imnovid (pomalido mide). Summary o f Product Characterist ics. Uxbridge, United Kingdo m: 
Celgene Europe Limited, Updated 17 January  2019.
58. DECADRON [package insert]. Whitehouse Station, NJ: [COMPANY_006] & Co., Inc. , January 2007.
59.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organizat ion for Research and Treat ment of Cancer QLQ -C30: a qualit y-of-life instrument for 
use in internat ional clinical trials in onco logy. Journal of the Nati onal Cancer Inst itute 
1993;85(5):365 -76.
60.Kvam AK, Wislo ff F, Fayers PM. Minimal important differences and response shift in 
healt h-related qualit y of life; a longitudinal study in patients with mult iple myelo ma. Health & 
Qualit y of Life Outc omes 2010;8:79.
61.Gimsing P, Carlson K, Turesson I, Fay ers P, Waage A, Vangsted A, et al. Effect of 
pamidronate 30 mg versus 90 mg on physical function in pat ients with newly diagnosed 
multiple myelo ma (Nordi c Myel oma Study  Group): a doubl e-blind, random ised controlled 
trial. Lancet Oncol ogy 2010;11(10):973 -82.
62.Commo n Termino logy Criteria f or Adverse Events (CTCAE). National Cancer Inst itute, 
National Inst itutes of Healt h, U.S. Department of Health and Human Services Series v4.03. 
June 14, 2010. Publi cation No. 09 -5410.
63.Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in 
healt h-related qualit y-of-life scores. Journal of Clinical Onco logy 1998;16(1):139 -44.
64.Kvam AK, Fayers PM, Wislo ff F. Responsiveness and minima l important score differences in 
qualit y-of-life questionnaires: a comparison of the EORTC QLQ -C30 cancer -specific 
questionnaire to the generic utilit y quest ionnaires EQ -5D and 15D in pat ients with multiple 
myelo ma. European Journal of Haematology  2011;87(4):[ADDRESS_143125] AS, Duh MS, Guerin A, Mishagina N, Antra`s L, et al. Health -related qualit y 
of life in pat ients with advanced renal cell carcinoma receiving pazopanib or placebo in a 
rando mized phase III trial. Eur J Cancer 2012;48(3): 311-23.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 98of [ADDRESS_143126] 2020
66.Stewart AK, Dimopoulos MA, Masszi T, Spi[INVESTIGATOR_42239] I, Orio l A, Hajek R, et al . Heal th-Related 
Qualit y of Life Result s From  the Open -Label, Randomized, Phase III ASPI[INVESTIGATOR_126879], Lenalido mide, and Dexamethasone Versus Lenalido mide a nd 
Dexamethasone in Pat ients Wit h Relapsed Mult iple My eloma. J Clin Onco l 2016.
67.Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicit y and 
response criteria of the Eastern Cooperative Onco logy Group. Am erican Journal o f Clinical 
Onco logy 1982;5(6):649 -55.
68.Greipp PR, San Mi guel J, Duri e BG, Crowl ey JJ, Barl ogie B, Bl ade J, et al . Internat ional 
staging system for mult iple myelo ma. Journal o f Clinical Onco logy 2005;23(15):3412-20.
69.Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. 
Consensus recommendations for the uniform reporting of clinical trials: re port of the 
International Myelo ma Workshop Consensus Panel 1. Blood 2011;117(18):4691 -5.
70.Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. Internat ional 
uniform  response criteria for mult iple myelo ma. Leukemia 2006;20(9):1467 -73.
71.Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratificat ion and response 
assessment of mult iple myelo ma. Leukemia 2009;23(1):3 -9.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 99of [ADDRESS_143127] been mo ved to Appendix Lfor reference only .
Study ProceduresTreatment Period (a)
Cycle X and Beyond, Day [ADDRESS_143128] Dose or Before 
Start of New Line of Treatment
Window, ± 1 week Window, + 1 week
Informed consent (reconsent) X (b)
Complete physical examination , including for PN (c,d) X
Symptom -directed physical examination, including for PN (c,d) X
Pregnancy test, Arm A (e) X
Pregnancy test, Arm B ( e) (increased frequency required per 
pomalidomide PI)XX
Hematology laboratory tests, Arm A ( d,f,g) X X
Hematology laboratory tests, Arm B (d,f,g) (increased frequency required 
per pomalidomide SmPC)X X
Chemistry laboratory tests (d,f,g) X X
Arm A: ixazomib Single dose of 5.5 mg on Days 1, 8, 15 
(if Cycle 1 dose tolerated)
Arm A: dexamethasone 20 mg (10 mg if aged ≥75 yr) Days 1, 2, 8, 9, 15, 16, 22, 23
Arm A: dexamethasone, if 4 mg dexamethasone is the only dosage 
available and patient is aged ≥75 yr12 mg o n Days 1, 8, 15, and 22; and 
8 mg on Days 2, 9, 16, and 23
Arm B: pomalidomide Days 1 -21
Arm B: dexamethasone 40 mg (20 mg if aged ≥75 yr) Days 1, 8, 15, 22
AE reporting (h) Recorded from the signing of informed consent form through [ADDRESS_143129] dose of study therapy
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 100of [ADDRESS_143130] 2020
CONFIDENTIALStudy ProceduresTreatment Period (a)
Cycle X and Beyond, Day [ADDRESS_143131] Dose or Before 
Start of New Line of Treatment
Window, ± 1 week Window, + 1 week
Concomitant medications/procedures Recorded from the signing of informed consent form through [ADDRESS_143132] dose of 
study therapy
NPM assessment Continuous from start of study therapy administration until death or termination of 
study by [CONTACT_126953]: new primary malignancy; PI: [INVESTIGATOR_126880].
Follow this Schedule of Events at the start of the next full treatment cycle upon implementation  of Amendment 06.Patients who do not continue treatment must 
complete the End of Treatment assessments, which should occur 30 days (+1 week) after the last dose of study drug or prior to the initiation of subsequent
antineoplastic therapy, whichever com es first.
(a) Tests and procedures should be performed on schedule, within a [ADDRESS_143133] clinician or designee should be consulted. If the study schedule is shifted, assessments should be shifted to be aligned with 
the new schedule. Note th at, except for hematology and chemistry laboratory samples (see footnote f below), all required tests and procedures for a sp ecific visit 
should be done on the same day as the study visit. 
(b) Before dosing on Day [ADDRESS_143134] be reconsented. Reconsenting should be done in 
person. Remote reconsenting is permitted as long as the process adheres to site, IRB/IEC, and GCP standards and local regulat ions. 
(c) Patients should be assessed and treated according to local standard of care. Collect and record only clinically significant findings as AEs in the eCRF.
(d) Alternative methods for administering study procedures/assessments may be considered when it is not possible for the pati ent to come to the study site due to 
extenuating circumstances (eg, due to the COVID -19 pandemic). Alternative methods should be considered for performing the assessments by [CONTACT_79017] (eg, remote assessment, having lab oratory assessment performed at a facility closer to the patient’s home). If any of the 
following study procedures/assessments is missed because a site visit is done remotely, the study  procedure/assessment is waived: symptom -directed phy sical 
examination, hematology, clinical chemistry.
(e) In Arm A, [ADDRESS_143135] be available and negative before dos ing. In Arm B, for women of childbearing potential, 2 pregnancy tests (with [ADDRESS_143136]) must be performed before starting pom+dex and results must be available and negative before dosing —the first within [ADDRESS_143137] month and monthly thereafter i n women with regular 
menstrual cycles, or ever y 2 weeks (at Day 15) in women with irregular menstrual cycles. In Arm B at the EOT v isit, the test must be a serum pregnancy test. The 
results of each test must be available and negative before the study therapy is administered. Pregnancy tests may also be rep eated during the study upon request 
by [CONTACT_80227]/IRBs or if required by [CONTACT_24550].
(f) Hematology and chemistry laboratory samples will be collected locally and may be collected up to 3 days before Day 1 of e ach cy cle or prio r to dosing on Day 
1. For Cycles 1 and 2 in both arms, the laboratory samples may be collected 24 hours prio r to dosing on Day 15 or before dosing on Day 15. In addition, for Arm 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 101of [ADDRESS_143138] 2020
CONFIDENTIALB (pom+dex) only, hematology samples will be collected at Cycle [ADDRESS_143139] assess any AEs or concomitant medication changes prior to dosing. Local laboratory evaluati ons and evaluation of SPEP and 
UPEP for confirmation of PD may be done more frequently at the investigator’s discretion (ie, for acute management of TEAEs).
(g) All central laboratory assessments are discontinued. Patients should be assessed and treated a ccording to local standard of care using local laboratory evaluations. 
Abnormal hematology and chemistry data are to be collected and recorded in the eCRF only to the extent that they are needed t o document or support an AE. 
Laborato ry assessments to infor m dosing decisions and routinely monitor patients do not need to be recorded in the eCRF.
(h) Patients should be assessed and treated per local standard of care. All AEs/SAEs will be recorded in the eCRF according t o the criteria outlined in Section 12.0. 
Patient safety outside the protocol assessments should be monitored during the time between on -site visits at the investigator's discretion, per standard of care. At 
minimum, there will be a phone call with an investigator within the specified -visit window timeframe, which will include an assessment of AEs/SAEs.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 102of [ADDRESS_143140] igators by  [CONTACT_45348] “Statement of Invest igator” (Form FDA 1572), whi ch must be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form  FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions perfo rmed and any 
data generated.
4.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects before the receipt of written 
approval  from relevant governing bodies/a uthori ties.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by [CONTACT_4215]/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to s ubjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within [ADDRESS_143141]’s medical chart. Valid informed consent is the most current 
versio n approved by [CONTACT_1201]/IEC. Each informed consent form shoul d contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include su ch a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , including 
eCRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by [CONTACT_126954]. The invest igator should 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 103of [ADDRESS_143142] and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by [CONTACT_4216] -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. This responsibilit y lies on 
the appropriate individual, designated by [CONTACT_126955].
13. Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 104of [ADDRESS_143143] igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), incl uding the following:
Millennium, its affiliates, and licensing partners.
Business partners assist ing Millennium, its affiliat es, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  [CONTACT_126956]:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, an d audi t of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medica tion.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within Millennium, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting invest igator site contact [CONTACT_35865], study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by 
[CONTACT_126957].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 105of [ADDRESS_143144] 2020
Appendix DRevised IMWG Diagnostic Criteria for MM
Source: Rajkumar et al 2014 [55].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 106of [ADDRESS_143145] 2020
Appendix EECOG Scale for Performance Status
Grade Description
0 Normal activity. Fully active, able to carry on all predisease performance without restriction.
1 Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to 
carry  out work of a light or sedentary nature (eg, light housework, office work).
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out any work 
activities. Up and about more than 50% of waking hours.
3 In bed > 50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.
5 Dead
Source: Oken et al 1982 [67].
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 107of [ADDRESS_143146] 2020
Appendix FISS Staging Criteria 
ISS
Stage Criteria
Stage I Serum 2-microglobulin <3.5 mg/L
Serum albumin ≥3.5 g/dL
Stage II Neither stage I nor stage III (a)
Stage III Serum 2-microglobulin ≥5.5 mg/L 
Source: Greipp et al 2005 [68].
(a) There are 2 categories for stage II: serum ß 2-microglobuli n <3.5 mg/L but serum albumin <3.5 g/dL; or serum 
2-microglobulin 3.5 to <5.5 mg/L irrespective of the serum albumin level.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 108of [ADDRESS_143147] 2020
Appendix GIMWG Uniform Response Criteria for MM
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 109of [ADDRESS_143148] 2020
Source: Rajkumar et al 2011 [69](adapted from Durie et al [70]and Kyle et al [71] with permission).
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 110of [ADDRESS_143149] 2020
Appendix HEORTC QLQ -C30 (version 3)
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 111of [ADDRESS_143150] 2020
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 112of [ADDRESS_143151] 2020
Appendix IEORTC QLQ -MY20
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 113of [ADDRESS_143152] 2020
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 114of [ADDRESS_143153] 2020
Appendix JEQ-5D-5L
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 115of [ADDRESS_143154] 2020
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 116of [ADDRESS_143155] 2020
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143156] 2020
CONFIDENTIALAppendix K Site HU Data Collection Form
CCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
on-Commercial Use Only and Subject to the Applica
Ixazomib
Study No. C16029 Page [ADDRESS_143157] 2020
CONFIDENTIALCCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
rcial Use Only and Subject to the Applicable T
Ixazomib
Study No. C16029 Page [ADDRESS_143158] 2020
CONFIDENTIALCCI
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
Non-Commercial Use Only and Subject to the Applicable T
Ixazomib
Study No. C16029 Page 120of [ADDRESS_143159] 2020
CONFIDENTIALAppendix LPrevious, Full Schedule of Events and PK Sampling Schedule (Schedules Before Implementation of 
Amendment 06)
Previous Schedule of Events
Study Procedures
ScreeningTreatment Period (a)EOT (b)Follow -up (c)
28-Day Cycles PFS OS
CycleC1 C2 (d) C3C4 and 
Beyond30 days 
after last 
dose or 
before start 
of new line 
of 
treatmentEvery 4 wk, 
Until PD or 
Subsequent 
TherapyEvery 12 
wk, After 
PD or 
Subseque
nt 
Therapy
Days -28 to -1 1 8 15 22 1 8 15 22 1 1
Window ±2 days +1 wk ±1 wk ±1 wk
Informed consent X
Inclusion/exclusion criteria (e) X
Demographics X
Complete medical history and disease staging X
Complete physical examination, including for 
PNX X
Symptom -directed phy sical examination, 
including for PNX X X X X
ECOG performance status X X X X X X
Vital signs (f) X X X X X X
Height (cm) X
Weight (kg) X X X X X X
12-Lead ECG X
Footnotes are on last table page.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 121of [ADDRESS_143160] 2020
CONFIDENTIALPrevious Schedule of Events (continued)
Study Procedures
ScreeningTreatment Period (a)EOT (b)Follow -up (c)
28-Day Cycles PFS OS
CycleC1 C2 (d) C3 C4 and Beyond30 days 
after last 
dose or 
before 
start of 
new line of 
treatmentEvery 
4wk, Until 
PD or 
Subsequen
t TherapyEvery 12 
wk, After 
PD or 
Subsequen
t Therapy
Days -28 to -1 1 8 15 22 1 8 15 22 1 1
Window ± 2 days +1 wk ± 1 wk ± 1 wk
EORTC QLQ -C30 (g) X X X X X X X
EORTC QLQ -MY20 (g) X X X X X X X
EQ-5D-5L (g) X X X X X X X X
HU assessment (g) X X X X X X
Imaging disease assessment
Bone (h) X
Soft-tissue plasmacyt oma (i) X X X (& every 3 
cycles 
hereafter)
Investigator’s assessment of disease 
response/status X X X X X X
Determination of dose escalation X (d)
Footnotes are on last table page.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143161] 2020
CONFIDENTIALPrevious Schedule of Events (continued)
Study Procedures
ScreeningTreatment Period (a)EOT (b)Follow-up (c)
28-Day Cycles PFS OS
CycleC1 C2 (d) C3 C4 and Beyond30 days 
after last 
dose or 
before 
start of 
new line of 
treatmentEvery 
4 wk, Until 
PD or 
Subsequen
t TherapyEvery 12 
wk, After 
PD or 
Subsequen
t Therapy
Days -28 to -1 1 8 15 22 1 8 15 22 1 1
Windo w ±2 days +1 wk ±1 wk ±1 wk
Samples/Laboratory Assessments
Pregnancy test, Arm A (j) X X X
Pregnancy test, Arm B (j) (increased frequency 
required per pom PI)XX X X X X X X
Hematology laboratory tests, Arm A (k) X X X X X X X X X
Hematology laboratory tests, Arm B (k) 
(increased frequency required per pom SmPC)XX X X X X X X X X X X X
Chemistry laboratory tests (k) X X X X X X X
LDH and β2-microglobulin X
M-protein (SPEP) X X (l) X X X X X
M-protein (UPEP [24-h urine]) X X (l) X X X X X
Serum free light chain assay X X (l) X X X X X
Immunofixation: serum and urine (m) X X (l) X X X X X
Quantification of immunoglobulins (n) X X (l) X X X X X
BMA or biopsy for disease assessment (o) X
Footnotes are on last table page.CCICCI
Property of TakeTa age.e.TakeNon-Commercial Use Only and Subject to the Applicable Terms of UseTe
capli
C3C3 CAp
ctth
1515 2uubub
dSub±2 days2 daydddSSS
ya nnd
yyya
Oly
XXOOOnO
XXUUUseUX XXlUUU
eciaU
Xeeercccec
m
X X(lomCo XCCCC
XXon
XN
oFoFoForFoo)):FFFF
da: For Ndakeda
Ixazomib
Study No. C16029 Page 123of [ADDRESS_143162] 2020
CONFIDENTIALPrevious Schedule of Events (continued)
Study Procedures
ScreeningTreatment Period (a)EOT (b)Follow -up (c)
28-Day Cycles PFS OS
CycleC1 C2 (d) C3 C4 and Beyond30 days 
after last 
dose or 
before start 
of new line 
of treatmentEvery 
4wk, Until 
PD or 
Subsequen
t TherapyEvery 12 
wk, After 
PD or 
Subsequen
t Therapy
Days -28 to -1 1 8 15 22 1 8 15 22 1 1
Window ± 2 days +1 wk ±1 wk ±1 wk
Study Therapy Administration
Arm A: ixazomib Single dose of 4 mg on 
Days 1, 8, 15Single dose of 5.5 mg on Days 1, 8, 15 
(if Cycle 1 dose tolerated)
Arm A: dexamethasone 20 mg 
(10 mg if aged ≥75 yr) Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28 -day cycle
Arm A: dexamethasone, if 4 mg 
dexamethasone is the only dosage 
available and patient is aged ≥75 yr12 mg dexamethasone on Days 1, 8, 15, and22 of every 28-day cycle ; 
and 
8 mg dexamethasone on Days 2, 9, 16, and 23 of every 28 -day cycle
Arm B: pomalidomide Days 1 -21 of each 28 -day cycle
Arm B: dexamethasone 40 mg 
(20 mg if aged ≥75 yr) Days 1, 8, 15, 22 of each cycle
AE reporting (r) Recorded from the signing of informed consent form through [ADDRESS_143163] dose of study therapy
Concomitant medications/procedures Recorded from the signing of informed consent form through [ADDRESS_143164] dose of study therapy
NPM assessment Continuous from start of study therapy administration until death or termination of study by [CONTACT_126958] X
Subsequent therapy X
Footnotes are on following page.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 124of [ADDRESS_143165] 2020
CONFIDENTIALBMA: bone marrow aspi[INVESTIGATOR_337]; C: study cycle; LDH: lactate dehydrogenase; NPM: new primary malignancy; PI: [INVESTIGATOR_126880]; PN: peripheral neuropathy; SmPC: Summary of 
Product Characteristics.
(a) Tests and procedures should be performed on schedule, within a [ADDRESS_143166] 
clinician or designee should be consulted. If the study schedule is shifted, assessments should be shifted to be aligned with the new schedule. Not e that, except for hematology and 
chemistry laboratory samples (see footnote k below), all required tests and procedures for a spe cific visit should be done on the same day as the study visit.
(b) Before discontinuing a patient from treatment for PD, the Progressive Disease Review form must be completed as soon as po ssible, permitting pertinent data to be confirmed by 
a Millennium pr oject clinician or designee. 
(c) Patients who have stopped treatment for any reason other than PD will first enter the PFS Follow -up period. Patients who have PD while on study therapy, during the Treatment 
period, will skip the PFS Follow -up period and w ill enter directly into the OS Follow -up period. Patients in the PFS Follow -up period who have PD or start subsequent anticancer 
therapy  will end PFS Follow -up and will enter into the OS Follow -up period. See Figure 6.bfor a detailed flow chart for both follow -up periods.
(d) All Arm A patients who tolerated the 4 mg dose of ixazomib in Cycle 1 (see Section 6.1.2 ) should dose escalate to 5.[ADDRESS_143167] clinician or designee; in that case, 
the patient must have Day [ADDRESS_143168] cycle of the 5.5 mg 
dose in the clinic rather than taking it at home.
(e) Confirmation of patient eligibility by a Millennium project clinician or designee is required before randomization. Cycle 1 Day  1 should be no later than 7 days after the date of 
randomizatio n. 
(f) Measurement of blood pressure and heart rate is to be performed at screening, along with temperature and respi[INVESTIGATOR_697] . During the Treatment period, measurement of blood 
pressure and heart rate is to be performed; temperature and respi[INVESTIGATOR_7137] e are collected only as clinically indicated.
(g) Patient -reported outcomes and HU assessment (eg, number of medical encounters) should be completed on the same day as the study visit , before any other study procedures are 
performed or study therapy is adm inistered. At any time point when a clinic visit is not otherwise required (ie, during the OS Follow -up period), the EQ -5D-5L questionnaire may be 
administered over the telephone by [CONTACT_43065].
(h) Imaging to assess status of bone disease will be d one at Screening (within 8 weeks before randomization) for all patients by [CONTACT_126931], CT, MRI, or PET -CT. 
Additional assessments for bone disease can be done at the discretion of the investigator (ie, for suspected increased or new bone lesi ons or PD) and should be done by [CONTACT_126959]. 
(i) Imaging to assess extramedullary disease will be done at Screening (within 8 weeks before randomization) for all patients by [CONTACT_126933], MRI, or PET -CT. In patients for whom 
extramedullary disease i s found at Screening, additional assessments should be done, using the same modality, at Cycle 1 Day 1 and every 3 cycles thereafter, unless the screening 
assessment is completed before 14 days prior to Cycle 1 Day 1; then the next assessment can be on Cyc le 3 Day  1.
(j) In Arm A, [ADDRESS_143169] be available and negative before dosing. In Arm B, for wo men of childbearing potential, 2 pregnancy tests (with [ADDRESS_143170]) must be performed before 
starting pom+dex and results must be available and negative before dosing —the first within [ADDRESS_143171] month and monthly thereafter in women with regular menstrual cycles, or every 2 wee ks (at Day 15) in women with irregular menstrual 
cycles. In Arm B at the EOT visit, the test must b e a serum pregnancy test. The results of each test must be available and negative before the study therapy is administered. P regnancy 
tests may also be repeated during the study upon request by [CONTACT_80227]/IRBs or if required by [CONTACT_427].
(k) Hematology and chemistry laboratory samples will be collected locally and may be collected up to 3 days before Day 1 of each cycle or pr ior to dosing on Day 1. For Cycles 1 and 
2 in both arms, the laboratory samples may be collected 24 hours prior to dosing on Day 15 or before dosing on Day 15. In addition, for Arm B (pom+dex) only, hematology samples 
will be collected at Cycle [ADDRESS_143172] assess any AEs or concomitant medication changes prior 
to dosing. Local laboratory evaluations and evaluation of SPEP and UPEP for confirmation of PD may be done more frequently at the investigator’s discretion (ie, for acute 
management of TEAEs). Clinical laboratory evaluations for disease assessments (SPEP, UPEP, serum free light chain, immunofixa tion, and immunog lobulin) must be sent to the 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143173] 2020
CONFIDENTIALcentral laboratory for evaluation until the data cutoff date for the study analysis has occurred. At that time, all central eff icacy and investigator assessments for protocol purposes will 
be stopped and not recorded in the eCRF—namely, PK, SPEP, UPEP, serum free light chain, , serology, C-reactive protein, immunof ixation, immunoglobulin, and 
LDH/albumin/ β2-microglobulin at screening .
(l) If the screening test was performed more than [ADDRESS_143174] dose (Cycle 1 Day 1), the test will be repeated befo re dosing. The test closest to the first dose will be 
considered Baseline. Note that 24-hour urine collection is permitted before screening if it is part of standard clinical practi ce at the site.
(m) Note that Cycle 1 Day 1 dosing may proceed if MM isotype testing has been submitted to, but not yet analyzed at, the central  laboratory. Immunofixation to also be done to 
confirm CR (undetectable M-protein by [CONTACT_126960]). 
Note that 24-hour urine collection is permitted before screening if it is part of standard clinical practice at the site.(n) Blood samples for IgM, IgG, and IgA will be obtained at Screening and throughout the study at the time points specified. If  the screening test was performed more than [ADDRESS_143175] dose (Cycle 1 Day1), the test will be repeated before dosing. The test closest to the first dose will be consi dered Baseline. Quantitative IgD and IgE will be done at 
Screening (and Baseline if needed) only. For the rare patient with documented IgD or IgE MM, the quantitative test for that ant ibody will be followed at the same time points as for 
IgG and IgA. (o) To be performed at a local laboratory to assess disease status at Baseline and will be repeated if the patient is considered  possibly to have resolution of serum and urine M-protein 
consistent with CR or to investigate suspected PD. A clinically indicated bone marrow aspi[INVESTIGATOR_126881] [ADDRESS_143176] dose.(p) (q) .
(r) When peripheral neuropathy occurs, each subsequent monthly evaluation will record the grade of peripheral neuropathy at tha t visit. (This is in contrast to other AEs where only 
increases in grade are recorded until the maximum grade is reached and then followed at that grade until complete resolution or  return to Baseline.) Peripheral neuropathy will be 
followed monthly until: 1) resolution of peripheral neuropathy, 2) the start of a second-line alternative antineoplastic treatm ent, or 3) [ADDRESS_143177].CCICCICCI
Property of [COMPANY_005]: For Non-Commercial Use Onlyd the gradd the grad
ed at that d at tha
condcond --y and Subject to the Applicable Terms of UseTe
gator assegator as
otein, immein, i
dosing. Tosing. 
at the siteat the sit
e central lcentral l
to perforto perf
ts specifies speci
will be conbe c
ative test ive tes
e patient ispatient
biopsy draopsy d
linelinly a
Ixazomib
Study No. C16029 Page 126of [ADDRESS_143178] 2020
CONFIDENTIALTable A Previous PK Sampling Schedule: Arm A (ixa+dex) Only (completed as of Amendment 06)
Cycle 1 Cycle 2 Cycles 3-4
Day 1 Day 15 Day 1 Day 15 Day 1
1 Hour Postdose 
(15 Minutes)4 Hours Postdose 
(45 Minutes)Any Time During 
Clinic Visit Predose (a)1 Hour Postdose 
(15 Minutes)4 Hours Postdose 
(45 Minutes)Any Time During 
Clinic Visit Predose (a)
X X X X X X X X
(a) All predose PK assessments should occur within [ADDRESS_143179] date and time of each PK sample collection should be recorded in the source documents and eCRF.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 127of [ADDRESS_143180] ions of the protocol affected by [CONTACT_51280] 06 are indicated. The 
corresponding text has been revised throughout the protocol. 
Change 1: To note thatthe data cutoff date for the study analysis, which is the only planned forma l 
analysis for this study , has now occurred.
The change occurs in Sect ion 6.1.4 Statistical Analyses :
Initial 
wording:Upon com pletion of this study , approximately  [ADDRESS_143181] been 
observed (after approximately [ADDRESS_143182] patient enrollment), for 80% 
power at a 2 -sided 0.20 level o f significance. Analysis o f all secondary endpoints will 
occur at the same t ime as the PFS analysis; no further analyses are planned.
Amended 
or new 
wording:Upon com pletion of this study , approximately  [ADDRESS_143183] been observed (after approximately [ADDRESS_143184] patient 
enrollment), for 80% power at a 2- sided 0.20 level of significance. Analysis o f all 
secondary  endp oints will occur at the same time as the PFS this study analysis , which 
is the only planned formal analysis for this study ; no further formal analyses are 
planned. Long -term safety data collected after the data cutoff date for the study 
analysis will be sum marized descriptively in a clinical study report addendum.
Rationale for Change: To clarify aspects of the study analysis.
Change 2: To note that, now that the data cutoff date for the study analysis has occurred, all 
central  efficacy and investigator assessments of response for protocol purposes are now 
discontinued. 
The primary  change occurs in Section 9.4.12 Disease Response Assessment by [CONTACT_10670] :
Initial 
wording:Patients will  be assessed for disease response according to the IMWG uniform 
response criteria, versio n 2011 (see Appendix G), unt il the PFS endpo int has been met  
for this study. At that time, all central efficacy and investigator assessments of disease 
response for protocol purposes will be stopped.
Amended 
or new 
wording:After the primary endpo int ofdata cutoff date for the study analysis (including for
PFS)has been met occurred , all central  efficacy  and investi gator assessments of 
response for protocol purposes will be discont inued ; patients will be fo llowed for 
survival and the appropriate data collected ..
Rationale for Change: To note that the data cutoff date for the study analysis has now occurred.
Secti on 2.0STUDY SUMMARY also contains this change. 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 128of [ADDRESS_143185] 2020
Change 3: To note that, now that the data cutoff date for the study analysis has occurred, the 
objective and endpo int of the study has changed to solely cont inue to collect long -term safet y dat a.
The primary change occurs in Section 5.0STUDY OBJECTIVES AND ENDPOINTS and Section 
6.1.3 Study  Assessments :
Added 
text:[Section 5.0]
As of Amendment 06, the objective and en dpoint are to continue to collect 
long-term safety data from patients who are continuing on ixazomib and 
dexamethasone or pomalidomide and dexamethasone because of continuing 
clinical benefit. Data collection for all other study objectives and endpoints is
complete and no further formal analyses will be conducted. However, the 
original lists of objectives and endpoints are retained below for reference only.
Added 
text:[Section 6.1.3]
Upon implementation of Amendment 06, data collection requirements will be 
limited to collection of AEs and SAE s. All other study assessments are no longer 
required. All central laboratory assessments are discontinued. Quality of life 
and HUassessments are discontinued. Patients will not be followed for the PFS 
or OS follow -up periods, because PFS and OS data are no longer being collected.
Rationale for Change: To clarify the study objective and endpo int at this point in the study .
The changes also occur in the fo llowing sect ions:
Secti on 2.0STUDY SUMMARY
Change 4: To note that as of the current amendment, now that the data cutoff date for the study  
analysis has occurred, only pat ients who conti nue to dem onstrate clinical benefit but have no 
access to study  drugs other than staying in the study  maystay in the study .
The primary  change occurs in Section 6.1.[ADDRESS_143186] ion 9.9Study  Closure :
Added 
text:[Section 6.1.3]
Only patients who continue to demonstrate cli nical benefit but who do not have 
other means of access to the study drugs will continue on the study. As no 
further formal statistical analyses will be performed, only assessments 
contributing to long- term safety data are required. Most study assessments 
besides safety are discontinued to ease the burden of protocol- mandated 
assessments on patients.
Patients continuing their current study treatment may do so until such time as 
other means of accessing the study drugs are arranged. When possible, patients 
should complete an EOT visit and transition onto an alternative supply of (eg, 
commercially available) ixazomib or pomalidomide, as well as dexamethasone, 
or onto another standard of care treatment. Discontinued patients will be 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 129of [ADDRESS_143187] of care.
Initial 
wording:[Section 9.8]
The consequence of study  withdrawal  is that no new informat ion will be collected 
from the withdrawn pat ient and added to the exist ing data or any database. However, 
every effort will be made to fo llow all pat ients for safet y.
Amended 
or new 
wording:[Section 9.8]
Upon implementation of Amendment 06, PFS and OS follow -up will no longer 
be performed. Patients will now complete the study immediately following the 
EOT visit. The consequence of study  withdrawal  is that no new inform ation will be 
collected from the withdrawn patient and added to the exist ing data or any database.
However, every  effort will be m ade to foll ow all pati ents f or safet y.
Deleted 
wording:[Section 9.7 and Section 9.9]
Patients rem aining on study  drug at the time o f study  closure (whether after 
completion of the study  analysis or any  other reason) will be provided continued 
access to study drug by [CONTACT_126961], either 
through commercial drug supply or through continued treatment in another extensio n 
or rollo ver study .
[Section 9.7]
Once study  therapy  has been discont inued, all study procedures outlined for the EOT 
visit will be co mpleted as specified in the Schedule of Events ( Appendix A). The 
primary  reason for study  therapy  discont inuat ion will be recorded on the eCRF.
Note that som e pati ents m ay discont inue study  therapy  for reasons other than PD 
before complet ing the full treatment course; these will remain in the study for 
posttreatment assessments as outlined in the Schedul e of Events ( Appendix A)until 
PD occurs.
Rationale for Change: To clarify which pat ients may remain on study  at thi s point.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Secti on 9.4.12 Disease Response Assessment by [CONTACT_10670]
Secti on 9.5Com pletion of Study  Treatm ent (f or Individual Pat ients)
Secti on 9.7Discont inuat ion of Treatment With Study  Therapy
Secti on 9.9Study  Closure
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 130of [ADDRESS_143188] 2020
Change 5: To cl arify that, as of the current amendment, the reason for a patient’s treatment 
discontinuat ion must be recorded in the eCRF but no approval by [CONTACT_126962].
The primary  change occurs in Section 9.7Discont inuat ion of Treatment With Study  Therapy :
Initial 
wording:Discontinuati on of  treatm ent wi th study  therapy  is to be reviewed and confirmed by 
[CONTACT_126963].
Amended 
or new 
wording:The reason for treatment discontinuation must be recorded in the eCRF but no 
approval is required.
Discontinuati on of  treatm ent wi th study  therapy  is to be reviewed and confirmed by 
[CONTACT_126963]. 
Rationale for Change: To clarify aspects of deciding to discont inue a patient’s treatment at this 
point in the study .
The fo llowing sect ions also contain this change:
Secti on 9.4.12 Disease Response Assessment by [CONTACT_10670]
Secti on 9.5Com pletion of Study  Treatm ent (f or Individual Pat ients)
Change 6: To cl arify that local laboratory  evaluat ions are to be used henceforth.
The primary  change occurs in Section [IP_ADDRESS] Clinical Chemistry and Hematology :
Added 
text:Upon implementation of Amendment 06, centralized clinical laboratory 
evaluations are no longer required and local laboratories are to be u sed. Local 
laboratory evaluations should be entered into the eCRF only if required to 
understand a TEAE. For dosing decisions and all other safety assessments for 
the patient, local hematology and chemistry laboratory results should be used 
and do not need to be entered into the eCRF. These laboratory evaluations may 
be done more frequently at the investigator’s discretion (ie, for acute 
management of TEAEs), per the investigator’s judgement of standard of care.
Rationale for Change: To clarify that central laboratory  assessments are discont inuedat thi s 
point in the study .
Secti on [IP_ADDRESS] Clinical Laboratory  Eval uations for Disease Assessments also contains this 
change.
Change 7: To simplify the Schedule o f Events to reflect the other changes noted.
The change occurs in Appendix AUpdated Schedul e of Events :
Descript i
on of 
changes:SOE changed to retain only  the f ollowing rows:
Inform ed consent (reconsent) .
Com plete physical  examinat ion.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 131of [ADDRESS_143189] 2020
Symptom -directed physical examinat ion.
Pregnancy tests .
Hem atology and chemistry  laboratory  tests .
Study  drug dosing.
AE reporti ng.
Concomitant medicat ions/procedures reporting .
NPM assessment .
SOE changed to retain only  the f ollowing col umns:
Cycle X Day  1; window now changed from ± 2 days to ±
1 week.
EOT; wi ndow remains the same at +1 week
.
Rationale for Change: To describe simplificat ion of the Schedule o f Events at this po int in the 
study .
Change 8: To cl arify that PK sample co llection is now com plete.
The change occurs in Sect ion 9.4.18 PK Sam ples and Measurements :
Added 
text:Upon implementation of Amendment 06, PK sample collection will be 
considered complete and no additional PK samples will be collected or 
quantified.
Rationale for Change: To clarify that PK sample collect ion is co mplete at this point in the study.
Change 9: To cl arify that the previous, full Schedule of Events and the now -completed PK 
sampling schedule have been mo ved to a new appendix ( Appendix L)for reference only.
The primary  change occurs in a new Appendix LPrevious, Full Schedule o f Events and PK 
Sampling Schedule (Schedules Before Implementati on of  Amendment 06):
Added 
text:[SOE and Table A in Append ix A now moved to a new Appendix L and labeled 
“Previous”]
Appendix LPrevious, Full Schedule of Events and PK Sampling Schedule 
(Schedules Before Implementation of Amendment 06)
…
Previous Schedule of Events
…
Table A Previous PK Sampling Schedule: Arm A (ixa+dex) Only
(completed as of Amendment 06)
…
Rationale for Change: To retain previous study  conduct i nformat ion for reference .
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 132of [ADDRESS_143190] ions also contain this change:
Secti on 6.1.3 Study  Assessments
Secti on 9.4Study  Procedures
Secti on 9.4.4 Physical Examinat ions
Secti on 9.4.6 ECOG Performance Status
Secti on 9.4.7 Vital Signs
Secti on 9.4.8 Height and Weight
Secti on 9.4.10 QOL and HU Ass essments
Secti on [IP_ADDRESS] QOL
Secti on [IP_ADDRESS] HU
Secti on [IP_ADDRESS] Clinical Chemistry and Hematology
Secti on [IP_ADDRESS] Clinical Laboratory  Eval uations for Disease Assessments
Secti on 9.4.18 PK Samples and Measurements
Change 10: Identify, as needed, text in the protocol that is no longer applicable as of the current 
amendment, now that the data cutoff date for the study  anal ysis has occurred.
The primary  change occurs in Section [IP_ADDRESS] Assessments During the Treatment Period and 
Secti on [IP_ADDRESS] Assessments During the Fo llow-up Peri ods: PFS and OS
Added 
text:[Section [IP_ADDRESS]]
Assessments Effective Only Before Amendment 06
…
Assessments Still in Effect as of Amendment 06
…
[Section [IP_ADDRESS]]
The following section describes the study design before Amendment 06 was 
implemented and is no longer relevant after that time but is retained below for 
reference only.
…
Figure 6.a Flow of Patients Through Follow -up Periods After the EOT Visit
(Only in Effect Before Amendment 06)
…
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page [ADDRESS_143191] 2020
Rationale for Change: To clarify protocol text that is no longer relevant at this point in the study.
The following sections also contain this change:
!Section  9.4.6 ECOG Performance Status
!Section  9.4.7 Vital Signs
!Section  9.4.8 Hei ght and Weight
!Section  9.4.10 QOL and HU Assessments
!Section  [IP_ADDRESS] QOL
!Section  [IP_ADDRESS] HU
!Section  9.4.11 Imaging Disease Assessment
!
Change 11: To add flexibility in study conduct in unavoidable circumstances (eg, the COVID-19 
pandemic).
The primary change occurs in Section  [IP_ADDRESS] Stora ge, Handling, and Accountability, 9.4 Study 
Procedures,  and 14.1 Study-Site Monitoring Visits:
Added 
text:[Section [IP_ADDRESS]]
In case of extenuating circumstances that prevent a patient from attending the 
study site (eg, the COVID-19 pandemic), sites may use alternative strategies to 
deliver study drug to patients (eg, via courier or site staff), per local standard 
practice and regulations and with prior approval from the investigator and the 
sponsor’s project clinician/designee.
…
In case of extenuating circumstances that prevent a patient from attending the 
study site (eg, the COVID-19 pandemic), drug packs and dosing diaries 
should be returned at the next available on-site clinic visit.
…
[Section 9.4]
In acknowledgement of hospi[INVESTIGATOR_307], local, state, or national government 
restrictions, or other site-related factors caused by [CONTACT_117551] 
(eg, the COVID-19 pandemic) that may prevent investigators from conducting 
the study according to the Schedule of Events at the clinical study site, 
investigators may continue patients in the study despi[INVESTIGATOR_126882]. Investigators are expected to evaluate the impact to the 
safety of the study participants and site personnel for patients to continue. In CCI
Property of [COMPANY_005]: For Non-Commercial Use Onumstanumsta
IDID--[ADDRESS_143192] clin
of extenof extOnly and Subjeable cirable cirbje
age, Hage, H
tss::nd
tudy situdy s
shouldshou
……Onto the Applicable Terms of Use
ject to
Ixazomib
Study No. C16029 Page 134of [ADDRESS_143193] 2020
evaluating such requests, the investigator/study site staff will give the highest 
priority to the safety and welfare of the patients. Patients must be willing and 
able to continue taking study medication and remain compliant with the 
protocol. For patients who are impacted by [CONTACT_86923] e unavoidable circumstances, 
any procedures not conducted per the study protocol will be documented in the 
eCRF.
If a patient misses an in -person study visit, the investigator/study team staff will 
speak directly with the patient by [CONTACT_126964] (eg, a 
computer -based video communication) during each visit window to assess 
subject safety and overall clinical status. During this contact [CONTACT_10970], the 
study site physician or other qualified site staff should at minimum conduct AE 
collecti on and an assessment of clinical symptoms. Other study assessments may 
be collected remotely as is feasible and may involve audio or video recording. 
Assessments/procedures that cannot be completed during the protocol -specified 
window because a site visit is done remotely (ie, symptom -directed physical 
examination, hematology, clinical chemistry) are waived.
…
[Section 14.1]
In the event a monitor cannot visit the site in a timely manner due to the 
COVID -[ADDRESS_143194] may be used to ensure data quality and 
integrity and maintain patient safety. Alternative monitoring approaches should 
be used only where allowed by [CONTACT_126965]/IEC.
…
Rationale for Change: To account for unavo idable circumstances affect ing study  conduct.
This change also occurs in Appendix AUpdated Schedule o f Events .
Change 12: To indicate that, given the changes in the current amendment, pat ients rem aining on 
study  will need to be reconsented.
The change occurs in Sect ion 9.4.1 Informed Consent :
Added 
text:As of Amendment 06, patients remaining on study treatment will need to be 
reconsented. Reconsenting should be done in person. Remote reconsenting is 
permitted as long as the process adheres to site, IRB/ IEC, and GCP standards 
and local regulations.
Rationale for Change: To clarify the need for reconsenting.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 135of [ADDRESS_143195] 2020
Change 13: Update language about management of clinical events in patients receiving ixazo mib.
The change occurs in Sect ion 8.8.1 Ixazomib :
Initial 
wording:Erythematous Rash With or Without Pruritus
…
The rare risks of Stevens -Johnson syndro me, toxic epi [INVESTIGATOR_77116] , drug 
reacti on wi th eosinophilia and systemic symptoms (DRESS syndrome), and 
pemphigus vulgaris have been reported in onco logy studies when ixazo mib was give n 
with concomi tant m edicat ions that are known to cause rash (eg, Bactrim, 
lenalido mide, aspi[INVESTIGATOR_248]), and/or in the setting of confounding treatment -emergent 
adverse events (TEAEs). These severe, potentially life -threatening or deadly 
condi tions may involve rash with skin peeling and mouth sores and should be 
clinically managed according to standard medical practice. Punch biopsies for 
histopathological analysis are encouraged at the discretion of the invest igator. 
Addit ional information regard ing these reactions can be found in the IB.
Thrombocytopenia
Blood counts shoul d be m onitored regul arly according to standard clinical pract ice. 
Thrombocy topeni a may be severe but has been manageable wit h platelet transfusio ns 
according to standard clinica l pract ice. Ixazo mib administration should be modified 
according to dose modificat ion recommendat ions in the protocol when 
thrombocy topenia occurs (see Section 8.4.3). Therapy  can be reinit iated at a reduced 
level upon recovery  of platel et counts. A rare r isk is thrombotic thrombocy topenic
purpura , arareblood disorder where blood clots form in small blood vessels
throughout the body characterized by [CONTACT_12703], petechiae, fever, or possibly 
more seri ous signs and symptom s. Thromboti c thrombocy topeni c purpura shoul d be 
managed symptomat ically according to standard medical pract ice.
…
Transverse Myelitis
One case of transverse myelitis has been reported in a patient receiving 
ixazo mib+LenDex twice weekly, given for 16 cy cles, fo llowed by  4 com plete cy cles 
of ixazo mib only in the maintenance phase (the patient received 2 addit ional doses 
beyo nd the 4 full cycles). During a break in therapy  (Oct -Dec 2013) the patient 
experienced progressive neuro logic deteri oration. The event of transverse myelit is 
was di agnosed 1 day  after the 22nd cy cle of ixazomib maintenance was init iated. It is 
not known whether ixazo mib causes transverse myelit is; however, because transverse 
myelit is happened to a patient receiving ixazo mib, the possibilit y that ixazomib may 
have con tributed to the transverse myelit is cannot be excluded. Transverse myelit is 
shoul d be managed according to standard medical practice.
…
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 136of [ADDRESS_143196] 2020
Amended 
or new 
wording:Erythematous Rash With or Without Pruritus
…
The rare risks of Stevens -Johnson syndro me, toxic epi[INVESTIGATOR_126883] , drug 
reacti on wi th eosinophilia and systemic symptoms (DRESS syndrome), and 
pemphigus vulgaris have been reported in oncology  studi es when ixazo mib (or 
placebo) was given wit h concomitant medicat ions that are known to cause rash (e g, 
Bactrim, lenalido mide, aspi[INVESTIGATOR_248]), and/or in the setting of confounding 
treatm ent-emergent adverse events (TEAEs). These severe, potentially 
life-threatening or deadly condit ions m ay invo lve rash with skin peeling and mouth 
sores and should be clinically managed according to standard medical practice. Punch 
biopsies for histopathological analysis are encouraged at the discret ion of the 
investigator. Additional informat ion regarding these reactions can be found in the IB.
Thrombocytopenia
Blood counts shoul d be m onitored regul arly as outlined in the protocol, with 
additional testing obtained according to standard clinical pract ice. 
Thrombocy topeni a may be severe but has been manageable wit h platelet transfusio ns 
according to standard clinical pract ice. Ixazo mib administration should be modified 
according to dose modificat ion recommendat ions in the protocol when 
thrombocy topenia occurs (see Section 8.4.3). Therapy  can be reinit iated at a reduced 
level upon recovery  of platel et counts. A rare risk is Thrombotic microangiopathy 
(TMA), including thromboti c thrombocy topeni cthrombocytopenia purpura (TTP) , 
aand hemolytic uremic syndrome (HUS) , are rare, serious blood disorder 
where disorders that cause low levels of platelets and red blood cells and result in
blood clots form in small  blood vessels throughout the body  characteri zed by 
[CONTACT_79093], petechi ae, fever, or possibly  more seri ous si gns and symptom s. 
Thromboti c thrombocy topeni c purpura . Symptoms may include fatigue, fever, 
bruising, nose bleeds, and decreased urination. These disorders, including fatal 
cases, have been reported in patients receiving ixazomib. TMA should be 
managed symptom atically according to standard medical pract ice.
…
Transverse Myelitis
One case of transverse myelitis has been reported ina pati ent receiving 
ixazo mib+LenDex twice weekly, given for 16 cy cles, fo llowed by  4 com plete cy cles 
of ixazo mib only in the maintenance phase (the patient received 2 addit ional doses 
beyo nd the 4 full cycles). During a break in therapy (Oct -Dec 2013) the patient 
experienced progressive neuro logic deteri oration. The event of transverse myelit is 
was di agnosed 1 day  after the 22nd cy cle of ixazomib maintenance was init iated
Transverse myelitis has been reported with ixazomib . Itis not known whether 
ixazo mib causes transverse myelit is; however, because transverse myelit is happened 
to a patient receiving ixazo mib, the possibilit y that ixazo mib may have contributed to 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 137of [ADDRESS_143197] medical practice.
…
Rationale for Change: To add informat ion currently available around clinical events.
Change 14: To cl arify details about ixazo mib packaging, handling, and storage guidelines.
The primary change occurs in Section 8.1Investigational Therapy: Ixazo mib Administration (Arm 
A), Secti on [IP_ADDRESS] Storage, Handling, and Accountabilit y, and Secti on [IP_ADDRESS] Preparation, 
Reconst itution, and Dispensation :
Added 
text:[Section 8.1]
…
Refer to Section [IP_ADDRESS] and the Study Manual for additional instructions 
regarding study therapy administration.
…
Section [IP_ADDRESS]
On receipt at the invest igative site, ixazo mib should remain in the blister pack and 
carton provided until use or dispensat ion. For storage condit ions, refer to the 
Pharmacy  Manual or equivalent. All excursions from the temperature storage 
guidelines shoul d immediately be brought to the sponsor’s attention for assessment 
and authorization for continued use. Ensure that the drug is used before the retest 
expi[INVESTIGATOR_126884]. Expi[INVESTIGATOR_126885].
…
Initial 
wording:[Section [IP_ADDRESS]]
Ixazo mib is dispensed in blisters in a child -resistant carton. For the 2.3, 3.0, 4.0, and 
5.5 m g capsule strengths, there are 3 capsules in each wallet/carton. 
Ixazo mib is an ant icancer drug, and as with other potentially toxic co mpounds, 
cauti on shoul d be exercised during handling.
…
Amended 
or new 
wording:[Section [IP_ADDRESS]]
Ixazo mib is dispensed in blisters a blister pack in a child -resistant carton. For the 2 .3, 
3.0, 4.0, and 5.5 mg capsule strengths, there are 3 capsules in each wallet/carton. 
Ixazo mib is an ant icancer drug, and as with other potentially toxic co mpounds, 
cauti on shoul d be exercised during handling. See the Pharmacy Manual for more 
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 138of [ADDRESS_143198] 2020
information.
…
Rationale for Change: To add clarificat ion to this protocol.
Change 15: To cl arify that PFS and OS data will be analyzed using unstratified tests, among 
others.
The change occurs in Sect ion [IP_ADDRESS] Analyses for Primary Efficacy Endpo intand [IP_ADDRESS]
Analyses of Secondary Efficacy :
Initial 
wording:[Section [IP_ADDRESS]]
…
A 2-sided, stratified log-rank test will be used to compare the treatment groups with 
respect to PFS at a 2 -sided al pha l evel of 0.20. In addit ion, an unadjusted stratified
Cox model will be used to estimate the HR and its 80% and 95% CIs for the treatment 
effect. The KM survival curves and KM medians (if estimable), along wit h their 
2-sided 95% CIs, will also be provided for each treatment group. 
[Section [IP_ADDRESS]]
OS wil l be analyzed on the basis o f the ITT populatio n and is defined as the t ime fro m 
rando mizat ion to death fro m any cause. Patients wit hout documentation of death at 
the time o f analysis will be censored at the date last known to be alive. A [ADDRESS_143199] to OS. In addit ion, an unadjusted stratified Cox m odel will be used to 
estimate the HR and its 80% and 95% CIs for the treatment effect. OS will be also 
tested at 2 -sided al pha=0.2. The KM survival curves and KM medians (if est imable), 
along wi th their 95% CIs, will also be provided for each study  group.
…
Amended 
or new 
wording:[Section [IP_ADDRESS]]
…
A 2-sided, stratified unstratified log-rank test will be used to compare the treatment 
groups with respect to PFS at a 2 -sided alpha level of 0.20. In addit ion, an unadjusted 
stratifiedunstratified Cox m odel will be used to estimate the HR and its 80% and 
95% CIs for the treatment effect. The KM survival curves and KM medians (if 
estimable), along with their 2 -sided 95% CIs, will also be provided for each treatment 
group. 
[Section [IP_ADDRESS]]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Ixazomib
Study No. C16029 Page 139of [ADDRESS_143200] to OS. In addit ion, an unadjusted stratifiedunstratified Cox m odel will 
be used to estimate the HR and its 80% and 95% CIs for the treatment effect. OS will 
be also tested at 2 -sided al pha=0.2. The KM survival curves and KM medians (if 
estimable), along wit h their 95% CIs, will also be provided for each study  group.
Rationale for Change: To provide correct information about statist ical test ing for this study .
Change 16: To add informat ion about submitting SAE reports.
The primary  change occurs in Section 10.2 Procedures for Recording and Reporting AEs and 
SAEs :
Added 
text:The paper SAE forms should be submitted via fax (see fax numbers below) 
within [ADDRESS_143201] be updated as soon as possible with the appropriate 
information.
Rationale for Change: To assist in timely submission of SAE reports.
Change 17: To correct a typographical error and clarify that there is only 1 study analysis planned 
(and as such, no interim analyses).
The change occurs in Sect ion 9.9Study  Closure :
Initial 
wording:Determinat ion of efficacy based on IA.
Amended 
or new 
wording:Determinat ion of efficacy based on IAthe study analysis .
Rationale for Change: To correct a ty pographical error.
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

  


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GHH䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢸䢢䣶䣱䢢䣃䢢䣒䣪䣣䣵䣧䢢䢴䢮䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣑䣲䣧䣰䢯䣎䣣䣤䣧䣮䢢䣕䣶䣷䣦䣻䢢䣅䣱䣯䣲䣣䣴䣫 䣰䣩䢢䣑䣴䣣䣮䢢䣋䣺䣣䣼䣱䣯䣫䣤䢱䣆䣧䣺䣣䣯䣧䣶䣪䣣䣵䣱䣰䣧䢢䣣䣰䣦
䣑䣴䣣䣮䢢䣒䣱䣯䣣䣮䣫䣦䣱䣯䣫䣦䣧䢱䣆䣧䣺䣣䣯䣧䣶䣪䣣䣵䣱䣰䣧䢢䣫䣰䢢䣔䣧䣮䣣䣲䣵䣧䣦䢢䣣䣰䣦䢱䣱䣴䢢䣔䣧䣨䣴䣣䣥䣶䣱䣴䣻䢢䣏 䣷䣮䣶䣫䣲䣮䣧䢢䣏䣻䣧䣮䣱䣯䣣
&OLQLFDO6FLHQFH$SSURYDO 6HS87&
%LRVWDWLVWLFV$SSURYDO 6HS87&
&OLQLFDO6FLHQFH$SSURYDO 6HS87&
3KDUPDFRYLJLODQFH$SSURYDO 6HS87&[COMPANY_003]
Property of [COMPANY_005]: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

6HSHS
6H